var title_f36_56_37760="Femoral anteversion";
var content_f36_56_37760=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Femoral anteversion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Femoral anteversion is the angle formed by the axis of the femoral neck and the transcondylar axis of the femur.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_56_37760=[""].join("\n");
var outline_f36_56_37760=null;
var title_f36_56_37761="Clinical microbiology review: Wound, skin, and soft tissue infections";
var content_f36_56_37761=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical microbiology review: Wound, skin, and soft tissue infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/56/37761/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/56/37761/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/56/37761/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/56/37761/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/56/37761/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/56/37761/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/56/37761/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 1997.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;This 22 year-old woman developed an abscess in a cervical lymph node following severe pharyngitis. What does the Gram stain of the fluid from this abscess show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef51800 \" href=\"mobipreview.htm?13/19/13631\">",
"     picture 1",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef66191 graphicRef78035 graphicRef80137 \" href=\"mobipreview.htm?42/57/43923\">",
"     picture 2A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CASE 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;This 52 year-old man developed cellulitis following trauma to his right leg. What does the Gram stain of the purulent drainage from this wound show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef56370 \" href=\"mobipreview.htm?6/10/6319\">",
"     picture 3",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_figure graphicRef67693 \" href=\"mobipreview.htm?7/47/7935\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CASE 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;This swab was obtained from a 43 year-old female, who had an erythematous, draining abdominal wound (and underlying abdominal abscess) after surgery for a ruptured appendix. What does the Gram stain show ? Question: (",
"    <a class=\"graphic graphic_picture graphicRef57077 \" href=\"mobipreview.htm?21/5/21586\">",
"     picture 4",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef68847 \" href=\"mobipreview.htm?24/59/25522\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CASE 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;This specimen was aspirated from a bullous lesion present on the arm of a 21 year-old male intravenous drug user. What does the Gram stain show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef52762 \" href=\"mobipreview.htm?23/63/24574\">",
"     picture 6",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef75923 graphicRef54920 graphicRef66744 graphicRef78449 \" href=\"mobipreview.htm?9/27/9658\">",
"     picture 7A-D",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CASE 5",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 38 year-old woman developed cellulitis several hours after being bitten by her cat. What does the Gram stain of the purulent drainage from the wound show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef60433 \" href=\"mobipreview.htm?33/41/34448\">",
"     picture 8",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef72249 \" href=\"mobipreview.htm?35/56/36736\">",
"     picture 9",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CASE 6",
"    </span>",
"    &nbsp;&mdash;&nbsp;This 82 year-old female presented with vesicular lesions in a dermatomal distribution. What does a Tzanck preparation from a skin lesion show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef75421 \" href=\"mobipreview.htm?17/36/17998\">",
"     picture 10",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef54430 \" href=\"mobipreview.htm?19/21/19806\">",
"     picture 11",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CASE 7",
"    </span>",
"    &nbsp;&mdash;&nbsp;This 38 year-old immigrant from southeast Asia presented with extensive papular skin lesions. What does an acid-fast stain of a skin biopsy show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef55248 \" href=\"mobipreview.htm?17/35/17968\">",
"     picture 12",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef78871 \" href=\"mobipreview.htm?18/45/19152\">",
"     picture 13",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1269 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-EDC393233E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_56_37761=[""].join("\n");
var outline_f36_56_37761=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CASE 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CASE 3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CASE 4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CASE 5",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CASE 6",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CASE 7",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1269\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1269|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/47/7935\" title=\"figure 1\">",
"      Gram stain wound 1 with answer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1269|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/19/13631\" title=\"picture 1\">",
"      Gram stain abscess 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/17/15647\" title=\"picture 2A\">",
"      Gram stain abscess 1A answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/6/17519\" title=\"picture 2B\">",
"      Gram stain abscess 1B answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/43/19133\" title=\"picture 2C\">",
"      Catalase test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/10/6319\" title=\"picture 3\">",
"      Gram stain wound 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/5/21586\" title=\"picture 4\">",
"      Gram stain abscess 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/59/25522\" title=\"picture 5\">",
"      Gram stain abscess 2 answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/63/24574\" title=\"picture 6\">",
"      Gram stain skin lesion 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/2/26670\" title=\"picture 7A\">",
"      Gram stain lesion 1A answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/22/5487\" title=\"picture 7B\">",
"      Gram stain lesion 1B answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/32/3590\" title=\"picture 7C\">",
"      Gram stain lesion 1C answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/20/17729\" title=\"picture 7D\">",
"      Gram stain lesion 1D answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/41/34448\" title=\"picture 8\">",
"      Gram stain skin lesion 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/56/36736\" title=\"picture 9\">",
"      Gram stain skin lesion 2 answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/36/17998\" title=\"picture 10\">",
"      Tzanck prep skin lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/21/19806\" title=\"picture 11\">",
"      Tzanck prep skin lesion answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/35/17968\" title=\"picture 12\">",
"      Acid fast stain skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/45/19152\" title=\"picture 13\">",
"      Acid fast stain biopsy answer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_56_37762="Patient information: Taking over-the-counter medicines during pregnancy (The Basics)";
var content_f36_56_37762=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16659\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/61/29661\">",
"         Amount of fiber in different foods",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/42/24226\">",
"         Patient information: Acid reflux (gastroesophageal reflux disease) during pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?37/1/37907\">",
"         Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/39/1650\">",
"         Patient information: Morning sickness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/59/41906\">",
"         Patient information: Nutrition before and during pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/55/23411\">",
"         Patient information: Pregnancy symptoms (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/29/37331\">",
"         Patient information: Prenatal care (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/63/37874\">",
"         Patient information: Nausea and vomiting of pregnancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Taking over-the-counter medicines during pregnancy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/taking-over-the-counter-medicines-during-pregnancy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6761859\">",
"      <span class=\"h1\">",
"       What are over-the-counter medicines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Over-the-counter (OTC) medicines are medicines that you can buy in a pharmacy or store without a doctor&rsquo;s prescription. They come in different forms, including pills, creams, and eye drops.",
"     </p>",
"     <p>",
"      People commonly use OTC medicines to treat:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Cough and cold",
"       </li>",
"       <li>",
"        Allergies",
"       </li>",
"       <li>",
"        Skin rashes or hives",
"       </li>",
"       <li>",
"        Diarrhea or constipation (trouble having bowel movements)",
"       </li>",
"       <li>",
"        Heartburn",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some OTC medicines can cure the condition that is causing the symptoms. But many OTC medicines do not cure the condition that is causing the symptoms. Instead, they only improve symptoms for a short time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6761874\">",
"      <span class=\"h1\">",
"       Are OTC medicines safe to take during pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some are probably safe, but others aren&rsquo;t. It depends on:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        The medicine &ndash; Experts know that some medicines are probably safe to take during pregnancy. Experts also know that other medicines are not safe and could harm a baby or cause problems during pregnancy. But for many OTC medicines, experts don&rsquo;t know the answer. That&rsquo;s because studies have not been done to check the safety of most OTC medicines in pregnant women.",
"       </li>",
"       <li>",
"        How far along the pregnancy is &ndash; Most birth defects happen in the first few months of pregnancy. If you take an OTC medicine during that time, you can increase the chance that the medicine will harm your baby.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The best way to know if an OTC medicine is safe to take during pregnancy is to ask your doctor or nurse. Call your doctor or nurse before you take any medicine during pregnancy.",
"     </p>",
"     <p>",
"      You can also get information about the safety of taking certain medicines during pregnancy by calling this free hotline (in the US): 1-866-626-6847.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6761889\">",
"      <span class=\"h1\">",
"       Which pain-relieving medicine is best to take during pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors usually recommend that pregnant women use",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (brand name: Tylenol&reg;) to treat pain. Check with your doctor before taking any other pain medicines.",
"     </p>",
"     <p>",
"      Doctors usually tell pregnant women to avoid taking medicines called &ldquo;NSAIDs,&rdquo; especially in the last 3 months of pregnancy. NSAIDs are a group of medicines that includes",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (sample brand names: Advil&reg;, Motrin&reg;), and",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/35/44597?source=see_link\">",
"       naproxen",
"      </a>",
"      (sample brand names: Aleve&reg;, Naprosyn&reg;). Taking a lot of NSAIDs in the last 3 months of pregnancy could harm your baby or cause problems during labor.",
"     </p>",
"     <p>",
"      If your pain or headache doesn&rsquo;t get better after you take a dose of",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      , tell your doctor or nurse. It&rsquo;s especially important to let your doctor or nurse know about these symptoms in the last half of pregnancy. These could be symptoms of a serious problem.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6761904\">",
"      <span class=\"h1\">",
"       What can I take to treat constipation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To treat constipation (trouble having bowel movements), you can add more fiber to your diet (",
"      <a class=\"graphic graphic_table graphicRef52349 \" href=\"mobipreview.htm?28/61/29661\">",
"       table 1",
"      </a>",
"      ). You can also use a fiber supplement.",
"     </p>",
"     <p>",
"      If your constipation doesn&rsquo;t get better, ask your doctor or nurse about taking a medicine called a &ldquo;laxative.&rdquo; These medicines can help you have bowel movements.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6761919\">",
"      <span class=\"h1\">",
"       Can I take herbal products?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ask your doctor or nurse before you take any herbal product or supplement. Some herbal products can harm an unborn baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6761934\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Talk to your doctor or nurse at your routine pregnancy check-ups. Ask him or her which OTC medicines are safe to use. That way, if you have symptoms, you will know which medicines to use.",
"       </li>",
"       <li>",
"        Ask questions if you&rsquo;re not sure how to use a medicine. You can ask the pharmacy worker or your doctor or nurse.",
"       </li>",
"       <li>",
"        Choose a medicine that treats only the symptoms or condition you have.",
"       </li>",
"       <li>",
"        Throw out medicine that has expired (gone bad).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6761949\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/1/37907?source=see_link\">",
"       Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/59/41906?source=see_link\">",
"       Patient information: Nutrition before and during pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/39/1650?source=see_link\">",
"       Patient information: Morning sickness (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/42/24226?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux disease) during pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/29/37331?source=see_link\">",
"       Patient information: Prenatal care (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/55/23411?source=see_link\">",
"       Patient information: Pregnancy symptoms (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/63/37874?source=see_link\">",
"       Patient information: Nausea and vomiting of pregnancy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/56/37762?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16659 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_56_37762=[""].join("\n");
var outline_f36_56_37762=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6761859\">",
"      What are over-the-counter medicines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6761874\">",
"      Are OTC medicines safe to take during pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6761889\">",
"      Which pain-relieving medicine is best to take during pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6761904\">",
"      What can I take to treat constipation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6761919\">",
"      Can I take herbal products?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6761934\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6761949\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16659\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/61/29661\">",
"      Amount of fiber in different foods",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/42/24226?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) during pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/1/37907?source=related_link\">",
"      Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/39/1650?source=related_link\">",
"      Patient information: Morning sickness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/63/37874?source=related_link\">",
"      Patient information: Nausea and vomiting of pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/59/41906?source=related_link\">",
"      Patient information: Nutrition before and during pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/55/23411?source=related_link\">",
"      Patient information: Pregnancy symptoms (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/29/37331?source=related_link\">",
"      Patient information: Prenatal care (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_56_37763="Entry into anterior culdesac";
var content_f36_56_37763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Entry into the vesicovaginal space (anterior cul-de-sac) during vaginal hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_56_37763=[""].join("\n");
var outline_f36_56_37763=null;
var title_f36_56_37764="Circumscribed morphea - inflammatory plaque";
var content_f36_56_37764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73769%7EDERM%2F57586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73769%7EDERM%2F57586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Circumscribed morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An indurated plaque with central hypopigmentation and peripheral erythema is present in this patient with circumscribed morphea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inflammatory morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An active plaque in the inflammatory stage is present on the left. Note the violaceous border.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_56_37764=[""].join("\n");
var outline_f36_56_37764=null;
var title_f36_56_37765="Acral acanthosis nigricans";
var content_f36_56_37765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F70582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F70582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acral acanthosis nigricans (acral acanthotic anomaly)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperpigmented thin plaques are present on the dorsal hand. The lesions are primarily located over the joints.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_56_37765=[""].join("\n");
var outline_f36_56_37765=null;
var title_f36_56_37766="Transfusion-associated immune and non immune-mediated hemolysis";
var content_f36_56_37766=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Transfusion-associated immune and non immune-mediated hemolysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/56/37766/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/56/37766/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/56/37766/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/56/37766/contributors\">",
"     Steven Kleinman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/56/37766/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/56/37766/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/56/37766/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolysis (or shortened red blood cell survival) in a patient receiving, or having recently received, a blood transfusion is more often than not an immune-mediated phenomenon, properly referred to as a hemolytic transfusion reaction (HTR). There are also a number of non-immune-mediated causes of RBC destruction associated with transfusion. These phenomena (sometimes referred to as \"pseudo-hemolytic transfusion reactions\") [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/1\">",
"     1",
"    </a>",
"    ], include RBC lysis caused by thermal injury, osmotic injury, mechanical injury, infection, congenital hemolytic anemia, acquired hemolytic anemia, and drugs.",
"   </p>",
"   <p>",
"    This review will highlight both hemolytic and \"pseudo-hemolytic\" transfusion reactions, with special emphasis on the mechanism of RBC destruction in each situation (",
"    <a class=\"graphic graphic_table graphicRef62191 \" href=\"mobipreview.htm?6/25/6555\">",
"     table 1",
"    </a>",
"    ). The general subject of immunologic blood transfusion reactions, which also includes anaphylactic and urticarial reactions, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11769?source=see_link\">",
"     \"Immunologic blood transfusion reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMMUNE MEDIATED HEMOLYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hemolytic transfusion reaction can occur either during or following a blood transfusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11769?source=see_link&amp;anchor=H7#H7\">",
"     \"Immunologic blood transfusion reactions\", section on 'Acute hemolytic reactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11769?source=see_link&amp;anchor=H11#H11\">",
"     \"Immunologic blood transfusion reactions\", section on 'Delayed hemolytic reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acute hemolytic transfusion reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a hemolytic transfusion reaction (HTR) occurs during or immediately after transfusion, it is labeled an acute HTR, is a medical emergency requiring immediate intervention, and is almost always a result of complement-mediated intravascular hemolysis caused by preformed antibodies in the recipient's plasma to the donor's red blood cells (RBCs). This medical emergency results from the rapid destruction of donor RBCs by preformed recipient antibodies, usually anti-A or anti-B but occasionally anti-Rh or anti-Jka, capable of fixing complement. Rapid intravascular hemolysis may lead to disseminated intravascular coagulation (DIC), shock, and acute renal failure due to acute tubular necrosis.",
"   </p>",
"   <p>",
"    The classic presenting triad of fever, flank pain, and red or brown urine (ie, hemoglobinuria) is rarely seen; fever and chills may be the only manifestation, except in patients under anesthesia, or in coma, for whom DIC may be the presenting mode.",
"   </p>",
"   <p>",
"    When an acute HTR is suspected, the transfusion must be stopped immediately, the patient should be hydrated with normal saline, and vigorous supportive care to maintain the patient's airway, blood pressure, urine output, and heart rate applied while serologic investigation is undertaken. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11769?source=see_link&amp;anchor=H7#H7\">",
"     \"Immunologic blood transfusion reactions\", section on 'Acute hemolytic reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Delayed hemolytic transfusion reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reaction that occurs days to weeks following a transfusion, characterized by mild anemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hyperbilirubinemia, is labeled a delayed HTR. Delayed HTRs are almost invariably the result of a primary or anamnestic immune response, with the recipient generating non-complement binding antibodies that coat donor RBCs, causing extravascular hemolysis.",
"   </p>",
"   <p>",
"    Delayed HTRs are most often due to an anamnestic antibody response occurring after reexposure to a foreign RBC antigen (often of the Kidd or Rh system) previously encountered via transfusion, transplantation, or pregnancy. Occurring anywhere from 3 to 21 days post transfusion, they are characterized by extravascular hemolysis (sequestration and removal of antibody-coated RBCs by macrophages in the spleen), which is usually gradual in onset and less severe than with acute HTRs.",
"   </p>",
"   <p>",
"    A falling hematocrit, slight fever, mild increase in serum unconjugated bilirubin, and spherocytosis on the blood smear may be found in association with a new positive direct antiglobulin (Coombs) test and a new positive antibody screen. In the absence of brisk hemolysis, no treatment is required, other than replacement of RBCs, if indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11769?source=see_link&amp;anchor=H11#H11\">",
"     \"Immunologic blood transfusion reactions\", section on 'Delayed hemolytic reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Hyperhemolytic crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;On rare occasions, a delayed hemolytic transfusion reaction is accompanied by hemolysis of the patient's own red cells, a condition termed \"hyperhemolysis\" or hyperhemolytic crisis. This phenomenon has been seen most often in multiply-transfused patients with sickle cell anemia, but has also been reported in patients with thalassemia and in other settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/2\">",
"     2",
"    </a>",
"    ]. The mechanism by which such \"bystander hemolysis\" occurs is not known. Treatment with intravenous immunoglobulin plus high dose corticosteroids has been reported to be successful in some cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the clinical manifestations of sickle cell disease\", section on 'Hyperhemolytic crisis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NON IMMUNE-MEDIATED HEMOLYSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Thermal Injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudo-hemolytic transfusion reactions related to thermal injury can occupy both ends of the thermal spectrum: the use of transfused blood that is too hot or too cold. Although the mechanism may differ, the end result, hemolysis of the transfused red blood cells prior to, during, or soon after transfusion, is the same.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Heat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythrocytes cannot tolerate temperatures above 40&ordm;C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/3\">",
"     3",
"    </a>",
"    ]. When exposed to such temperatures, almost always when blood is administered via a blood warming device, the red blood cell membrane is damaged, leading to changes in viscosity, fluidity, deformability, permeability, and osmotic fragility. Heat-damaged RBCs, if not already hemolyzed, are rapidly cleared from the circulation by the spleen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42214?source=see_link&amp;anchor=H4#H4\">",
"     \"Transfusion reactions caused by chemical and physical agents\", section on 'Thermal hemolysis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=see_link&amp;anchor=H21#H21\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Heat denaturation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is imperative that any in-line blood warming device be standardized to prevent warming the blood above 38&ordm;C, as well as be equipped with an audible warning system. In addition, it is strongly recommended that other methods of warming blood, such as the use of microwaves or phototherapy units, or by simply holding the unit under uncontrolled hot water, be avoided, as fatal hemolytic episodes have been reported under such circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cold",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythrocytes exposed to below-freezing temperatures without a cryoprotective agent (eg, glycerol) can sustain either a dehydration injury if the freezing rate is slow (ie, less than",
"    <span class=\"nowrap\">",
"     10&ordm;C/min),",
"    </span>",
"    or membrane damage caused by intracellular ice crystal formation, if the freezing rate is rapid (ie, more than",
"    <span class=\"nowrap\">",
"     10&ordm;C/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/4\">",
"     4",
"    </a>",
"    ]. In either situation, RBC hemolysis can occur prior to transfusion, a happenstance that can occasionally be detected by observing purplish discoloration of the contents of the blood bag.",
"   </p>",
"   <p>",
"    To prevent this form of red cell damage, it is imperative that RBCs be stored and transported within narrow temperature ranges (1&ordm;C to 6&ordm;C for storage and 1&ordm;C to 10&ordm;C for transport) in carefully, and continually, monitored refrigeration units equipped with audible alarms. Inadequately deglycerolized RBCs, if transfused, can undergo intravascular osmotic lysis; one such circumstance was reported to have been the cause of death in a 1000 gram infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infusion of blood at refrigerator temperatures may exacerbate hemolysis in patients with cold agglutinins. All products, including blood, for intravenous use in such patients should be warmed using approved blood warming devices. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Heat'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33672?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins\", section on 'Special precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Osmotic Injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythrocytes are sensitive to changes in osmotic pressure and will rapidly hemolyze when admixed with hypotonic solutions. By convention, and fiat, the only solutions that can be mixed with RBCs are 0.9 percent (\"normal\") saline, ABO-compatible plasma, and 5 percent albumin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/6\">",
"     6",
"    </a>",
"    ]. RBCs must not be mixed with any drug or any hypotonic solution, such as 5 percent dextrose, 5 percent dextrose in 0.225 percent saline, 3.3 percent dextrose in 0.3 percent saline, or 0.45 percent saline. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=see_link&amp;anchor=H27#H27\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Osmotic attack'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For different reasons RBCs should not be mixed with Lactated Ringer's solution, because the calcium in this solution can chelate the citrate in the",
"    <span class=\"nowrap\">",
"     anticoagulant/preservative",
"    </span>",
"    and lead to clot formation in the unit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, attention must be directed toward the occasional and inadvertent administration of a hypotonic solution, which results when distilled water is accidentally substituted for normal saline as a diluent. This may occur either when such solutions are directly infused into the patient's circulation, or indirectly when a hypotonic solution has been used for bladder irrigation after prostate surgery and the hypotonic solution enters the circulation through prostatic venous channels. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/46/43753?source=see_link&amp;anchor=H25#H25\">",
"     \"Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins\", section on 'Water as a hemolytic agent'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mechanical Injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Donor RBCs can be damaged during transfusion by mechanical forces created during their passage through fine needles, narrow openings, kinked or twisted intravenous lines, mechanical pumps, or by defective blood administration sets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/8\">",
"     8",
"    </a>",
"    ]. Both donor and recipient RBCs can be damaged (lysed) by artificial cardiac valves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/9\">",
"     9",
"    </a>",
"    ] or by transit through extracorporeal circulation devices used in cardiac surgery, hemodialysis, plasmapheresis, or cytapheresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/10\">",
"     10",
"    </a>",
"    ], use of transjugular intrahepatic portosystemic shunts (TIPS), and certain percutaneous mechanical thrombectomy devices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=see_link&amp;anchor=H13#H13\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Malfunctioning cardiac valves'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=see_link&amp;anchor=H15#H15\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Insertion of foreign bodies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=see_link&amp;anchor=H24#H24\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Thrombectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If hemolysis is noted during or after a transfusion in any of these clinical settings, it is incumbent upon the physician to distinguish between an immune-mediated acute HTR and a pseudo-hemolytic transfusion reaction caused by mechanical injury to either the transfused RBCs, the patient's RBCs, or both.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that 0.05 to 0.1 percent of blood is contaminated at the time of collection. Given differing storage conditions, and the ability of microorganisms to grow under such conditions, the risk of sepsis after the transfusion of RBCs is estimated at one in approximately 5 million, while the risk of clinically symptomatic bacterial infection after the transfusion of platelets (prior to the implementation of bacterial detection methodology) was estimated at one in one in 2500 transfusion episodes for pooled platelets and one in 15,000 for apheresis platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Absent a definitive culture, bacterial contamination of RBC units can be suspected if the unit is observed to contain particulate matter or clots, gross hemolysis, a change in color,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of gas bubbles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/14/10471?source=see_link\">",
"     \"Transfusion transmitted bacterial infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients transfused with infected blood can manifest all of the symptoms of an acute HTR, including fever, chills, hypotension, tachycardia, shock, hemoglobinemia, and hemoglobinuria.",
"   </p>",
"   <p>",
"    Although much more rare, transfusion of a unit contaminated by a malarial protozoan could manifest as unexplained fevers several days to weeks after transfusion, thereby mimicking a delayed HTR. Much as in the management of the acute HTR, any suspicion that a contaminated unit is being infused should be met by immediate discontinuation of the transfusion, attention to the patient's clinical status, and a careful evaluation of the blood bag for contaminating microorganisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Exacerbation of a congenital hemolytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythrocytes from donors with certain forms of congenital hemolytic anemia can, when subjected to the appropriate milieu, hemolyze in the recipient, mimicking an acute or delayed HTR. The most common such hemolytic anemia is glucose-6-phosphate dehydrogenase (G6PD) deficiency. RBCs with this enzyme deficiency are susceptible to lysis when exposed to oxidant stress as, for example, when exposed to certain drugs (sulfonamides, phenacetin, vitamin K,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    , and others), infections such as viral hepatitis, the ingestion of fava beans, or alterations in plasma pH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/14\">",
"     14",
"    </a>",
"    ]. G6PD-deficient RBCs will survive almost normally in recipients not subjected to oxidant stress, with the exception of premature infants, in whom hemolysis has been reported without oxidant exposure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/25/4505?source=see_link\">",
"     \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RBCs from donors with sickle cell trait, while able to survive normally in most recipients, have been shown to have shortened survival in recipients subjected to hypoxic conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Exacerbation of an acquired hemolytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are at least two forms of acquired hemolytic anemia that can contribute to hemolysis in conjunction with a transfusion: paroxysmal nocturnal hemoglobinuria (PNH) and autoimmune hemolytic anemia (AIHA).",
"   </p>",
"   <p>",
"    Since the RBCs of patients with PNH have enhanced sensitivity to the action of complement, any antigen-antibody reaction capable of activating complement (eg, donor RBC-recipient antibody; donor WBC-recipient antibody; recipient RBC-donor antibody) can trigger hemolysis in a recently transfused patient with PNH. At various times, both washed RBCs (to remove donor plasma) and leukoreduced RBCs (to eliminate donor WBCs) have been advocated to decrease the frequency of such reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14121?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations of paroxysmal nocturnal hemoglobinuria\", section on 'Determinants of hemolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with AIHA, autoantibody-induced lysis of transfused RBCs can either mimic or mask alloantibody-induced hemolysis. A thorough search for underlying alloantibodies in patients with AIHA is essential prior to transfusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/62/14313?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Red blood cell transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of drugs and chemical agents that can cause hemolysis and, in the appropriate patient population, mimic a hemolytic transfusion reaction. Both lead [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/17\">",
"     17",
"    </a>",
"    ] and copper [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/18\">",
"     18",
"    </a>",
"    ] have been reported to cause hemolysis in a percentage of patients with acute, toxic exposure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/46/43753?source=see_link&amp;anchor=H19#H19\">",
"     \"Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins\", section on 'Lead'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/46/43753?source=see_link&amp;anchor=H20#H20\">",
"     \"Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins\", section on 'Copper'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The list of drugs includes those mentioned above as contributing to an oxidant stress in patients with G6PD, high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/19\">",
"     19",
"    </a>",
"    ], interferon alfa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/20\">",
"     20",
"    </a>",
"    ], intravenous immunoglobulin (IGIV, IVIG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/21\">",
"     21",
"    </a>",
"    ], Rho (D) immune globulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/22\">",
"     22",
"    </a>",
"    ], and the group of drugs classically associated with immune hemolysis by a variety of mechanisms (eg, penicillin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    , cephalosporins, and alpha",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37766/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/46/43753?source=see_link&amp;anchor=H18#H18\">",
"     \"Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins\", section on 'Other nonautoimmune causes of drug- and toxin-induced hemolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As is true for all other categories of \"pseudo-hemolytic transfusion reactions,\" hemolysis caused by exposure to a toxic chemical or drug must be ruled out when the available evidence does not irrefutably establish transfusion as the cause of hemolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15146629\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolysis (increased destruction of red cells) in a patient receiving, or having recently received, a blood transfusion is referred to as a hemolytic transfusion reaction (HTR). A number of immune and non-immune causes are known (",
"    <a class=\"graphic graphic_table graphicRef62191 \" href=\"mobipreview.htm?6/25/6555\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Immune mediated hemolysis",
"      </strong>",
"      &mdash; Immune mediated HTR can be either acute or delayed. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Immune mediated hemolysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acute hemolysis is usually due to the rapid destruction of donor RBCs by preformed recipient antibodies capable of fixing complement, usually anti-A or anti-B but occasionally anti-Rh or anti-Jka. Rapid intravascular hemolysis may lead to disseminated intravascular coagulation (DIC), shock, and acute renal failure due to acute tubular necrosis.",
"     </li>",
"     <li>",
"      Delayed HTRs are most often due to an anamnestic antibody response occurring after reexposure to a foreign RBC antigen (often of the Kidd or Rh system) previously encountered via transfusion, transplantation, or pregnancy.",
"     </li>",
"     <li>",
"      On rare occasions, a delayed HTR is accompanied by hemolysis of the patient's own red cells (\"hyperhemolysis\" or hyperhemolytic crisis). The mechanism by which such bystander hemolysis occurs is not known.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Non immune mediated hemolysis",
"      </strong>",
"      &mdash; Non-immune causes of HTR include exposure of the red cell product to excessive heat or cold, osmotic or mechanical injury, hemolytic agents produced by invading organisms, and certain drugs. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Non immune-mediated hemolysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37766/abstract/1\">",
"      Beauregard P, Blajchman MA. Hemolytic and pseudo-hemolytic transfusion reactions: an overview of the hemolytic transfusion reactions and the clinical conditions that mimic them. Transfus Med Rev 1994; 8:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37766/abstract/2\">",
"      Darabi K, Dzik S. Hyperhemolysis syndrome in anemia of chronic disease. Transfusion 2005; 45:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37766/abstract/3\">",
"      Utoh J, Harasaki H. Damage to erythrocytes from long-term heat stress. Clin Sci (Lond) 1992; 82:9.",
"     </a>",
"    </li>",
"    <li>",
"     Mollison PL, Engelfriet CP, Contreras M. Blood transfusion in clinical medicine, Blackwell, London 1993. p.498.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37766/abstract/5\">",
"      Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990; 30:583.",
"     </a>",
"    </li>",
"    <li>",
"     Fridey JL. Standards for blood banks and transfusion services, 22nd ed, American Association of Blood Banks, Arlington, VA 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37766/abstract/7\">",
"      Ryden SE, Oberman HA. Compatibility of common intravenous solutions with CPD blood. Transfusion 1975; 15:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37766/abstract/8\">",
"      Dubey A, Verma A, Sonker A, et al. Transfusion medicine illustrated. Sudden increased incidence of transfusion reactions reported from a ward: root cause analysis. Transfusion 2009; 49:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37766/abstract/9\">",
"      Ismeno G, Renzulli A, Carozza A, et al. Intravascular hemolysis after mitral and aortic valve replacement with different types of mechanical prostheses. Int J Cardiol 1999; 69:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37766/abstract/10\">",
"      Martin R, McKenty S, Thisdale Y, et al. Hemolysis during cardiopulmonary bypass. J Cardiothorac Anesth 1989; 3:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37766/abstract/11\">",
"      Mair DC, Eastlund T, Rosen G, et al. Hemolysis during percutaneous mechanical thrombectomy can mimic a hemolytic transfusion reaction. Transfusion 2005; 45:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37766/abstract/12\">",
"      Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev 2003; 17:120.",
"     </a>",
"    </li>",
"    <li>",
"     Holland PV. The diagnosis and management of transfusion reactions and other adverse effects of transfusion. In: Clinical practice of transfusion medicine, 2nd ed, Petz LD, Swisher SN (Eds), Churchill-Livingstone, New York 1989. p.713.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37766/abstract/14\">",
"      McCurdy PR, Morse EE. Glucose-6-phosphate dehydrogenase deficiency and blood transfusion. Vox Sang 1975; 28:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37766/abstract/15\">",
"      Krevans JR. In vivo behaviour of sickle trait erythrocytes when exposed to continuous hypoxia. Clin Res 1959; 7:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37766/abstract/16\">",
"      Sirchia G, Zanella A. Transfusion of PNH patients. Transfusion 1990; 30:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37766/abstract/17\">",
"      Valentine WN, Paglia DE, Fink K, Madokoro G. Lead poisoning: association with hemolytic anemia, basophilic stippling, erythrocyte pyrimidine 5'-nucleotidase deficiency, and intraerythrocytic accumulation of pyrimidines. J Clin Invest 1976; 58:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37766/abstract/18\">",
"      Manzler AD, Schreiner AW. Copper-induced acute hemolytic anemia. A new complication of hemodialysis. Ann Intern Med 1970; 73:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37766/abstract/19\">",
"      Wood L, Jacobs P. Cyclophosphamide-related intravascular haemolysis during continuous-flow plasma exchange. J Clin Apher 1985; 2:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37766/abstract/20\">",
"      Sacchi S, Kantarjian H, O'Brien S, et al. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13:2401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37766/abstract/21\">",
"      Brox AG, Cournoyer D, Sternbach M, Spurll G. Hemolytic anemia following intravenous gamma globulin administration. Am J Med 1987; 82:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37766/abstract/22\">",
"      Hong F, Ruiz R, Price H, et al. Safety profile of WinRho anti-D. Semin Hematol 1998; 35:9.",
"     </a>",
"    </li>",
"    <li>",
"     Brecher, ME. Technical Manual 14th Edition. American Association of Blood Banks, Bethesda, MD 2002; 439-445.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7932 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-4EAA1F1B94-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_56_37766=[""].join("\n");
var outline_f36_56_37766=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15146629\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMMUNE MEDIATED HEMOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acute hemolytic transfusion reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Delayed hemolytic transfusion reaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Hyperhemolytic crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NON IMMUNE-MEDIATED HEMOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Thermal Injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Heat",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cold",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Osmotic Injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mechanical Injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Exacerbation of a congenital hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Exacerbation of an acquired hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15146629\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7932\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7932|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/25/6555\" title=\"table 1\">",
"      Transfusion assoc hemolysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33672?source=related_link\">",
"      Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/25/4505?source=related_link\">",
"      Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14121?source=related_link\">",
"      Clinical manifestations of paroxysmal nocturnal hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/46/43753?source=related_link\">",
"      Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42214?source=related_link\">",
"      Transfusion reactions caused by chemical and physical agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/14/10471?source=related_link\">",
"      Transfusion transmitted bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/62/14313?source=related_link\">",
"      Treatment of autoimmune hemolytic anemia: Warm agglutinins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_56_37767="Trypanosomal chancre";
var content_f36_56_37767=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trypanosomal chancre",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 412px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical skin reaction two weeks after the first onset of local symptoms following the bite of an infected tsetse fly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of August Stich, MD, MSc, DTMH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_56_37767=[""].join("\n");
var outline_f36_56_37767=null;
var title_f36_56_37768="Complex regional pain syndrome in children";
var content_f36_56_37768=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complex regional pain syndrome in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/56/37768/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/56/37768/contributors\">",
"     David D Sherry, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/56/37768/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/56/37768/contributors\">",
"     Thomas JA Lehman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/56/37768/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/56/37768/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/56/37768/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/56/37768/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complex regional pain syndrome (CRPS) is an amplified musculoskeletal pain syndrome that is characterized by extreme pain in a limb out of proportion to the history and physical findings, accompanied by one or more signs of autonomic dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/1\">",
"     1",
"    </a>",
"    ]. Although CRPS was first reported in 1864 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/2\">",
"     2",
"    </a>",
"    ], it was not until 1971 that CRPS was described in a child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/3\">",
"     3",
"    </a>",
"    ]. Since the initial pediatric report, CRPS is increasingly recognized in pediatric pain, rheumatology, and neurology clinics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and management of CRPS in children will be reviewed here. CRPS in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32344?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6122?source=see_link\">",
"     \"Prevention and management of complex regional pain syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative names for CRPS in the literature include reflex sympathetic dystrophy (RSD), algodystrophy, causalgia, Sudeck atrophy, transient osteoporosis, and acute atrophy of bone. In 1995, a consensus conference grouped these disorders under a single heading of complex regional pain syndrome (CRPS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CRPS is divided into two categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I occurs in patients with CRPS without a definable nerve lesion.",
"     </li>",
"     <li>",
"      Type II, also referred to as causalgia, occurs in cases where a definable nerve lesion is present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with CRPS overwhelmingly have type I disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Childhood vs adult CRPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CRPS in children substantially differs from that seen in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/4-6,8-16\">",
"     4-6,8-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children are less likely than adults to have a history of an inciting injury or noxious insult.",
"     </li>",
"     <li>",
"      The leg is more often involved, and the skin temperature of the involved extremity is more often cooler in children than adults.",
"     </li>",
"     <li>",
"      Neurologic symptoms are less pronounced in children.",
"     </li>",
"     <li>",
"      Psychologic issues play a more prominent role in children than adults.",
"     </li>",
"     <li>",
"      Children with CRPS do not have the three stages of disease generally seen in adult patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32344?source=see_link&amp;anchor=H8#H8\">",
"       \"Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults\", section on 'Clinical stages'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children typically have a better outcome and are much more responsive to physical and occupational therapy alone than are adults.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of CRPS is unknown but likely involves the local and central nervous system, as well as psychologic and genetic factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Local factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant preceding trauma is not a common event in most pediatric series, but CRPS can follow surgery, fractures, motor vehicle accidents, soft tissue injury, and injections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Role of the central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data supporting the role of the central nervous system (CNS) in the pathogenesis and spread of pain in CRPS include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In adults, magnetoencephalography demonstrates extensive reorganization of the S1 cortex on the contralateral side of the affected limb, which is reversed once the pain subsides [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Functional magnetic resonance imaging (fMRI) in children demonstrates changes in basal ganglia and parietal lobe activation that persist even after CRPS resolution, and findings suggestive of pain-induced activation of endogenous pain modulatory system [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CNS involvement is suggested by hemisensory impairment beyond the painful area, and the increased frequency of mechanical allodynia (pain produced normally by non-noxious stimulation) and movement disorders with sensory deficits [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Psychologic issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychologic stress and other comorbid psychologic disorders are commonly reported in pediatric CRPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/4,10,14,22-24\">",
"     4,10,14,22-24",
"    </a>",
"    ]. It is unclear whether these psychologic disorders are due to CNS factors that play a role in the etiology of CRPS or the result of the stress and anxiety related to CRPS.",
"   </p>",
"   <p>",
"    Children with CRPS are often described as overly mature with an incongruent affect (eg, cheerful appearance while reporting severe pain). In addition, conversion symptoms are not uncommon. The author has cared for children with CRPS who have developed conversional nonepileptic seizures, blindness, paralysis, conversion gait, muscle spasms (both stiff limbs or movement disorders), and incapacitating dizziness. Other psychologic conditions seen in children with CRPS include eating disorders, suicidal gestures, and self-cutting behavior. Data from our center suggest that children with the worst prognoses are those who have a prior suicide attempt. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/11/38071?source=see_link\">",
"     \"Evaluation and management of suicidal behavior in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=see_link\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Genetic predisposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic factors may be involved in the pathogenesis of CRPS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of patients recruited through the Dutch Association of CRPS patients, 31 families were identified who had two or more affected members [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/25\">",
"       25",
"      </a>",
"      ]. Patients with a family history of CRPS developed the disease at a younger age and appeared to have more severe findings than sporadic cases.",
"     </li>",
"     <li>",
"      In a study from a tertiary metabolic genetic practice, eight children who had dysautonomic conditions secondary to maternally inherited mitochondrial disease also met the diagnostic criteria for CRPS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The author cares for identical twins with CRPS and multiple families with more than one member affected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of CRPS in children is unknown. In a population study of Olmsted county, the overall risk of CRPS was 5.46 per 100,000 person years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/27\">",
"     27",
"    </a>",
"    ]. However, this mainly reflected adult CRPS, as the median age at diagnosis was 46 years. Although there appears to be an increase in identified pediatric cases, it is unclear whether this is due to an increase in the incidence of CRPS or improved detection.",
"   </p>",
"   <p>",
"    In a large pediatric series, CRPS is more common in girls (70 percent), and the mean age at diagnosis is 13 years of age (range of 5 to 17 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/5,6,10\">",
"     5,6,10",
"    </a>",
"    ]. Although the youngest reported child with CRPS was two years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/28\">",
"     28",
"    </a>",
"    ], CRPS is unusual under the age of seven years.",
"   </p>",
"   <p>",
"    Most children who have developed CRPS postimmunization have been between 11 and 13 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. It is possible that the immunization is causal. Alternatively, the development of CRPS may be related to the injury associated with the needle jab. However, CRPS is not associated with immunization in younger children, who receive many more vaccine injections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CRPS is defined as pain that is out of proportion to the history and physical findings of the patient and is associated with at least one sign of autonomic dysfunction. Pain typically occurs in a single extremity, most commonly a lower extremity, but pain at multiple sites can occur.",
"   </p>",
"   <p>",
"    In one large case series of 70 children with CRPS, the following findings and their incidences were observed in the affected extremity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pain &mdash; 100 percent",
"     </li>",
"     <li>",
"      Allodynia (pain due to normally non-noxious stimuli) &mdash; 86 percent",
"     </li>",
"     <li>",
"      Edema &mdash; 77 percent",
"     </li>",
"     <li>",
"      Cyanosis &mdash; 73 percent",
"     </li>",
"     <li>",
"      Hyperhidrosis (excessive sweating) &mdash; 31 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain typically occurs in a lower extremity but may occur in an upper extremity or at multiple sites. Most patients will experience allodynia and are unable to tolerate light touch or clothing on the limb. The borders of allodynia vary by 4 to 6 cm with retesting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/5\">",
"     5",
"    </a>",
"    ]. Children with CRPS frequently hold the involved extremity in an unusual position, and the limb is cool and cyanotic (",
"    <a class=\"graphic graphic_figure graphicRef63159 \" href=\"mobipreview.htm?22/58/23458\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef53380 \" href=\"mobipreview.htm?5/38/5732\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients typically have an incongruent affect, that is they appear cheerful while reporting pain that they score as a 10 out of 10 on a pain scale (10 is the maximum score for pain).",
"   </p>",
"   <p>",
"    The history may elicit the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Minor trauma that may or may not be temporally related to the onset of pain",
"     </li>",
"     <li>",
"      Increasing pain over time",
"     </li>",
"     <li>",
"      Pain that is no better or worsens with immobilization",
"     </li>",
"     <li>",
"      Pain that may spread beyond the initial site with new areas that may or may not have overt signs of autonomic dysfunction",
"     </li>",
"     <li>",
"      Migratory pain in some cases",
"     </li>",
"     <li>",
"      A greater degree of disability than expected, although children with CRPS continue to be involved in many activities and are often quite accomplished",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Autonomic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs of autonomic dysfunction include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decreased skin temperature",
"     </li>",
"     <li>",
"      Cyanosis",
"     </li>",
"     <li>",
"      Edema",
"     </li>",
"     <li>",
"      Increased sweating",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Sleep disturbances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disturbed or interrupted sleep commonly occurs in children with CRPS. The vast majority will complain of difficulty getting to sleep and frequent awakenings, but generally they do not fall asleep during the day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Psychologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed previously, psychologic stress and dysfunction are common in children with CRPS and their families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/14\">",
"     14",
"    </a>",
"    ]. Children with CRPS are often described as bright, high achieving, and accomplished and whose pain becomes the central focus of the family, leading to significant stress within the family.",
"   </p>",
"   <p>",
"    Other psychologic conditions seen in children with CRPS include conversion symptoms (eg, conversion gait, stiffness, or somatization), eating disorders, and self-cutting behaviors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other less common clinical findings in children with CRPS include dystrophic skin changes (",
"    <a class=\"graphic graphic_picture graphicRef74927 \" href=\"mobipreview.htm?12/43/12977\">",
"     picture 2",
"    </a>",
"    ), bony edema, osteoporosis, and increased hair growth over the affected area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, CRPS is diagnosed clinically upon fulfilling the definition of the disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain that is out of proportion to the history and physical findings",
"     </li>",
"     <li>",
"      Accompanied by at least one sign of autonomic dysfunction (ie, coolness, cyanosis, edema, or increased sweating)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no laboratory studies that confirm or exclude the diagnosis of CRPS. Laboratory evaluation, which includes blood studies and imaging, is primarily performed to determine whether another pathologic process is present early in the disease course when the characteristic findings of CRPS are not present and the diagnosis is less certain. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Blood tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following blood tests generally are normal in children with CRPS:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Serum electrolytes, BUN, and creatinine",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate (ESR)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other conditions in the differential diagnosis for CRPS may have abnormal blood tests (eg, elevated ESR in juvenile idiopathic arthritis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographs and other imaging modalities (ie, magnetic resonance imaging [MRI], bilateral thermography, and bone scans) do not reliably differentiate CRPS from other disease processes, such as trauma.",
"   </p>",
"   <p>",
"    Radiographs of the affected extremity are normal in patients with CRPS and are generally obtained to exclude the presence of a fracture or, uncommonly, a tumor. However, a normal radiograph does not entirely exclude the presence of a fracture. In some patients, radiographs may show evidence of osteoporosis in the later stages of CRPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/3,31\">",
"     3,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children with CRPS, technetium bone scintigraphy usually show decrease uptake, but a spotty increased pattern may be seen (the pattern more common in adult CRPS) or the study may be normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. A normal bone scan excludes osteomyelitis, osteoid osteoma, or a stress fracture, but it does not exclude the diagnosis of CRPS. An abnormal scan is also subject to differing interpretations, especially if the findings are subtle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Magnetic resonance scans in children with CRPS can show bony edema and small joint effusions, but it is difficult to distinguish these findings from trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Such edema should not dissuade one from the diagnosis of CRPS if the history is not suggestive of trauma, the clinical findings are typical of CRPS, or the duration is such that trauma should be healed.",
"   </p>",
"   <p>",
"    Ultrasound should only be performed in patients in whom a diagnosis of thrombus is highly suspected as the cause of pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the clinical diagnosis of CRPS is made, it is counterproductive to do further studies, as they delay treatment and put doubts about the diagnosis in the mind of the patient and family. The following studies have been used to diagnosis CRPS in children, but generally they are not helpful. We do not recommend their routine use in the evaluation of pediatric CRPS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electromyographic or nerve conduction studies are usually normal in children with CRPS. In some cases, there may be a nonspecific slight slowing of the nerve conduction.",
"     </li>",
"     <li>",
"      Autonomic testing includes measurements of resting sweat output, resting skin temperature, and quantitative sudomotor axon reflex test (QSART). Although these tests are used in adult patients, they play no role in the diagnosis of children with CRPS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32344?source=see_link&amp;anchor=H10#H10\">",
"       \"Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults\", section on 'Autonomic testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tilt table testing is generally normal in children with CRPS and is not helpful in the diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thermography is not helpful in the diagnosis of pediatric CRPS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of CRPS includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trauma, which is distinguished from CRPS by history and imaging studies.",
"     </li>",
"     <li>",
"      Inflammatory conditions (eg, juvenile idiopathic arthritis or osteomyelitis) are differentiated from CRPS by local findings of swelling, enthesitis, erythema, and systemic findings of fever. Laboratory findings often include elevations of inflammatory markers such as white cell count, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/56/35717?source=see_link\">",
"       \"Classification of juvenile arthritis (JRA/JIA)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33289?source=see_link\">",
"       \"Evaluation and diagnosis of hematogenous osteomyelitis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tumors &mdash; The physical finding of soft tissue mass and corresponding radiological findings differentiates bony tumors (eg, osteosarcoma) from CRPS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=see_link\">",
"       \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment goals for pediatric CRPS are restoration of function and relief of pain. If pain cannot be totally eliminated, the goal is adjusted to assist the child in developing skills to cope with residual pain while maintaining function.",
"   </p>",
"   <p>",
"    There is no proven definitive treatment, the disease course varies with unpredictable and sometimes rapid remission of symptoms, and the underlying cause of the disease is unknown.",
"   </p>",
"   <p>",
"    Treatment options include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Physical and occupational therapy",
"     </li>",
"     <li>",
"      Psychotherapy",
"     </li>",
"     <li>",
"      Pharmacological therapy",
"     </li>",
"     <li>",
"      Pain-reducing procedures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The consensus of expert clinicians in the field is that physical and occupational therapy and psychotherapy are the mainstays of treatment for this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/4,5,9,10,12,16,17,22,39,40\">",
"     4,5,9,10,12,16,17,22,39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Physical and occupational therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case series have reported excellent outcomes in children with the use of physical and occupational therapy in children with CRPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/4,5,41\">",
"     4,5,41",
"    </a>",
"    ]. These programs are geared toward having the child maintain function of the affected limb and work through the pain. The frequency, duration, and intensity of therapy required vary. Some individuals may need five to six hours of daily physical and occupational therapy for several weeks to restore full function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one case series of 103 children, an initial daily exercise program that included four hours of aerobic, functionally directed exercises, hydrotherapy, desensitization, and without medications or pain reduction procedures resulted in complete remission in 92 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/5\">",
"     5",
"    </a>",
"    ]. The mean duration of the exercise program was 14 days. All patients had a screening psychologic evaluation, and 79 (77 percent) were referred for psychologic counseling. Of the patients who were followed for more than two years, 88 percent remained symptom free despite one-third of patients having a recurrence of their disease during the follow-up period. Relapses were responsive to reinstating the exercise regimen.",
"   </p>",
"   <p>",
"    A small trial of 28 children with CRPS compared once weekly to three times weekly physical therapy sessions for six weeks along with weekly cognitive-behavioral sessions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/41\">",
"     41",
"    </a>",
"    ]. Both groups showed improvement in the five outcome measures of pain and physical functioning at a mean follow-up of 10 weeks. Excellent functional outcome was reported in 21 of the 24 patients who participated in long-term follow-up (mean 2.5 years). The study sample was too small to determine whether the frequency of sessions had an effect on outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Psychologic and behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no clinical trials evaluating the effectiveness of psychologic and behavioral therapy, these interventions are generally used based on observational reports of their beneficial effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/5,6,27,41\">",
"     5,6,27,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychologic and behavioral therapeutic interventions include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Relaxation training",
"     </li>",
"     <li>",
"      Biofeedback",
"     </li>",
"     <li>",
"      Cognitive-behavioral therapy to improve stress management",
"     </li>",
"     <li>",
"      Family intervention to eliminate reinforcement of negative behaviors (avoidance of school or social obligations)",
"     </li>",
"     <li>",
"      Family intervention to promote coping techniques",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our practice, we have found that these interventions are helpful, as they decrease the stress and anxiety that commonly occur in these children and their families. As a rule, we find that family therapy is most useful in younger patients, whereas older children require both individual and family intervention.",
"   </p>",
"   <p>",
"    A substantial number of children have comorbid psychologic conditions, such as conversion, depression, school avoidance, or an eating disorder, and require consultations with a child psychologist or psychiatrist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no prospective randomized clinical trials of pharmacologic agents in the treatment of CRPS in children. In addition, there are no trials comparing intensive physical therapy alone or in combination with a pharmacologic agent. As a result, the role of pharmacologic agents in the treatment of children with CRPS remains uncertain and controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some experts, including the author, advocate only intensive physical therapy without medications because of the potential of drug side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/5,42\">",
"     5,42",
"    </a>",
"    ]. Although small case reports or series report beneficial effects of medications, the efficacy of these medications has not been confirmed in clinical trials. Medications utilized include opioids, tricyclic antidepressants, anticonvulsants,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/31/35316?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    , nonsteroidal agents, intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    , and glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/17,43-45\">",
"     17,43-45",
"    </a>",
"    ]. In one small case series of six patients, glucocorticoids therapy was not effective in reducing the symptoms of CRPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Pain-reducing procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials to support the use of transcutaneous electrical nerve stimulation (TENS), regional sympathetic nerve block, epidural and intrathecal anesthetics, sympathectomy, or amputation in children with CRPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/6,17,42,43,46-51\">",
"     6,17,42,43,46-51",
"    </a>",
"    ]. Based upon the author's experience, these procedures are not required in the vast majority of children with CRPS.",
"   </p>",
"   <p>",
"    These procedures are discussed in greater detail separately in adults with CRPS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6122?source=see_link&amp;anchor=H18#H18\">",
"     \"Prevention and management of complex regional pain syndrome in adults\", section on 'Invasive therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our center, care is provided by a multidisciplinary team that includes a physical therapist, child psychologist or behavior therapist, and a clinician experienced in treating pediatric CRPS. The goals of therapy are the return and maintenance of full functionality and to provide the child with the necessary tools to deal with pain, especially when and if there is a recurrence of the disease.",
"   </p>",
"   <p>",
"    Treatment is most effective when coupled with patient and family education. The earlier one starts treatment, the less the child suffers. However, our outcomes are associated with psychologic variables (attempted suicide and eating disorders portended more relapses), not duration of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our management approach is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Education",
"      </strong>",
"      &mdash; A complete explanation of CRPS is provided to the patient and family. This includes acknowledging the existence of real pain, but that the pain does not signify damage even though it is at times severe (amplified). We emphasis that the most effective therapy based on our experience is to use the affected limb despite pain and desensitizing techniques if allodynia is present.",
"     </li>",
"     <li>",
"      <strong>",
"       Physical and occupational therapy",
"      </strong>",
"      &mdash; A home exercise and desensitization regimen is developed for each individual and encourages the patient to use the affected limb as much as possible. The regimen's goals are 45 minutes of daily aerobic activities and 5 to 10 minute blocks of desensitization (ie, rubbing, brushing, patting, and clothing) performed multiple times through the day.",
"      <br/>",
"      <br/>",
"      If, after four to eight weeks, the patient is not making significant progress, they are admitted to a more intense daily physical and occupational therapy program of six hours focused on restoring function regardless of pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/52\">",
"       52",
"      </a>",
"      ]. Patients are treated in the ambulatory setting with one-on-one supervision. Parents are not allowed in the gym. Parents are encouraged to return to their normal daily routine and take care of their own needs. If there are significant psychologic issues, patients are admitted to the inpatient service for more in-depth behavioral and psychologic intervention.",
"     </li>",
"     <li>",
"      <strong>",
"       Psychologic and behavioral therapy",
"      </strong>",
"      &mdash; All children and their families undergo psychologic screening to detect any undue stress and comorbid psychologic conditions. Patients with significant psychologic issues are referred to a pediatric psychologist or psychiatrist.",
"      <br/>",
"      <br/>",
"      Patients who require the intense physical and occupational program also have scheduled twice weekly sessions (more if indicated) that address any psychologic issues (\"talk time\"), as well as music and art therapy sessions.",
"     </li>",
"     <li>",
"      <strong>",
"       Medications",
"      </strong>",
"      &mdash; Any medications for pain are stopped or, if needed, are tapered. No further diagnostic tests are ordered.",
"     </li>",
"     <li>",
"      <strong>",
"       Sleep interventions",
"      </strong>",
"      &mdash; Sleep disturbances are managed by nonpharmacologic sleep hygiene recommendations. These include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      No caffeine beverages",
"     </li>",
"     <li>",
"      No television or radio in the bedroom",
"     </li>",
"     <li>",
"      Set bedtime and get up times",
"     </li>",
"     <li>",
"      Darken room",
"     </li>",
"     <li>",
"      No exercise two hours prior to bedtime",
"     </li>",
"     <li>",
"      If the child is unable to fall asleep within 30 minutes, they are allowed to get up and do a quiet, boring activity without disturbing their parents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       School work and transition",
"      </strong>",
"      &mdash; Patients who require a more intense physical and occupational therapy regimen are not expected to do school work during this time period. However, academic accommodations and resources are allowed so patients can make up work prior to their return to school. In the transition back to school, any physical accommodations (eg, use of elevator and increase time between classes) are eliminated, since the children are functional; in children with residual pain, accommodations enable and perpetuate their disability. Academic testing is helpful in identifying previously unidentified or unaddressed learning difficulties in some children that can greatly increase the stress of school [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Primary care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many centers have a multidisciplinary team addressing the needs of these children, pediatric CRPS may be managed in the community with the help of a local physical therapist and psychologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike adults, there is no intervention to prevent the first episode of CRPS in children, because pediatric CRPS is uncommon and rarely occurs after bony fractures. In elderly adults, daily supplementation of vitamin C following a wrist fracture has been associated with a decrease in the incidence of CRPS from 10 to 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/53\">",
"     53",
"    </a>",
"    ]. Based on these findings our center prescribes vitamin C to children with CRPS if they have a fracture, require surgery, or have a significant soft tissue injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6122?source=see_link&amp;anchor=H3#H3\">",
"     \"Prevention and management of complex regional pain syndrome in adults\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of children with CRPS have a favorable prognosis. In a previously discussed case series, complete remission was achieved in 95 of 103 patients (92 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37768/abstract/5\">",
"     5",
"    </a>",
"    ]. Of the 30 percent of patients who relapsed, most relapsed within the first six months of their presentation and generally responded to the reintroduction of physical and occupational therapy. The psychologic aspects of a relapse must be addressed in affected children, as these children are more likely to develop other stress-related conditions, such as nonlimb pain (eg, headache or abdominal pain), self-cutting, eating disorders, school avoidance, or conversion symptoms. The children at greater risk of a relapse had more psychologic issues at presentation (ie, prior suicide attempts and eating disorders).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/17/9490?source=see_link\">",
"       \"Patient information: Complex regional pain syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complex regional pain syndrome (CRPS) is an amplified musculoskeletal pain syndrome that is characterized by extreme pain in a limb out of proportion to the history and physical findings, and one or more signs of autonomic dysfunction (ie, coolness, cyanosis, edema, or increased sweating).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pathogenesis of CRPS is unknown but is likely to be multifactorial involving local, central nervous system, and genetic factors. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CRPS is more common in girls, and the mean age of presentation is 13 years of age. CRPS is unusual below 7 years of age. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestation of CRPS include pain, autonomic dysfunction, sleep disturbances, and psychologic stress and dysfunction. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain typically presents in a single lower extremity. Most patients experience allodynia (pain due to normally non-noxious stimulation) and are unable to tolerate light touch or clothing on the limb. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One or more signs of autonomic dysfunction are present in the affected limb, which include decreased skin temperature, cyanosis, edema, or increased sweating. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Autonomic dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychologic stress and dysfunction are common in children with CRPS and their families. Other psychologic conditions seen in children with CRPS include conversion reactions, school avoidance, eating disorders, and self-cutting behavior. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Psychologic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CRPS is diagnosed clinically based on the presence of pain out of proportion to the history and physical findings and one finding of autonomic dysfunction. There are no laboratory studies that confirm or exclude CRPS. Laboratory evaluation is primarily performed to exclude other conditions that may present with extremity pain include trauma (eg, fracture), inflammatory conditions (eg, osteomyelitis and juvenile idiopathic arthritis), and tumors (eg, osteosarcoma). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment goals are restoration of function and relief of pain. If pain cannot be totally limited, the goal shifts to helping the child cope with pain while maintaining function. Management of pediatric CRPS is challenging because there is no proven definitive treatment, and the disease course varies with unpredictable and sometimes rapid remission of symptoms. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children with CRPS, treatment options include physical and occupational therapy, psychotherapy, pharmacological therapy, and pain-reducing procedures. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest physical and occupational therapy as initial therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest the addition of psychologic and behavioral therapy, as these measures address the stress and anxiety that commonly occur in affected patients and their families (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We do not suggest pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). There are no data that medications provide additional benefit over nonpharmacologic measures, and they have potential severe side effects.",
"     </li>",
"     <li>",
"      In our practice, pain-reducing procedures have not been necessary; however, they may have a role in those patients that are refractory to therapy. These procedures should be used for discrete finite trials, not prolonged treatment.",
"     </li>",
"     <li>",
"      There are no measures to prevent pediatric CRPS, because it is uncommon in children and rarely occurs after bony fractures. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of children with CRPS have a favorable outcome with restored function of the affected limb. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Merskey H, Bogduk N. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms, 2nd edition, IASP Press, Seattle 1994.",
"    </li>",
"    <li>",
"     Mitchell S, Morehouse G, Keen W. Gunshot wounds and other injuries of nerves, Lippincott, New York 1864.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/3\">",
"      Matles AI. Reflex sympathetic dystrophy in a child. A case report. Bull Hosp Joint Dis 1971; 32:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/4\">",
"      Bernstein BH, Singsen BH, Kent JT, et al. Reflex neurovascular dystrophy in childhood. J Pediatr 1978; 93:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/5\">",
"      Sherry DD, Wallace CA, Kelley C, et al. Short- and long-term outcomes of children with complex regional pain syndrome type I treated with exercise therapy. Clin J Pain 1999; 15:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/6\">",
"      Wilder RT, Berde CB, Wolohan M, et al. Reflex sympathetic dystrophy in children. Clinical characteristics and follow-up of seventy patients. J Bone Joint Surg Am 1992; 74:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/7\">",
"      Stanton-Hicks M, J&auml;nig W, Hassenbusch S, et al. Reflex sympathetic dystrophy: changing concepts and taxonomy. Pain 1995; 63:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/8\">",
"      Tan EC, Zijlstra B, Essink ML, et al. Complex regional pain syndrome type I in children. Acta Paediatr 2008; 97:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/9\">",
"      Ashwal S, Tomasi L, Neumann M, Schneider S. Reflex sympathetic dystrophy syndrome in children. Pediatr Neurol 1988; 4:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/10\">",
"      Barbier O, Allington N, Rombouts JJ. Reflex sympathetic dystrophy in children: review of a clinical series and description of the particularities in children. Acta Orthop Belg 1999; 65:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/11\">",
"      Berde CB, Lebel A. Complex regional pain syndromes in children and adolescents. Anesthesiology 2005; 102:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/12\">",
"      Kachko L, Efrat R, Ben Ami S, et al. Complex regional pain syndromes in children and adolescents. Pediatr Int 2008; 50:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/13\">",
"      Kesler RW, Saulsbury FT, Miller LT, Rowlingson JC. Reflex sympathetic dystrophy in children: treatment with transcutaneous electric nerve stimulation. Pediatrics 1988; 82:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/14\">",
"      Sherry DD, Weisman R. Psychologic aspects of childhood reflex neurovascular dystrophy. Pediatrics 1988; 81:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/15\">",
"      Silber TJ, Majd M. Reflex sympathetic dystrophy syndrome in children and adolescents. Report of 18 cases and review of the literature. Am J Dis Child 1988; 142:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/16\">",
"      Stanton RP, Malcolm JR, Wesdock KA, Singsen BH. Reflex sympathetic dystrophy in children: an orthopedic perspective. Orthopedics 1993; 16:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/17\">",
"      Wilder RT. Management of pediatric patients with complex regional pain syndrome. Clin J Pain 2006; 22:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/18\">",
"      Richards S, Chalkiadis G, Lakshman R, et al. Complex regional pain syndrome following immunisation. Arch Dis Child 2012; 97:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/19\">",
"      Maih&ouml;fner C, Handwerker HO, Neund&ouml;rfer B, Birklein F. Cortical reorganization during recovery from complex regional pain syndrome. Neurology 2004; 63:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/20\">",
"      Lebel A, Becerra L, Wallin D, et al. fMRI reveals distinct CNS processing during symptomatic and recovered complex regional pain syndrome in children. Brain 2008; 131:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/21\">",
"      Rommel O, Gehling M, Dertwinkel R, et al. Hemisensory impairment in patients with complex regional pain syndrome. Pain 1999; 80:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/22\">",
"      Ruggeri SB, Athreya BH, Doughty R, et al. Reflex sympathetic dystrophy in children. Clin Orthop Relat Res 1982; :225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/23\">",
"      Silber TJ. Anorexia nervosa and reflex sympathetic dystrophy syndrome. Psychosomatics 1989; 30:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/24\">",
"      Silber TJ. Eating disorders and reflex sympathetic dystrophy syndrome: is there a common pathway? Med Hypotheses 1997; 48:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/25\">",
"      de Rooij AM, de Mos M, Sturkenboom MC, et al. Familial occurrence of complex regional pain syndrome. Eur J Pain 2009; 13:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/26\">",
"      Higashimoto T, Baldwin EE, Gold JI, Boles RG. Reflex sympathetic dystrophy: complex regional pain syndrome type I in children with mitochondrial disease and maternal inheritance. Arch Dis Child 2008; 93:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/27\">",
"      Sandroni P, Benrud-Larson LM, McClelland RL, Low PA. Complex regional pain syndrome type I: incidence and prevalence in Olmsted county, a population-based study. Pain 2003; 103:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/28\">",
"      G&uuml;ler-Uysal F, Ba��aran S, Geertzen JH, G&ouml;nc&uuml; K. A 2 1/2-year-old girl with reflex sympathetic dystrophy syndrome (CRPS type I): case report. Clin Rehabil 2003; 17:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/29\">",
"      Jastaniah WA, Dobson S, Lugsdin JG, Petty RE. Complex regional pain syndrome after hepatitis B vaccine. J Pediatr 2003; 143:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/30\">",
"      Genc H, Karagoz A, Saracoglu M, et al. Complex regional pain syndrome type-I after rubella vaccine. Eur J Pain 2005; 9:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/31\">",
"      Kozin F, Haughton V, Ryan L. The reflex sympathetic dystrophy syndrome in a child. J Pediatr 1977; 90:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/32\">",
"      Goldsmith DP, Vivino FB, Eichenfield AH, et al. Nuclear imaging and clinical features of childhood reflex neurovascular dystrophy: comparison with adults. Arthritis Rheum 1989; 32:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/33\">",
"      Laxer RM, Allen RC, Malleson PN, et al. Technetium 99m-methylene diphosphonate bone scans in children with reflex neurovascular dystrophy. J Pediatr 1985; 106:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/34\">",
"      Tondeur M, Sand A, Ham H. Interobserver reproducibility in the interpretation of bone scans from patients suspected of having reflex sympathetic dystrophy. Clin Nucl Med 2005; 30:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/35\">",
"      Graif M, Schweitzer ME, Marks B, et al. Synovial effusion in reflex sympathetic dystrophy: an additional sign for diagnosis and staging. Skeletal Radiol 1998; 27:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/36\">",
"      Sch&uuml;rmann M, Zaspel J, L&ouml;hr P, et al. Imaging in early posttraumatic complex regional pain syndrome: a comparison of diagnostic methods. Clin J Pain 2007; 23:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/37\">",
"      Meier PM, Alexander ME, Sethna NF, et al. Complex regional pain syndromes in children and adolescents: regional and systemic signs and symptoms and hemodynamic response to tilt table testing. Clin J Pain 2006; 22:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/38\">",
"      Lightman HI, Pochaczevsky R, Aprin H, Ilowite NT. Thermography in childhood reflex sympathetic dystrophy. J Pediatr 1987; 111:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/39\">",
"      Dietz FR, Mathews KD, Montgomery WJ. Reflex sympathetic dystrophy in children. Clin Orthop Relat Res 1990; :225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/40\">",
"      Wesdock KA, Stanton RP, Singsen BH. Reflex sympathetic dystrophy in children. A physical therapy approach. Arthritis Care Res 1991; 4:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/41\">",
"      Lee BH, Scharff L, Sethna NF, et al. Physical therapy and cognitive-behavioral treatment for complex regional pain syndromes. J Pediatr 2002; 141:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/42\">",
"      Buchta RM. Reflex sympathetic dystrophy in a 14-year-old female. J Adolesc Health Care 1983; 4:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/43\">",
"      Wheeler DS, Vaux KK, Tam DA. Use of gabapentin in the treatment of childhood reflex sympathetic dystrophy. Pediatr Neurol 2000; 22:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/44\">",
"      Lalwani K, Shoham A, Koh JL, McGraw T. Use of oxcarbazepine to treat a pediatric patient with resistant complex regional pain syndrome. J Pain 2005; 6:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/45\">",
"      Low AK, Ward K, Wines AP. Pediatric complex regional pain syndrome. J Pediatr Orthop 2007; 27:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/46\">",
"      di Vadi PP, Brill S, Jack T, et al. Intravenous regional blocks with guanethidine and prilocaine combined with physiotherapy: two children with complex regional pain syndrome, type 1. Eur J Anaesthesiol 2002; 19:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/47\">",
"      Geertzen JH, Rietman JS, Smit AJ, Zimmerman KW. A young female patient with reflex sympathetic dystrophy of the upper limb in whom amputation became inevitable. Prosthet Orthot Int 1997; 21:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/48\">",
"      Krasna MJ, Jiao X, Sonett J, et al. Thoracoscopic sympathectomy. Surg Laparosc Endosc Percutan Tech 2000; 10:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/49\">",
"      Petje G, Radler C, Aigner N, et al. Treatment of reflex sympathetic dystrophy in children using a prostacyclin analog: preliminary results. Clin Orthop Relat Res 2005; :178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/50\">",
"      Tong HC, Nelson VS. Recurrent and migratory reflex sympathetic dystrophy in children. Pediatr Rehabil 2000; 4:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/51\">",
"      Wettrell G, Hallb&ouml;&ouml;k T, Hultquist C. Reflex sympathetic dystrophy in two young females. Acta Paediatr Scand 1979; 68:923.",
"     </a>",
"    </li>",
"    <li>",
"     Sherry DD. DVD: Amplified musculoskeletal pain in children. Diagnosis and treatment. A guide for physical and occupational therapists. www.childhoodrnd.org 2002. 46 minutes.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37768/abstract/53\">",
"      Zollinger PE, Tuinebreijer WE, Breederveld RS, Kreis RW. Can vitamin C prevent complex regional pain syndrome in patients with wrist fractures? A randomized, controlled, multicenter dose-response study. J Bone Joint Surg Am 2007; 89:1424.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6411 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-219.243.220.100-CF9D26F5DA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_56_37768=[""].join("\n");
var outline_f36_56_37768=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Childhood vs adult CRPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Local factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Role of the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Psychologic issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Genetic predisposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Autonomic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Sleep disturbances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Psychologic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Blood tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Physical and occupational therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Psychologic and behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Pain-reducing procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6411\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6411|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/58/23458\" title=\"figure 1\">",
"      CRPS child hand",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6411|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/38/5732\" title=\"picture 1\">",
"      CRPS child foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/43/12977\" title=\"picture 2\">",
"      CRPS dystrophic skin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/56/35717?source=related_link\">",
"      Classification of juvenile arthritis (JRA/JIA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32344?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33289?source=related_link\">",
"      Evaluation and diagnosis of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/11/38071?source=related_link\">",
"      Evaluation and management of suicidal behavior in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=related_link\">",
"      Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/17/9490?source=related_link\">",
"      Patient information: Complex regional pain syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6122?source=related_link\">",
"      Prevention and management of complex regional pain syndrome in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_56_37769="Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors";
var content_f36_56_37769=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/56/37769/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/56/37769/contributors\">",
"     Thomas F DeLaney, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/56/37769/contributors\">",
"     Francis J Hornicek, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/56/37769/contributors\">",
"     Henry J Mankin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/56/37769/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/56/37769/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/56/37769/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/56/37769/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/56/37769/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/56/37769/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ewing sarcoma (ES) and peripheral primitive neuroectodermal tumor (PNET, previously called peripheral neuroepithelioma) were originally described in the early 1900s as distinct clinicopathologic entities. It became evident that these entities are actually part of a spectrum of neoplastic diseases known as the Ewing sarcoma family of tumors (EFT), which also includes extraosseous ES (EES), PNET, malignant small-cell tumor of the thoracopulmonary region (Askin's tumor), and atypical ES. Because of their similar histologic and immunohistochemical characteristics and shared nonrandom chromosomal translocations, these tumors are considered to be derived from a common cell of origin. Although the histogenetic origin has been debated over the years, increasing evidence from immunohistochemical, cytogenetic, and molecular genetic studies supports a mesenchymal progenitor cell origin for all EFT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7770?source=see_link\">",
"     \"Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24490?source=see_link&amp;anchor=H44#H44\">",
"     \"Diseases of the chest wall\", section on 'Malignant neoplasms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The EFT can develop in almost any bone or soft tissue, but is most common in the pelvis, axial skeleton, and femur; patients typically present with localized pain and swelling. Although overt metastatic disease is found in fewer than 25 percent at the time of diagnosis, subclinical metastatic disease is presumed to be present in nearly all patients because of the 80 to 90 percent relapse rate in patients undergoing local therapy alone. As a result, systemic chemotherapy has evolved as an important component of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advances in multidisciplinary management of EFT over the past 30 years have resulted in a marked improvement in survival and a greater likelihood of limb-sparing surgery rather than amputation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37690?source=see_link\">",
"     \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\"",
"    </a>",
"    .) In data derived from the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute, five year survival rates for patients with ES rose from 36 to 56 percent during the periods 1975 to 1984 and 1985 to 1994 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/3\">",
"     3",
"    </a>",
"    ]. With modern multidisciplinary treatment, long-term survival can be achieved in 70 to 80 percent of patients presenting with nonmetastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/4,5,7\">",
"     4,5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Here we will discuss the clinical presentation, diagnosis, and staging of EFT. The epidemiology, pathology, molecular genetics, and treatment of these tumors, principles underlying the performance of a diagnostic bone biopsy, and central (supratentorial) PNET are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7770?source=see_link\">",
"     \"Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35673?source=see_link\">",
"     \"Bone tumors: Diagnosis and biopsy techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14122?source=see_link\">",
"     \"Treatment of the Ewing sarcoma family of tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/47/25338?source=see_link\">",
"     \"Radiation therapy for Ewing sarcoma family of tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35946?source=see_link&amp;anchor=H20#H20\">",
"     \"Uncommon brain tumors\", section on 'Supratentorial primitive neuroectodermal tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Primary sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;EFT most often arises in the long bones of the extremities (predominantly the femur, but also the tibia, fibula and humerus), and the bones of the pelvis. The spine, hands, and feet are affected considerably less often [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In a compilation of data from 975 patients from the European Intergroup Cooperative Ewing Sarcoma Studies (EI-CESS) trials, the distribution of primary sites was as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Axial skeleton &ndash; 54 percent (pelvis 25 percent, ribs 12 percent, spine 8 percent, scapula 3.8 percent, skull 3.8 percent, clavicle 1.2 percent)",
"     </li>",
"     <li>",
"      Appendicular skeleton &ndash; 42 percent (femur 16.4 percent, fibula 6.7 percent, tibia 7.6 percent, humerus 4.8 percent, foot 2.4 percent, radius 1.9 percent, and hand 1.2 percent)",
"     </li>",
"     <li>",
"      Other bones &ndash; 0.7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A minority of Ewing sarcomas arise in soft tissue. Compared to undifferentiated ES of bone, patients with extraosseous Ewing sarcomas (EES) are more frequently older, more likely to be female, and arise more often within the axial rather than the appendicular skeleton [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/8,10-12\">",
"     8,10-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with EFT typically present with localized pain or swelling of a few weeks or months duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Trauma, often minor, may be the initiating event that calls attention to the lesion. The pain may be mild at first, but intensifies fairly rapidly; it may be aggravated by exercise and is often worse at night. A distinct soft tissue mass can sometimes be appreciated. When present, it is usually firmly attached to the bone and moderately to markedly tender to palpation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Swelling of the affected limb with erythema over the mass is not uncommon.",
"   </p>",
"   <p>",
"    Patients with juxta-articular lesions may present with loss of joint motion, while lesions involving the ribs can be associated with direct pleural extension and large extraosseous masses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/18\">",
"     18",
"    </a>",
"    ]. When the spine or sacrum is involved, nerve root irritation or compression can result in back pain, radiculopathy, or symptoms of spinal cord compression (eg, weakness or loss of bowel",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bladder control). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6585?source=see_link\">",
"     \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Constitutional symptoms or signs, such as fever, fatigue, weight loss, or anemia, are present in about 10 to 20 percent of patients at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/13\">",
"     13",
"    </a>",
"    ]. Fever is related to cytokines produced by the tumor cells, and along with other systemic symptoms, is associated with advanced disease.",
"   </p>",
"   <p>",
"    Approximately 80 percent of patients present with clinically localized disease, although as noted previously, subclinical metastatic disease is presumed to be present in nearly all. Overt metastases may become evident within weeks to months in the absence of effective therapy. The significance of this lies in the frequent delay between the onset of symptoms and diagnosis, which in one report averaged over nine months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/15,19\">",
"     15,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with primary pelvic tumors are significantly more likely to present with metastatic disease compared to other sites (25 versus 16 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/9\">",
"     9",
"    </a>",
"    ]. Other factors that may be associated with clinically evident metastatic disease at presentation include high level of lactic dehydrogenase (LDH), the presence of fever, an interval between onset of symptoms and diagnosis less than three months, and age older than 12 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/20\">",
"     20",
"    </a>",
"    ]. In one series, the rate of metastatic disease at presentation in the subset of patients with none of these risk factors was only 4 percent with two factors it was 23 percent, while it was almost double (44 percent) if three or four factors were present.",
"   </p>",
"   <p>",
"    Sites of metastatic disease at diagnosis are similar to those seen with recurrent disease; lung and",
"    <span class=\"nowrap\">",
"     bone/bone",
"    </span>",
"    marrow metastases predominate, in roughly equal proportions. The spine is the most frequently involved bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Lung metastases represent the first site of distant spread in 70 to 80 percent of cases, and are the leading cause of death for patients with EFT. Lymph node, liver, and brain involvement are distinctly uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/14,23\">",
"     14,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     STAGING EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of the initial evaluation are to establish the diagnosis, evaluate local disease extent, and determine the presence and sites of metastatic spread. Clinical staging includes all of the data obtained prior to definitive therapy, including the results of imaging, laboratory studies, physical examination, and tissue biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiographic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic work-up is usually initiated with a plain radiograph of the affected area. ES involving bone typically presents as a poorly marginated destructive lesion, most often associated with a soft tissue mass. The tumors tend to be large, and in long bones are metaphyseal or diaphyseal in location (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62643 \" href=\"mobipreview.htm?39/49/40734\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef50795 \" href=\"mobipreview.htm?13/34/13864\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The radiographic appearance has been described as \"permeative\" or \"moth-eaten\", indicative of a series of finely destructive lesions that become confluent over time. The cortex at the site of the lesion is often expanded, and the periosteum displaced by the underlying tumor, resulting in the clinical sign of Codman's triangle. The characteristic periosteal reaction produces layers of reactive bone, deposited in an \"onion peel\" appearance (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61818 \" href=\"mobipreview.htm?17/0/17408\">",
"     image 2",
"    </a>",
"    ). The soft tissue component of the tumor rarely shows any calcification or ossification. Sclerosis, if present, represents a secondary bone reaction rather than the primary bone formation that characterizes osteosarcoma. A pathologic fracture is present at diagnosis in 10 to 15 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/13,15\">",
"     13,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared to plain radiographs, a CT scan of the primary site better delineates the extent of cortical destruction and soft tissue disease (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56503 \" href=\"mobipreview.htm?11/56/12162\">",
"     image 3",
"    </a>",
"    ). A multi-institutional study of 387 patients that included both children and adults concluded that CT and MRI were equally accurate for local staging of bone and soft tissue tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/24\">",
"     24",
"    </a>",
"    ]. However, MRI is preferred in most cases because of its superior definition of tumor size, local intraosseous and extraosseous extent, and the relationship of the tumor to fascial planes, vessels, nerves, and organs (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64832 \" href=\"mobipreview.htm?20/38/21093\">",
"     image 4",
"    </a>",
"    ). Imaging of the entire involved bone is necessary to exclude the presence of skip lesions (ie, medullary disease within the same bone, but not in direct contiguity with the primary lesion).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For EFT presenting as primary bone tumors, the differential diagnosis includes both benign and malignant conditions. The most common nonmalignant possibility is subacute osteomyelitis, which may present similarly (especially the presence of fever and an elevated sedimentation rate), and be associated with intense radiotracer uptake on bone scan and a soft tissue mass on other imaging studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/25\">",
"     25",
"    </a>",
"    ]. Aspiration of a tumor may yield purulent-appearing material; however, it will be sterile on culture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42726?source=see_link\">",
"     \"Hematogenous osteomyelitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    \"Benign\" bone tumors that can present as lytic lesions include eosinophilic granuloma and giant cell tumor of bone. Destructive eosinophilic granulomas usually occur at a younger age and are not associated with a sizable soft tissue mass.",
"   </p>",
"   <p>",
"    Malignant tumors that should be considered in the differential include other common solid tumors of childhood, including osteosarcoma, primary lymphoma of bone, malignant fibrous histiocytoma of bone (spindle cell sarcoma), acute leukemia, and metastasis from a non-bone tumor, particularly neuroblastoma (",
"    <a class=\"graphic graphic_table graphicRef81481 \" href=\"mobipreview.htm?41/39/42620\">",
"     table 1",
"    </a>",
"    ). A primarily lytic osteosarcoma may be difficult to distinguish from Ewing sarcoma on imaging studies. Most often, however, osteosarcoma is located in the metaphysis and usually has a rim of bone formation, which is very uncommon in ES. Primary lymphoma of bone occurs in an older age group, and is generally associated with less bone destruction than ES. Chondrosarcoma is uncommon in this age group; furthermore, the soft tissue mass usually contains calcifications.",
"   </p>",
"   <p>",
"    EES and soft tissue PNETs must be distinguished from a variety of benign and malignant soft tissue tumors (",
"    <a class=\"graphic graphic_table graphicRef78933 graphicRef59405 graphicRef68105 \" href=\"mobipreview.htm?9/38/9839\">",
"     table 2A-C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H12227065#H12227065\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Metastatic work-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for imaging studies in patients with EFT are available from the Children&rsquo;s Oncology Group Bone Tumor Committee (",
"    <a class=\"graphic graphic_table graphicRef68393 \" href=\"mobipreview.htm?23/22/23917\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    The metastatic work-up should include a CT scan of the chest to evaluate the thorax for metastatic disease. Criteria to guide the evaluation of suspected pulmonary metastases are available from the Children&rsquo;s Oncology Group that were adopted from the European Ewing Tumor Working Group Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G 99) (",
"    <a class=\"graphic graphic_table graphicRef78727 \" href=\"mobipreview.htm?25/25/26011\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radionuclide bone scan is recommended to evaluate the entire skeleton for the presence of multiple lesions.",
"   </p>",
"   <p>",
"    The utility of PET or integrated PET-CT for initial staging is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/29-34\">",
"     29-34",
"    </a>",
"    ]. At least three series note better sensitivity for PET over bone scan or other conventional imaging modalities for detection of bone metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/32,34,35\">",
"     32,34,35",
"    </a>",
"    ]. However, one potential problem is that because integrated PET-CT scanning usually scans from the neck through the femurs, the bones are not all visualized as they would with a bone scan. PET has not yet replaced radionuclide bone scan for initial staging at many institutions. In contrast to the situation with bone metastases, the sensitivity of PET for detection of lung metastases appears to be lower than that of thoracic CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], although integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    is superior to CT alone in this regard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PET may have greater utility for monitoring the response to chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy (particularly neoadjuvant chemotherapy), and in the postoperative evaluation for possible recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/37\">",
"     37",
"    </a>",
"    ]. Nevertheless, PET or",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    is increasingly used for the initial staging of patients with Ewing sarcoma. Consensus-based guidelines from the National Comprehensive Cancer Network recommend a PET scan",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bone scan for initial workup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/38\">",
"     38",
"    </a>",
"    ], and a baseline PET is recommended at presentation by the Children&rsquo;s Oncology Group, if the primary bone tumor is negative on bone scintigraphy (",
"    <a class=\"graphic graphic_table graphicRef68393 \" href=\"mobipreview.htm?23/22/23917\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24919346\">",
"    <span class=\"h3\">",
"     Staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;No commonly used staging systems exist for EFT as they do for other solid tumors. Although there are tumor, node, and metastasis (TNM) staging systems for primary tumors of both bone (",
"    <a class=\"graphic graphic_table graphicRef62124 \" href=\"mobipreview.htm?25/43/26301\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/39,40\">",
"     39,40",
"    </a>",
"    ] and soft tissue (",
"    <a class=\"graphic graphic_table graphicRef66617 \" href=\"mobipreview.htm?23/13/23773\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/41\">",
"     41",
"    </a>",
"    ] available from the Musculoskeletal Tumor Society and the American Joint Committee on Cancer",
"    <span class=\"nowrap\">",
"     (AJCC)/International",
"    </span>",
"    Union Against Cancer (UICC), they are not in widespread use for EFT. An obvious deficiency of these staging systems is that they do not specify the primary site, which is one of the most important prognostic factors (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Prognostic factors'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In addition, at least for soft tissue tumors, features of primary tumor classification in the 2002 edition (",
"    <a class=\"graphic graphic_table graphicRef69154 \" href=\"mobipreview.htm?10/30/10733\">",
"     table 7",
"    </a>",
"    ) are not maintained in the 2010 version. Specifically, the inclusion of both superficial and deep tumors within the same prognostic groups for tumors of the same size eliminates a criterion that previously stratified patient risk, without supporting data to suggest it is unnecessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H351701269#H351701269\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial laboratory studies should include a complete blood count, serum chemistries, and lactate dehydrogenase (LDH), which is a known prognostic factor in patients with EFT (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Prognostic factors'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/9,42,43\">",
"     9,42,43",
"    </a>",
"    ]. For cases in which neuroblastoma is in the differential diagnosis, urine catecholamine levels may be useful, since they are elevated in neuroblastoma but normal in EFT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/15/14585?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of neuroblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Bone marrow aspirate and biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the predilection of EFT for spread to bone marrow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/44\">",
"     44",
"    </a>",
"    ], some clinicians advocate bone marrow biopsy (at least unilateral) in all patients to exclude widespread metastatic disease. Neither MRI nor bone scan are sufficient to evaluate the possibility of bone marrow metastases. Although MRI is sensitive to changes in the marrow, they are not specific. Any decrease in the marrow fat content may alter the signal, creating difficulty in differentiating tumor from active hematopoiesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Tumor biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The considerations for appropriate biopsy of a soft tissue or bone mass resemble those for other soft tissue and bone sarcomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35673?source=see_link\">",
"     \"Bone tumors: Diagnosis and biopsy techniques\"",
"    </a>",
"    .) The surgeon should be consulted",
"    <strong>",
"     before",
"    </strong>",
"    any biopsy is carried out, and the procedure should be carefully planned to obtain adequate diagnostic tissue without compromising a later operation, particularly the opportunity for limb salvage. Biopsies should take place after the completion of imaging studies of the primary site, and the surgeon, radiation oncologist, medical or pediatric oncologist, and pathologist should review these studies in detail so that each member of the team is fully informed of the diagnostic considerations.",
"   </p>",
"   <p>",
"    Adequate amounts of tissue are necessary in order to provide sufficient diagnostic material. The extensive pathologic evaluation that is often required to ascertain the correct diagnosis within the group of \"small round blue cell tumors\" means that tissue is usually needed for special studies, and these samples require special handling. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35673?source=see_link&amp;anchor=H21#H21\">",
"     \"Bone tumors: Diagnosis and biopsy techniques\", section on 'Specimen handling'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis is most often established by CT guided core-needle biopsy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56503 \" href=\"mobipreview.htm?11/56/12162\">",
"     image 3",
"    </a>",
"    ). If only necrotic material is obtained on core biopsy, an open biopsy may be required. In either case, specimens should be obtained for microbiology to rule out osteomyelitis (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Differential diagnosis'",
"    </a>",
"    above). Fine needle aspiration biopsy is not acceptable as the only diagnostic material, and should only be used to sample metastatic sites, or areas suspicious for recurrence when the histologic diagnosis is known. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35673?source=see_link&amp;anchor=H12#H12\">",
"     \"Bone tumors: Diagnosis and biopsy techniques\", section on 'Biopsy techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clinical and biologic characteristics can assist in defining prognosis and directing the intensity of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/45\">",
"     45",
"    </a>",
"    ]. These include the presence or absence of metastases, primary tumor location and size, age, the response to therapy, and the presence of certain chromosomal translocations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Disease extent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key prognostic factor in ES is the presence or absence of metastases. Approximate five-year survival rates for patients with localized disease are 70 percent, while they average 33 percent for those who have overt metastases at diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14122?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of the Ewing sarcoma family of tumors\", section on 'Treatment for localized disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14122?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of the Ewing sarcoma family of tumors\", section on 'Treatment for advanced disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The location of distant disease also impacts outcomes. In the European Intergroup experience, the five year relapse-free survival rates for patients with localized and metastatic disease at presentation were 55 and 21 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/9\">",
"     9",
"    </a>",
"    ] . Patients with bone and lung metastases fared significantly worse than those with bone metastases alone, who in turn, fared worse than those with isolated lung metastases. Approximately 30 percent of patients with metastases limited to the lungs will survive five years, as compared to only 10 percent of those with bone or bone marrow involvement.",
"   </p>",
"   <p>",
"    Patients with limited pulmonary metastases who are candidates for resection may have a reasonable opportunity for cure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14122?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of the Ewing sarcoma family of tumors\", section on 'Pulmonary metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Tumor site and size",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients presenting with localized disease, those with axial primary tumors (ie, pelvis, rib, spine, scapula, skull, clavicle, sternum) have a worse treatment outcome than those with extremity lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/9,46\">",
"     9,46",
"    </a>",
"    ]. In one series, the five year relapse-free survival rates were 40 versus 61 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, patients with small primary tumors (&lt;100 mL) fare better than those with larger tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/9,47\">",
"     9,47",
"    </a>",
"    ]. Fever, anemia, and elevated serum LDH all correlate with a greater volume of disease and a poorer prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/9,20,42,43\">",
"     9,20,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The poorer prognosis of large primary tumors, and those involving the pelvis and spine, is at least partly attributable to the difficulty in achieving wide negative resection margins, and higher rates of local failure after radiotherapy for large lesions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37690?source=see_link&amp;anchor=H14#H14\">",
"     \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\", section on 'Non-extremity lesions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/47/25338?source=see_link\">",
"     \"Radiation therapy for Ewing sarcoma family of tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extraosseous as compared to osseous origin does not have an adverse influence on survival. Origin has a significant adverse influence on outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/11,48,49\">",
"     11,48,49",
"    </a>",
"    ]. In fact, EFT that arise in skin or subcutaneous sites have a generally favorable prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/49-51\">",
"     49-51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with apparently localized disease have only a 10 to 20 percent likelihood of cure if treated with surgery or radiotherapy alone; this is improved dramatically when chemotherapy is added to treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14122?source=see_link\">",
"     \"Treatment of the Ewing sarcoma family of tumors\"",
"    </a>",
"    .) Both the completeness of surgical resection and the response to induction therapy are important prognostic factors. Patients who are left with significant amounts of viable tumor in the resected specimen following neoadjuvant chemotherapy do worse than those with minimal or no residual tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/9,52-55\">",
"     9,52-55",
"    </a>",
"    ]. These topics are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37690?source=see_link&amp;anchor=H27#H27\">",
"     \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\", section on 'Neoadjuvant chemotherapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/47/25338?source=see_link&amp;anchor=H7#H7\">",
"     \"Radiation therapy for Ewing sarcoma family of tumors\", section on 'Adjuvant RT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most but not all studies, the presence of neural differentiation (eg, as in PNETs) does not have an adverse influence on survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/10,56-58\">",
"     10,56-58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older age has been linked to a poor prognosis in some reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/59-61\">",
"     59-61",
"    </a>",
"    ], but not others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Younger children seem to have a better prognosis than older ones. As an example, in one report, the five-year relapse-free survival was significantly better for children younger than 10 compared to older children (86 versus 55 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The situation for adults is less clear. Although many series have reported a less favorable outcome in adults (particularly older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/59\">",
"     59",
"    </a>",
"    ]) as compared to children, a greater tumor bulk in adults or use of lower doses of alkylating agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/64\">",
"     64",
"    </a>",
"    ] may explain some of these observations. Others have noted that adults fare as well as children, particularly when full dose chemotherapy protocols are utilized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Molecular findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The EFT are characterized by distinct nonrandom chromosomal translocations, which all involve the Ewing sarcoma (EWS) gene on chromosome 22. These translocations result in the fusion of distinct genes on different chromosomes, and these fused genes then encode hybrid proteins, which are thought to be involved in tumorigenesis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7770?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors\", section on 'Molecular genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At least 18 different structural possibilities for gene fusions have been reported in these tumors. There are two sources of variability: the EWS fusion partner (eg, FLI1, ERG, ETV1, E1A, or FEV) and the breakpoint locations within the genes. This molecular heterogeneity may have some influence on the prognosis of EFT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/66-69\">",
"     66-69",
"    </a>",
"    ]. As an example, a better outcome has been reported for patients with localized tumors expressing the most common chimeric transcript (the so-called type I transcript in which EWS exon 7 is fused to FLI1 exon 6, which is present in about 60 percent of cases) compared to other fusion types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. However, more recent treatment protocols appear to have eliminated prognostic differences based upon fusion type [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies evaluating the prognostic significance of other cytogenetic and molecular alterations in EFT are limited. However, deletion of the short arm of chromosome 1p, homozygous deletions of CDKN2A and",
"    <span class=\"nowrap\">",
"     p16/p14ARF,",
"    </span>",
"    and p53 mutations have all been associated with poor response to chemotherapy and a worse prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/66,71,72\">",
"     66,71,72",
"    </a>",
"    ]. The association of genetic variants of EFT with clinically significant features will require further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Use of prognostic factors for treatment stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted previously, there is no widely accepted formal staging system for EFT. One of the most important uses of a staging system is to stratify patients for treatment purposes based upon expected outcome. Because of the very powerful prognostic power of the presence of metastatic disease, most studies in EFT have stratified patients by the presence or absence of metastatic disease. Although the primary site (ie, extremity versus pelvis or spine) also has prognostic significance, only a few studies have used site as the basis for determining the aggressiveness of therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14122?source=see_link\">",
"     \"Treatment of the Ewing sarcoma family of tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some investigators consider patients with localized disease, but who show features of poor prognosis, as \"advanced\" or \"high-risk\", grouping them for the purposes of treatment with others who have overt metastatic disease. The selection of treatment based upon individual prognostic factors is referred to as risk-adapted therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37769/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14122?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of the Ewing sarcoma family of tumors\", section on 'Treatment for advanced disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The data indicating prognostic differences among patients with varying fusion genes raise the possibility that heterogeneity in the structure of chimeric transcripts may also be used to define clinically distinct risk groups. As an example, a direct comparison between treatment response and EWS fusion type may reveal a role of certain chimeras in therapy resistance. However, prospective clinical studies are just beginning to be performed to address this hypothesis. Inclusion of EWS fusion-type determination into future clinical trials is appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/3/31794?source=see_link\">",
"       \"Patient information: Ewing sarcoma (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/63/33778?source=see_link\">",
"       \"Patient information: Bone cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30948226\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ewing sarcoma (ES) and peripheral primitive neuroectodermal tumors (PNET) comprise the same spectrum of neoplastic diseases known as the Ewing sarcoma family of tumors (EFT), which also includes malignant small-cell tumor of the chest wall (Askin tumor). Because of their similar histologic and immunohistochemical characteristics and shared nonrandom chromosomal translocations, these tumors are considered to be derived from a common cell of origin, although its histogenic origin is debated. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    EFT most often arises in the long bones of the extremities (predominantly the femur, but also the tibia, fibula and humerus), and the bones of the pelvis. The spine, hands, and feet are affected considerably less often. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Primary sites'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with EFT typically present with localized pain or swelling of a few weeks or months duration. Trauma, often minor, may be the initiating event that calls attention to the lesion. Constitutional symptoms or signs, such as fever, fatigue, weight loss, or anemia, are present in about 10 to 20 percent of patients at presentation. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Signs and symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The goals of the initial evaluation are to establish the diagnosis, evaluate local disease extent, and determine the presence and sites of metastatic spread. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Staging evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnostic work-up is usually initiated with a plain radiograph of the affected area. EFT involving bone typically presents as a poorly marginated destructive lesion with a permeative or &ldquo;moth-eaten&rdquo; appearance, most often associated with a soft tissue mass. While CT scan better delineates the extent of cortical destruction and soft tissue disease, definition of tumor size, local intraosseous and extraosseous extent, and the relationship of the tumor to fascial planes, vessels, nerves, and organs is best achieved by magnetic resonance imaging (MRI). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Radiographic studies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The metastatic work-up includes a CT scan of the chest to evaluate the thorax for metastatic disease, and a radionuclide bone scan to evaluate the entire skeleton for the presence of multiple lesions. PET or",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    is increasingly used for the initial staging and response assessment of EFT. Some clinicians advocate bone marrow biopsy (at least unilateral) in all patients to exclude widespread metastatic disease. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Metastatic work-up'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Bone marrow aspirate and biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A biopsy should be carefully planned to obtain adequate diagnostic tissue without compromising a later operation, particularly the opportunity for limb salvage. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Tumor biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Several clinical and biologic characteristics can assist in defining prognosis and directing the intensity of therapy. These include the presence or absence of metastases, primary tumor location and size, age, the response to therapy, and the presence of certain chromosomal translocations. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Prognostic factors'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/1\">",
"      Jedlicka P. Ewing Sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions. Int J Clin Exp Pathol 2010; 3:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/2\">",
"      Nesbit ME Jr, Gehan EA, Burgert EO Jr, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 1990; 8:1664.",
"     </a>",
"    </li>",
"    <li>",
"     Smith MAS, Gurney JG, Ries LA. Cancer in adolescents 15 to 19 years old. In: Cancer incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995, Pub #99-4649, Smith MAS, Gurney JG, Ries LA, et al (Eds), National Cancer Institute, Bethesda, MD 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/4\">",
"      J&uuml;rgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 1988; 61:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/5\">",
"      Grier H, Krailo M, Link M, et al. Improved outcome in non-metastatic Ewing's sarcoma (EWS) and PNET of bone with the addition of ifosfamide (I) and etoposide (E) to vincristine (V), Adriamycin (Ad), cyclophosphamide (C) and actinomycin (A): A Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) report (abstract). Proc Am Soc Clin Oncol 1994; 13:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/6\">",
"      Gatta G, Capocaccia R, Stiller C, et al. Childhood cancer survival trends in Europe: a EUROCARE Working Group study. J Clin Oncol 2005; 23:3742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/7\">",
"      Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol 2009; 27:2536.",
"     </a>",
"    </li>",
"    <li>",
"     Ginsberg JP, Woo SY, Hicks MJ, Horowitz ME. Ewing's sarcoma family of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. In: Priniciples and Practice of Pediatric Oncology, 4th, Pizzo PA, Poplack DG (Eds), Lippincott, Williams and Wilkins, Philadelphia 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/9\">",
"      Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000; 18:3108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/10\">",
"      Raney RB, Asmar L, Newton WA Jr, et al. Ewing's sarcoma of soft tissues in childhood: a report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991. J Clin Oncol 1997; 15:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/11\">",
"      Applebaum MA, Worch J, Matthay KK, et al. Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. Cancer 2011; 117:3027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/12\">",
"      Pradhan A, Grimer RJ, Spooner D, et al. Oncological outcomes of patients with Ewing's sarcoma: is there a difference between skeletal and extra-skeletal Ewing's sarcoma? J Bone Joint Surg Br 2011; 93:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/13\">",
"      Rud NP, Reiman HM, Pritchard DJ, et al. Extraosseous Ewing's sarcoma. A study of 42 cases. Cancer 1989; 64:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/14\">",
"      Parasuraman S, Langston J, Rao BN, et al. Brain metastases in pediatric Ewing sarcoma and rhabdomyosarcoma: the St. Jude Children's Research Hospital experience. J Pediatr Hematol Oncol 1999; 21:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/15\">",
"      Widhe B, Widhe T. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am 2000; 82:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/16\">",
"      Mendenhall CM, Marcus RB Jr, Enneking WF, et al. The prognostic significance of soft tissue extension in Ewing's sarcoma. Cancer 1983; 51:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/17\">",
"      Mankin HJ. Ewing sarcoma. Curr Opinion Ortho 2000; 11:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/18\">",
"      Askin FB, Rosai J, Sibley RK, et al. Malignant small cell tumor of the thoracopulmonary region in childhood: a distinctive clinicopathologic entity of uncertain histogenesis. Cancer 1979; 43:2438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/19\">",
"      Sneppen O, Hansen LM. Presenting symptoms and treatment delay in osteosarcoma and Ewing's sarcoma. Acta Radiol Oncol 1984; 23:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/20\">",
"      Ferrari S, Bertoni F, Mercuri M, et al. Ewing's sarcoma of bone: relation between clinical characteristics and staging. Oncol Rep 2001; 8:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/21\">",
"      Wilkins RM, Pritchard DJ, Burgert EO Jr, Unni KK. Ewing's sarcoma of bone. Experience with 140 patients. Cancer 1986; 58:2551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/22\">",
"      Miser JS, Krailo MD, Tarbell NJ, et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol 2004; 22:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/23\">",
"      Cangir A, Vietti TJ, Gehan EA, et al. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 1990; 66:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/24\">",
"      Panicek DM, Gatsonis C, Rosenthal DI, et al. CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: Report of the Radiology Diagnostic Oncology Group. Radiology 1997; 202:237.",
"     </a>",
"    </li>",
"    <li>",
"     Campanacci M. Bone and Soft Tissue Tumors, 2nd, Springer Verlag, New York 1999. p.653.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/26\">",
"      Meyer JS, Nadel HR, Marina N, et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 2008; 51:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/27\">",
"      Juergens C, Weston C, Lewis I, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 2006; 47:22.",
"     </a>",
"    </li>",
"    <li>",
"     Protocol information available online at file://clinicaltrials.gov/ct2/show/NCT00020566?term=EURO+Ewing+99&amp;rank=1 (Accessed on June 30, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/29\">",
"      Hawkins DS, Rajendran JG, Conrad EU 3rd, et al. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer 2002; 94:3277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/30\">",
"      Franzius C, Sciuk J, Brinkschmidt C, et al. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med 2000; 25:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/31\">",
"      McCarville MB, Christie R, Daw NC, et al. PET/CT in the evaluation of childhood sarcomas. AJR Am J Roentgenol 2005; 184:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/32\">",
"      V&ouml;lker T, Denecke T, Steffen I, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007; 25:5435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/33\">",
"      Franzius C, Daldrup-Link HE, Sciuk J, et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 2001; 12:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/34\">",
"      Gy&ouml;rke T, Zajic T, Lange A, et al. Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours. Nucl Med Commun 2006; 27:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/35\">",
"      Franzius C, Sciuk J, Daldrup-Link HE, et al. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 2000; 27:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/36\">",
"      Kleis M, Daldrup-Link H, Matthay K, et al. Diagnostic value of PET/CT for the staging and restaging of pediatric tumors. Eur J Nucl Med Mol Imaging 2009; 36:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/37\">",
"      Hawkins DS, Schuetze SM, Butrynski JE, et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 2005; 23:8828.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer NEtwork (NCCN) guidelines available online at www.nccn.org (Accessed on June 30, 2011).",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.281.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/40\">",
"      Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res 1986; :9.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.291.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/42\">",
"      Glaubiger DL, Makuch R, Schwarz J, et al. Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma. Cancer 1980; 45:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/43\">",
"      Bacci G, Capanna R, Orlandi M, et al. Prognostic significance of serum lactic acid dehydrogenase in Ewing's tumor of bone. Ric Clin Lab 1985; 15:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/44\">",
"      Oberlin O, Bayle C, Hartmann O, et al. Incidence of bone marrow involvement in Ewing's sarcoma: value of extensive investigation of the bone marrow. Med Pediatr Oncol 1995; 24:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/45\">",
"      Terrier P, Llombart-Bosch A, Contesso G. Small round blue cell tumors in bone: prognostic factors correlated to Ewing's sarcoma and neuroectodermal tumors. Semin Diagn Pathol 1996; 13:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/46\">",
"      Rodr&iacute;guez-Galindo C, Liu T, Krasin MJ, et al. Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer 2007; 110:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/47\">",
"      Barbieri E, Emiliani E, Zini G, et al. Combined therapy of localized Ewing's sarcoma of bone: analysis of results in 100 patients. Int J Radiat Oncol Biol Phys 1990; 19:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/48\">",
"      Perotti D, Corletto V, Giardini R, et al. Retrospective analysis of ploidy in primary osseous and extraosseous Ewing family tumors in children. Tumori 1998; 84:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/49\">",
"      Shannon Orr W, Denbo JW, Billups CA, et al. Analysis of prognostic factors in extraosseous Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital experience. Ann Surg Oncol 2012; 19:3816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/50\">",
"      Chow E, Merchant TE, Pappo A, et al. Cutaneous and subcutaneous Ewing's sarcoma: an indolent disease. Int J Radiat Oncol Biol Phys 2000; 46:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/51\">",
"      Lee CS, Southey MC, Slater H, et al. Primary cutaneous Ewing's sarcoma/peripheral primitive neuroectodermal tumors in childhood. A molecular, cytogenetic, and immunohistochemical study. Diagn Mol Pathol 1995; 4:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/52\">",
"      Paulussen M, Ahrens S, Dunst J, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 2001; 19:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/53\">",
"      Rosito P, Mancini AF, Rondelli R, et al. Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: a preliminary report of 6 years of experience. Cancer 1999; 86:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/54\">",
"      Wunder JS, Paulian G, Huvos AG, et al. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am 1998; 80:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/55\">",
"      Oberlin O, Deley MC, Bui BN, et al. Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer 2001; 85:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/56\">",
"      J&uuml;rgens H, Bier V, Harms D, et al. Malignant peripheral neuroectodermal tumors. A retrospective analysis of 42 patients. Cancer 1988; 61:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/57\">",
"      Bacci G, Ferrari S, Bertoni F, et al. Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the istituto rizzoli. J Clin Oncol 2000; 18:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/58\">",
"      Parham DM, Hijazi Y, Steinberg SM, et al. Neuroectodermal differentiation in Ewing's sarcoma family of tumors does not predict tumor behavior. Hum Pathol 1999; 30:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/59\">",
"      Baldini EH, Demetri GD, Fletcher CD, et al. Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome. Ann Surg 1999; 230:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/60\">",
"      Craft A, Cotterill S, Malcolm A, et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol 1998; 16:3628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/61\">",
"      Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/62\">",
"      Bacci G, Ferrari S, Comandone A, et al. Neoadjuvant chemotherapy for Ewing's sarcoma of bone in patients older than thirty-nine years. Acta Oncol 2000; 39:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/63\">",
"      Fizazi K, Dohollou N, Blay JY, et al. Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol 1998; 16:3736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/64\">",
"      Gupta AA, Pappo A, Saunders N, et al. Clinical outcome of children and adults with localized Ewing sarcoma: impact of chemotherapy dose and timing of local therapy. Cancer 2010; 116:3189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/65\">",
"      Verrill MW, Judson IR, Wiltshaw E, et al. The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours. Ann Oncol 1997; 8:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/66\">",
"      Hattinger CM, Rumpler S, Strehl S, et al. Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors. Genes Chromosomes Cancer 1999; 24:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/67\">",
"      Zoubek A, Dockhorn-Dworniczak B, Delattre O, et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 1996; 14:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/68\">",
"      de Alava E, Kawai A, Healey JH, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998; 16:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/69\">",
"      Lin PP, Brody RI, Hamelin AC, et al. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. Cancer Res 1999; 59:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/70\">",
"      van Doorninck JA, Ji L, Schaub B, et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2010; 28:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/71\">",
"      de Alava E, Antonescu CR, Panizo A, et al. Prognostic impact of P53 status in Ewing sarcoma. Cancer 2000; 89:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37769/abstract/72\">",
"      Huang HY, Illei PB, Zhao Z, et al. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 2005; 23:548.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7744 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-D60132E406-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_56_37769=[""].join("\n");
var outline_f36_56_37769=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30948226\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Primary sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      STAGING EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiographic studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Metastatic work-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24919346\">",
"      - Staging system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Bone marrow aspirate and biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Tumor biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Disease extent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tumor site and size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Response to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Molecular findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Use of prognostic factors for treatment stratification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30948226\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7744\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7744|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?39/49/40734\" title=\"diagnostic image 1\">",
"      Ewings sarcoma left tibia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?17/0/17408\" title=\"diagnostic image 2\">",
"      Radiograph onion skinning Ewing sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/56/12162\" title=\"diagnostic image 3\">",
"      CT guided biopsy Ewing sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/38/21093\" title=\"diagnostic image 4\">",
"      MRI appearance Ewing sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7744|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/34/13864\" title=\"figure 1\">",
"      Bone tumor locations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7744|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/39/42620\" title=\"table 1\">",
"      Classify primary malignant bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/41/7837\" title=\"table 2A\">",
"      Histolog classification STS I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/30/11757\" title=\"table 2B\">",
"      Histolog classification STS II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/41/11933\" title=\"table 2C\">",
"      Histolog classification STS III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/22/23917\" title=\"table 3\">",
"      Imaging guidelines from COG for Ewing family of tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/25/26011\" title=\"table 4\">",
"      Criteria for pulmonary metastatic disease in Ewings sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/43/26301\" title=\"table 5\">",
"      TNM staging bone tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/13/23773\" title=\"table 6\">",
"      2010 TNM staging STS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/30/10733\" title=\"table 7\">",
"      2002 AJCC staging of STS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37690?source=related_link\">",
"      Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35673?source=related_link\">",
"      Bone tumors: Diagnosis and biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6585?source=related_link\">",
"      Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24490?source=related_link\">",
"      Diseases of the chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/15/14585?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7770?source=related_link\">",
"      Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42726?source=related_link\">",
"      Hematogenous osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/63/33778?source=related_link\">",
"      Patient information: Bone cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/3/31794?source=related_link\">",
"      Patient information: Ewing sarcoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/47/25338?source=related_link\">",
"      Radiation therapy for Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14122?source=related_link\">",
"      Treatment of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35946?source=related_link\">",
"      Uncommon brain tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_56_37770="In vitro fertilization";
var content_f36_56_37770=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   In vitro fertilization",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/56/37770/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/56/37770/contributors\">",
"     Richard Paulson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/56/37770/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/56/37770/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/56/37770/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/56/37770/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/56/37770/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro fertilization (IVF) refers to a procedure designed to overcome infertility and produce a pregnancy as a direct result of the intervention. In general, the ovaries are stimulated by a combination of fertility medications and then one or more oocyte(s) are aspirated from ovarian follicles. These are fertilized in the laboratory (\"in vitro\"), after which, one or more embryo(s) are transferred into the uterine cavity. These steps occur over about a two-week interval of time, which is called an IVF cycle.",
"   </p>",
"   <p>",
"    The first pregnancy after the fertilization of a human egg in vitro and the first birth from an in vitro-fertilized embryo were reported more than three decades ago [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Since then, more than four million pregnancies have been achieved worldwide by IVF and its modifications (",
"    <a class=\"graphic graphic_table graphicRef72805 \" href=\"mobipreview.htm?41/63/43003\">",
"     table 1",
"    </a>",
"    ), known generically as assisted reproductive technologies (ARTs). As experience has accumulated, success rates have increased, and the indications for these procedures have expanded, ART now accounts for 1 to 3 percent of live births in the United States and Europe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete infertility evaluation should be performed on both partners prior to embarking on IVF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3367?source=see_link\">",
"     \"Causes of female infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40921?source=see_link\">",
"     \"Evaluation of female infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33481?source=see_link\">",
"     \"Evaluation of male infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial experience with IVF involved women with tubal disease that could not be surgically corrected. With its efficacy established, IVF has been made available to women with other causes of infertility, including one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tubal factor (IVF is primary therapy if tubes are completely blocked)",
"     </li>",
"     <li>",
"      Severe male factor infertility (mild male factor may be treated with inseminations; if male factor is severe, IVF is primary therapy of choice)",
"     </li>",
"     <li>",
"      Diminished ovarian reserve (time to conception is critical and success with other therapies is low)",
"     </li>",
"     <li>",
"      All other causes of infertility, after failing treatment with less invasive therapies (eg, ovulatory dysfunction, endometriosis, unexplained infertility)",
"     </li>",
"     <li>",
"      Ovarian failure (although donor eggs must be used in this case)",
"     </li>",
"     <li>",
"      Uterine factor (if severe, such as Asherman syndrome or irreparable distortion of the uterine cavity, gestational surrogacy may be needed in conjunction with IVF)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disadvantages of IVF include the high cost, the need for procedures and drugs associated with some risk to the woman, an increased rate of multiple gestation (which accounts for much of the direct cost of pregnancies conceived via IVF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/3\">",
"     3",
"    </a>",
"    ]), and possibly a slight increase in fetal complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/6/2154?source=see_link\">",
"     \"Pregnancy outcome after assisted reproductive technology\"",
"    </a>",
"    .) Therefore, alternative treatment options, including observation, should be considered when counseling women with open fallopian tubes and without severe male factor infertility. Although such women may have some indications for IVF (eg, pelvic disease, endometriosis, unexplained fertility, failed",
"    <span class=\"nowrap\">",
"     gonadotropin/intrauterine",
"    </span>",
"    insemination therapy), they also have substantial treatment-independent pregnancy rates (see",
"    <a class=\"local\" href=\"#H27\">",
"     'Outcome'",
"    </a>",
"    below). In young women, treatable causes of subfertility should be treated prior to initiating IVF because treatment may enhance the likelihood of natural conception. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/5/14425?source=see_link\">",
"     \"Overview of treatment of female infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, in the absence of absolute impediments for conception (blocked fallopian tubes, severe male factor), couples may be offered three to six cycles of superovulation and intrauterine insemination (IUI) before proceeding to IVF. A reasonable course when counseling young couples with no clear block to conception is to complete a total of one year of unprotected intercourse and one year of conventional treatment, since conception is quite likely during this time (about 85 percent conceive during the first year and a further 50 percent during the second year). A shorter period is generally used in older couples, as conventional treatment is less successful and time plays a much greater role in the probability of conception. It is not unreasonable to offer IVF as a primary treatment option to couples with the female partner over 40 years of age (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Younger maternal age'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    IVF has also been used to achieve pregnancy in gestational carriers of women who do not have a uterus or in whom pregnancy is medically contraindicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15015?source=see_link\">",
"     \"Surrogate pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pre-cycle factors associated with success",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several preprocedure factors can affect the success of IVF (age, infertility diagnosis, past reproductive-obstetrical history) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Younger maternal age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average age of women undergoing ART in the US is 36 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/5\">",
"     5",
"    </a>",
"    ]. The major determinant of the success of IVF is the age of the woman. Although IVF may largely overcome infertility in younger women, it does not reverse the age-dependent decline in fertility in older women, particularly those over 40 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. In 2009, the percentage of cycles using fresh nondonor embryos that resulted in a live birth by maternal age was as follows: younger than 35 (41.2 percent), 35 to 37 (31.6 percent), 38 to 40 (22.3 percent), 41 to 42 (12.4 percent), and 43 to 44 (4.9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This decrease in success parallels that with other forms of fertility treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/7\">",
"     7",
"    </a>",
"    ]. In IVF, the diminished success is due both to decreased ovarian responsiveness to gonadotropin stimulation, resulting in a decreased number of oocytes available for IVF, and a decreased implantation rate per embryo transferred due to poor egg quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In addition, the risk of spontaneous abortion is significantly higher in older women.",
"   </p>",
"   <p>",
"    The upper limit for performing IVF without donor eggs is controversial and varies by site, but typically ranges from 41 to 45 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/10\">",
"     10",
"    </a>",
"    ]. In one series in which IVF with autologous eggs was attempted in women aged 45 to 49 years, 70 of 231 (30 percent) had their cycle cancelled before retrieval, the overall pregnancy rate per retrieval was 21 percent (34 of 161), but only 5 of the 34 pregnancies resulted in live born delivery and all of these were in women 45 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/11\">",
"     11",
"    </a>",
"    ]. The live birth rate per cycle initiated was 5 of 231 (2.1 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31865?source=see_link\">",
"     \"Effect of advanced age on fertility and pregnancy in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Adequate ovarian reserve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum follicle stimulating hormone (FSH) and estradiol concentrations may help predict the success of the IVF procedure. A high day 3 level is a poor prognostic factor.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated serum FSH concentrations in the early follicular phase (cycle day three) are associated with a poor prognosis for pregnancy after IVF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/12\">",
"       12",
"      </a>",
"      ]. However, a single measurement may not be sufficient since FSH concentrations fluctuate from cycle to cycle. In one study addressing this issue, 6 percent of women with one elevated day three serum FSH value (&gt;20",
"      <span class=\"nowrap\">",
"       mIU/mL)",
"      </span>",
"      and several normal values subsequently became pregnant after IVF, whereas no woman with high serum FSH values on two or more occasions later became pregnant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/13\">",
"       13",
"      </a>",
"      ]. Others have reported similar findings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/14\">",
"       14",
"      </a>",
"      ]. A meta-analysis of 21 studies concluded that basal FSH as a screening test to predict either poor ovarian response or nonpregnancy had clinical value only in women with extremely high FSH concentrations for any given assay [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/15\">",
"       15",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The utility of this test is limited by the lack of standardization of FSH assays. There is as much as a three-fold difference between FSH measurements on the same serum samples with different FSH assays [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/16\">",
"       16",
"      </a>",
"      ]. As a result, marginally elevated serum FSH levels must be interpreted in the context of a given assay, and individual programs must evaluate their own outcomes in the face of specific FSH values in order to appropriately counsel patients. However, very high levels (two or more times the upper range of normal for a given assay) have high negative predictive value.",
"     </li>",
"     <li>",
"      High day three serum estradiol concentrations are also associated with a poor pregnancy outcome after IVF because they appear to be associated with rapid premature follicle recruitment and reduced oocyte numbers. In one report, no pregnancies occurred in women with a serum estradiol concentration above 75",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (275",
"      <span class=\"nowrap\">",
"       pmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/17\">",
"       17",
"      </a>",
"      ]. As with FSH measurements, estradiol levels vary widely with different assays and must be interpreted accordingly. A high serum estradiol level does not appear to have the same negative prognostic value during subsequent cycles as that associated with high FSH levels on day 3.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We measure serum FSH and estradiol on cycle day 3 (third day of menstrual bleeding) in all women over the age of 35 years who are contemplating IVF, and we do not start IVF cycles in those with serum FSH concentrations &gt;20",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    or serum estradiol concentrations &gt;100",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (367",
"    <span class=\"nowrap\">",
"     pmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    A variety of other tests are available for measurement of ovarian reserve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/18\">",
"     18",
"    </a>",
"    ]. Other centers may use one of the following tests to help in selecting women who are likely to have a poor response to IVF:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    challenge test (CCCT), ultrasound assessment of antral follicle count or ovarian volume, exogenous FSH ovarian reserve test (EFORT), or measurement of inhibin B or anti-M&uuml;llerian hormone (AMH) levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/19-28\">",
"     19-28",
"    </a>",
"    ]. No one test has been proven superior to the others.",
"   </p>",
"   <p>",
"    For the ultrasound-based tests, a systematic review concluded that an abnormally low antral follicle count was a better predictor of poor response than ovarian volume, but neither ultrasound-based test was highly predictive of a low chance of pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/25\">",
"     25",
"    </a>",
"    ]. Measurement of day 3 FSH and estradiol levels have the advantage of simplicity and cost effectiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/20\">",
"     20",
"    </a>",
"    ]. Virtually all ART programs perform some type of ovarian reserve testing; however, the value of performing any of these tests has been questioned, given their limitations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/18,29\">",
"     18,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the values of repeated FSH measurements are high, other forms of therapy (eg, oocyte donation) should be considered. There appears to be no age-related decline in fertility when oocyte donation is used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24807?source=see_link\">",
"     \"Oocyte donation for assisted reproduction\"",
"    </a>",
"    .) Younger women who have a poor ovarian response to exogenous gonadotropins should also be tested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Absence of hydrosalpinges",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have consistently shown that the presence of a hydrosalpinx is associated with poor IVF outcome: the live birth rate is one-half that of women without hydrosalpinges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/30\">",
"     30",
"    </a>",
"    ]. Moreover, randomized trials have demonstrated that salpingectomy prior to IVF in women with hydrosalpinges improves pregnancy rates and, therefore, should be recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Hydrosalpingeal fluid may impair establishment of a successful pregnancy by negatively impacting upon the transferred embryo or endometrial receptivity to implantation. These adverse effects may be mediated by microorganisms, endotoxins, cytokines, lack of nutrients, oxidative stress, mechanical factors,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the woman's genotype (HOXA10) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/32\">",
"     32",
"    </a>",
"    ]. Laparoscopic salpingectomy is cost-effective in this patient population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/18/9513?source=see_link&amp;anchor=H11#H11\">",
"     \"Reproductive surgery for female infertility\", section on 'Salpingectomy before in vitro fertilization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Factors with no or a negative effect on success",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Leiomyoma",
"      </strong>",
"      &mdash; The effect of leiomyomas on IVF is dependent on their location: submucosal myomas decrease the chance of success, whereas subserosal myomas do not appear to have any effect. The effect of intramural myomas is unclear. A meta-analysis of 19 observational studies showed a significant decrease in live birth (RR 0.79, 95% CI 0.70&ndash;0.88) and clinical pregnancy rates (RR 0.85, 95% CI 0.77&ndash;0.94) in women with non-cavity-distorting intramural fibroids compared with those without fibroids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/34\">",
"       34",
"      </a>",
"      ]. However, no study has yet confirmed that removing them improves outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30662?source=see_link\">",
"       \"Reproductive issues in women with uterine leiomyomas (fibroids)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Endometrioma",
"      </strong>",
"      &mdash; Whether an asymptomatic endometrioma should be removed prior to IVF is controversial; there is no consensus on the optimum approach [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/36\">",
"       36",
"      </a>",
"      ]. We do not routinely resect endometriomas prior to initiating IVF as surgery does not improve outcomes of ART and may damage ovarian reserve [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38136?source=see_link&amp;anchor=H14#H14\">",
"       \"Pathogenesis and treatment of infertility in women with endometriosis\", section on 'Endometrioma'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5863?source=see_link&amp;anchor=H9#H9\">",
"       \"Diagnosis and management of ovarian endometriomas\", section on 'Infertility'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Smoking",
"      </strong>",
"      &mdash; Cigarette smoking reduces IVF success rates (fewer ova retrieved) and is associated with numerous adverse effects on general health [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]; we recommend that smokers be advised to stop smoking. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18968?source=see_link\">",
"       \"Benefits and risks of smoking cessation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"       \"Overview of smoking cessation management in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Previous pregnancy history",
"      </strong>",
"      &mdash; A previous live birth is associated with higher likelihood of successful IVF, but a history of one or more miscarriages does not substantially reduce the likelihood of success [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Previous unsuccessful IVF cycle",
"      </strong>",
"      &mdash; Lack of success in an IVF cycle does not appreciably decrease success rates during subsequent treatment until approximately the fourth IVF cycle [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Obesity",
"      </strong>",
"      &mdash; Infertility is more prevalent among overweight and obese women, and IVF may be slightly less successful in these women. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/11/29882?source=see_link&amp;anchor=H7#H7\">",
"       \"The impact of obesity on fertility and pregnancy\", section on 'Subfertility'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      <strong>",
"       and acupuncture",
"      </strong>",
"      &mdash; Meta-analyses have not demonstrated a statistical improvement in clinical pregnancy rates with use of aspirin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/42-44\">",
"       42-44",
"      </a>",
"      ] or acupuncture [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/45\">",
"       45",
"      </a>",
"      ] anytime during the IVF cycle.",
"     </li>",
"     <li>",
"      <strong>",
"       Acquired or inherited thrombophilia",
"      </strong>",
"      &mdash; Although high quality data are not available, the presence of anticardiolipin or lupus anticoagulant antibodies alone or one of the common inherited thrombophilias does not appear to adversely impact IVF success rates. The available evidence suggests",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      is not routinely indicated when these women undergo IVF. Indications for heparin prophylaxis once pregnancy is confirmed are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/0/44041?source=see_link\">",
"       \"Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26714?source=see_link\">",
"       \"Inherited thrombophilias in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CONTROLLED OVARIAN HYPERSTIMULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first successful birth after IVF was achieved in a spontaneous ovulatory cycle; a single oocyte was obtained and a single embryo was transferred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/2\">",
"     2",
"    </a>",
"    ]. However, success rates using this method were low and most investigators adopted the use of ovarian stimulation strategies to achieve synchronous development of multiple follicles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/46\">",
"     46",
"    </a>",
"    ]. As a result, multiple mature oocytes could be retrieved and fertilized. The transfer of multiple embryos at one time appreciably increased the chance that at least one would implant and produce a live birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/47\">",
"     47",
"    </a>",
"    ]. A natural consequence of this practice was an increase in multiple gestations.",
"   </p>",
"   <p>",
"    Whereas multiple follicular development may be achieved by orally administered selective estrogen receptor modulators, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , most programs utilize stimulation regimens that include daily injections of exogenous FSH. A gonadotropin-releasing hormone (GnRH) analog is used to prevent the endogenous luteinizing hormone (LH) surge.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/60/26564?source=see_link\">",
"     Human chorionic gonadotropin",
"    </a>",
"    (hCG) is used in place of LH to initiate the ovulatory cascade and is given when the follicles are judged mature.",
"   </p>",
"   <p>",
"    The American College of Chest Physicians recommend against use of routine thrombosis prophylaxis in women undergoing IVF, unless they develop ovarian hyperstimulation syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2702884\">",
"    <span class=\"h2\">",
"     Long and short protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Long protocols\" involve starting medications in the menstrual cycle before the IVF cycle-- this can be done with either a GnRH agonist or antagonist or oral contraceptive pills. In general, because of cost, GnRH agonists are preferred over GnRH antagonists for the long protocol.",
"   </p>",
"   <p>",
"    \"Short protocols\" refer to a regimen in which medications are started at the time of the natural menstrual cycle. Stimulation is achieved with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12565?source=see_link\">",
"     human menopausal gonadotropins",
"    </a>",
"    (hMG) or FSH and spontaneous ovulation is blocked with either a GnRH agonist (by using the initial stimulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    followed by the down regulation) or with a GnRH antagonist. GnRH antagonists are preferred over GnRH agonists for the short protocol.",
"   </p>",
"   <p>",
"    If a GnRH agonist is used for pituitary suppression, a meta-analysis of randomized trials found that long protocols were more successful than short protocols (clinical pregnancy rate OR 1.50, 95% CI 1.16-1.93) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of long and short protocols are shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef76439 \" href=\"mobipreview.htm?33/12/33998\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2356164\">",
"    <span class=\"h3\">",
"     GnRH agonist (long) protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;One commonly used regimen begins with a GnRH agonist, administered daily for about two weeks or until down-regulation is complete (\"long protocol\"). Pituitary gonadotropin production is inhibited, thereby maximizing control of the cycle. Pituitary suppression of LH secretion is important to prevent a surge of endogenous LH prior to full maturation of the cohort of ovarian follicles. In the United States, a daily dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    acetate 0.5 to 1 mg subcutaneously is most commonly used; a single depot injection containing higher doses of the drug is an alternative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/50\">",
"     50",
"    </a>",
"    ]. Down-regulation is verified by serum estradiol measurement less than 30",
"    <span class=\"nowrap\">",
"     pg/mL.",
"    </span>",
"    If the GnRH agonist is initiated in the luteal phase of the cycle prior to the IVF cycle, the initial stimulatory effect of the agonist is blocked by the endogenous secretion of progesterone and estradiol. Alternatively, an oral contraceptive can be used prior to the initiation of the IVF cycle in order to time the onset of menses and to block the initial stimulatory effect of the GnRH agonist on pituitary secretion. One regimen uses two weeks of oral contraceptives with the GnRH agonist initiated after one week and used concurrently for one week, then the GnRH agonist is continued alone for another week.",
"   </p>",
"   <p>",
"    When stimulation begins, hMG (or FSH, or both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/51\">",
"     51",
"    </a>",
"    ]) is administered in a dose of 225 to 300",
"    <span class=\"nowrap\">",
"     IU/day",
"    </span>",
"    subcutaneously to stimulate follicular growth, with the GnRH agonist being continued at a lower dose to prevent a premature surge in luteinizing hormone (LH) secretion. The hMG dose is subsequently adjusted according to follicular growth (as determined by transvaginal ultrasonography) and serum estradiol concentrations (an indicator of granulosa cell proliferation). In a \"step-down\" protocol, the starting dose of gonadotropin is high and this is followed by gradual reductions in dose during the cycle depending on the response. In a \"step-up\" protocol, the starting dose of gonadotropin is low and is then gradually increased during the cycle depending on the response.",
"   </p>",
"   <p>",
"    One meta-analysis evaluated seven randomized trials that compared the effectiveness of hMG versus recombinant FSH following a long down-regulation protocol in IVF&ndash;ICSI cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/52\">",
"     52",
"    </a>",
"    ]. Use of hMG was associated with a significant increase in live birth rate (RR 1.18, 95% CI 1.02&ndash;1.38; pooled risk difference 4 percent 95% CI 1&ndash;7 percent). There were no significant differences between the drugs in spontaneous abortion, multiple pregnancy, cancellation, or ovarian hyperstimulation syndrome rates. However, because of patient selection issues and the myriad of other factors which influence the outcome of IVF, the issue of hMG versus FSH alone remains controversial, and a definitive advantage of one type of stimulation over the other has not yet been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3357294\">",
"    <span class=\"h3\">",
"     GnRH agonist flare protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who are poor responders to stimulation, the GnRH agonist may be administered in conjunction with ovarian stimulation, so that the initial (agonistic) response of the pituitary can be used for ovarian stimulation. These so-called &ldquo;flare&rdquo; protocols are initiated at the time of spontaneous menstruation or after several days or weeks of oral contraceptive pills. One such regimen uses a low dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    , 40 mcg twice daily, started on day 3 of bleeding or three to five days after the last oral contraceptive pill. This regimen is called a &ldquo;microdose Lupron flare&rdquo; and is most often combined with 600 IU of FSH or hMG. The leuprolide provides additional stimulation to the growing follicles, and subsequently prevents premature LH surges, as down-regulation is complete by day 5 of stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of FSH with recombinant LH versus FSH alone has also been studied. In a meta-analysis of these two approaches in women &ge;35 years of age undergoing ART (long protocol: five trials, GnRH antagonist: one trial, microdose flare: one trial), the combination of FSH and recombinant LH resulted in a higher implantation rate (OR 1.36, 95% CI 1.05-1.78) and clinical pregnancy rate (OR 1.37, 95% CI 1.03-1.83) in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/54\">",
"     54",
"    </a>",
"    ]. In five of the trials, the recombinant LH dose was 150 U beginning on cycle day 6 or 7. This study supports the concept that LH in combination with FSH improves ovarian stimulation as compared with FSH alone; this is consistent with the meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/52\">",
"     52",
"    </a>",
"    ] that suggested hMG is superior to FSH, since hMG contains both FSH and LH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2356171\">",
"    <span class=\"h3\">",
"     GnRH antagonist (short) protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;GnRH antagonists result in more rapid pituitary desensitization than GnRH agonists. If a GnRH antagonist is used, then no pretreatment with an agonist is necessary. Stimulation is begun either at the time of menses (\"short protocol\") or after a variable pretreatment period with oral contraceptives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/55\">",
"     55",
"    </a>",
"    ]. An antagonist is administered when the follicles are large (typically &gt;14 mm in greatest diameter) and the risk of premature ovulation first threatens cycle cancellation. Alternatively, some programs first administer the GnRH antagonist on a particular cycle day, usually day 7. Daily injections of the antagonist are then continued until hCG administration. One meta-analysis found that, compared to a long GnRH agonist protocol, use of GnRH antagonists reduced the incidence of ovarian hyperstimulation syndrome by 60 percent (OR 0.43, 95% CI 33-0.57; absolute risk reduction 4 percent), with only a slight decrease in the clinical pregnancy rate (OR 0.84, 95% CI 0.75-0.94) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2356269\">",
"    <span class=\"h3\">",
"     Triggers for ovulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the ovarian follicles are judged to be mature (two or more follicles with a mean diameter of 18 mm or more and a serum estradiol level of 200",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [734",
"    <span class=\"nowrap\">",
"     pmol/L]",
"    </span>",
"    per co-dominant follicle), a trigger is administered to initiate the ovulatory cascade.",
"   </p>",
"   <p>",
"    Both urinary and recombinant hCG preparations are available to trigger ovulation. A meta-analysis found no difference in clinical outcomes between recombinant and urinary hCG for induction of final follicular maturation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/57\">",
"     57",
"    </a>",
"    ]. A dose of 250 mcg of recombinant hCG appears to be equivalent to the standard doses of urinary hCG (5000 to 10,000 units) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the concerns with hCG administration is the associated risk of ovarian hyperstimulation syndrome (see below), due in part to the long half-life of hCG. Recombinant human LH (15,000 to 30,000 IU), which has a shorter half-life, has been compared to hCG (5,000 IU) as the ovulatory trigger in 259 women undergoing IVF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/59\">",
"     59",
"    </a>",
"    ]. An LH dose between 15 and 30,000 IU was as effective as hCG for number of oocytes retrieved, embryo number, and clinical pregnancy, and recombinant LH was associated with a significantly lower risk of ovarian hyperstimulation syndrome than hCG.",
"   </p>",
"   <p>",
"    GnRH agonists have also been used for ovulation triggering. In the US,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    acetate is generally used, in doses of 1 to 4 mg, given in a single injection or in two doses 12 hours apart. The pituitary responds with a surge of LH, and therefore cannot be down-regulated with the GnRH agonist during earlier phases of the cycle. Thus, this method is generally only used in association with the GnRH antagonist protocol. A meta-analysis concluded that ovulation triggering with GnRH agonists was associated with significantly lower pregnancy and live birth rates than hCG, although the rate of ovarian hyperstimulation syndrome was also less [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2356276\">",
"    <span class=\"h2\">",
"     Other options",
"    </span>",
"    &nbsp;&mdash;&nbsp;A",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"      clomiphene",
"     </a>",
"     /gonadotropin",
"    </span>",
"    regimen has also been used for ovulation induction, but a systematic review found insufficient evidence to recommend its use in routine IVF practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/61\">",
"     61",
"    </a>",
"    ]. Nevertheless, protocols utilizing clomiphene and gonadotropins may be useful in minimal stimulation regimens or in poor responders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9626?source=see_link\">",
"     \"Ovulation induction with clomiphene citrate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Poor responders and high responders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seven to 20 percent of cycles are discontinued before egg retrieval; the rate increases with increasing age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/5\">",
"     5",
"    </a>",
"    ]. A cycle may be cancelled if there is poor or excessive ovarian response. About 84 percent of discontinued cycles are due to no or inadequate egg production and 5 percent are due to hyperresponsiveness.",
"   </p>",
"   <p>",
"    The term \"poor responder\" is used to describe women who require large doses of medication to stimulate the ovary but produce less than an optimal number of oocytes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    achieve relatively low estradiol levels. The diagnosis has been applied to (1) women who have had a poor ovarian response after going through an IVF cycle, as well as (2) women who are likely to have a poor response based on their older age and a pre-cycle abnormal test of ovarian reserve (also called &ldquo;expected poor responder&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/63\">",
"     63",
"    </a>",
"    ]); however, there is wide variation in the specific criteria used in research studies to define poor responders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/64\">",
"     64",
"    </a>",
"    ]. There are no interventions that are highly effective for improving poor ovarian response in such women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. The important consideration in these patients is whether or not to proceed with IVF using a modified approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High responders produce a large number of mature oocytes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    high estradiol levels. Modification of the stimulation protocol is important to avoid ovarian hyperstimulation syndrome (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Ovarian hyperstimulation syndrome'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FOLLICLE ASPIRATION AND FERTILIZATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Oocyte retrieval",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently, oocyte retrieval is achieved almost exclusively by the transvaginal ultrasound-guided follicle aspiration method. It is performed 34 to 36 hours after hCG administration. Under direct ultrasonographic visualization and some type of",
"    <span class=\"nowrap\">",
"     analgesia/anesthesia",
"    </span>",
"    (most commonly, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    , although conscious sedation or regional block may also be used) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/68\">",
"     68",
"    </a>",
"    ], a needle is introduced sequentially into each follicle and the follicular contents are aspirated (",
"    <a class=\"graphic graphic_picture graphicRef82492 \" href=\"mobipreview.htm?11/23/11647\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are few complications of transvaginal follicle aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/69\">",
"     69",
"    </a>",
"    ]; only one series found a substantial risk of infection and the reported 3 percent incidence of infection fell to 0 percent with the use of prophylactic antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/70\">",
"     70",
"    </a>",
"    ]. The use of prophylactic antibiotics has not been studied extensively; limited available data on antibiotic use prior to embryo transfer suggest no benefit in improving clinical pregnancy rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/71\">",
"     71",
"    </a>",
"    ]. Because infections have been reported in case reports, most practitioners continue to use antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/72\">",
"     72",
"    </a>",
"    ]. Infections are thought to be primarily due to the reactivation of chronic processes, such as in patients with hydrosalpinges that harbor chronic inflammation. Since hydrosalpinges are most commonly removed prior to IVF, the need for antibiotics may be less, although their use may reduce genital tract colonization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Before transvaginal ultrasound-guided aspiration, oocytes were aspirated under direct visual guidance via laparoscopy. This method is still occasionally used in conjunction with GIFT, in women whose ovaries are not in the pelvis (such as after ovarian transposition prior to radiation therapy), or if the patient has no vaginal canal (eg, congenital absence of the vagina).",
"   </p>",
"   <p>",
"    In an analysis of data from over 400,000 treatment cycles in women of different age groups, the live birth rate rose with an increasing number of eggs retrieved per cycle, up to 15 eggs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Fertilization in vitro",
"    </span>",
"    &nbsp;&mdash;&nbsp;To achieve fertilization, recovered oocytes are mixed with spermatozoa in a small volume of culture medium. Among couples with mild male factor infertility, the probability of fertilization may be increased by the use of high concentrations of sperm or preincubation of sperm in special buffer solutions. In one study of 39 such couples, incubation of the sperm for 24 hours in TEST-yolk buffer resulted in a higher percentage of fertilized oocytes than with standard prepared sperm (58 versus 43 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Past failure of fertilization or the presence of severe male factor infertility requires the use of micromanipulation and intracytoplasmic sperm injection (ICSI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/75\">",
"     75",
"    </a>",
"    ]. The availability of",
"    <span class=\"nowrap\">",
"     ICSI/IVF",
"    </span>",
"    has resulted in pregnancy rates in couples with male factor infertility that are comparable to those in couples without male factor infertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/76\">",
"     76",
"    </a>",
"    ]. Fertilization rates of approximately 70 percent can be achieved with microinjection of freshly ejaculated sperm. Success has also been achieved with sperm obtained from the epididymis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/77\">",
"     77",
"    </a>",
"    ] or directly from the testis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/78\">",
"     78",
"    </a>",
"    ]. However, in couples with non-male-factor infertility, IVF with ICSI offers no clinical advantage when compared with conventional IVF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. In fact, the delivery rate is slightly higher with IVF alone than for IVF with ICSI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, ICSI should be reserved for those with severe male factor infertility or previously failed fertilization. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15546?source=see_link\">",
"     \"Intracytoplasmic sperm injection\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EMBRYO MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed discussion of culture media and embryo growth in vitro is beyond the scope of this review, and can be found elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Briefly, fertilization of the oocyte is confirmed by observing two pronuclei within the zygote about 17 hours after insemination or ICSI. After fertilization, the individual cells of each embryo (\"blastomeres\") divide every 12 to 14 hours, so that the embryo reaches approximately 8 cells by 72 hours after egg retrieval. Embryos between days 2 and 4 are called \"cleavage stage embryos.\" The blastocyst stage is reached by about day 5 after retrieval, and implantation is expected by day 7 after egg retrieval, so transfer should take place prior to this time (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Embryo transfer'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    \"Hatching\" is a natural process in which an embryo expands and eventually breaks through the zona pellucida in order to implant on the surface of the endometrium (the lining of the uterus). \"Assisted hatching\" refers to a laboratory procedure whereby the zona pellucida around the day 3 embryo is mechanically or chemically opened to assist the embryo in hatching from the zona about three days later. The procedure may improve the percentage of embryos that implant in selected cases with poor prognosis (eg, &ge;2 failed IVF cycles and poor embryo quality and older women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]), but its use is still controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If preimplantation genetic diagnosis (PGD) is planned, embryo biopsy is typically performed about 72 hours after oocyte aspiration. Embryo culture is then continued while the biopsied blastomere is analyzed and until embryo transfer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23431?source=see_link\">",
"     \"Preimplantation genetic diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Embryo transfer",
"    </span>",
"    &nbsp;&mdash;&nbsp;After fertilization, embryos are maintained in culture for a variable period of time. Most programs (55 percent) transfer embryos to the uterus about 72 hours after egg retrieval (four to eight cell, cleavage stage) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/5\">",
"     5",
"    </a>",
"    ]; there is a slight increase in pregnancy rates with day 3 versus day 2 transfer. The additional 24 hours in culture from day 2 to day 3 allows identification of embryos that stop dividing and thus are not viable.",
"   </p>",
"   <p>",
"    Day 5 transfer (blastocyst stage) is the next most common time for transfer (36 percent of procedures). It has been theorized that fewer (one or two) blastocysts (as compared with cleavage stage embryos) need to be transferred to maintain overall success rates, while decreasing the high order multiple pregnancy rate. In addition, delaying the transfer until the blastocyst stage allows selection of better quality embryos for transfer and transfer at the time a naturally fertilized in vivo embryo reaches the uterine cavity (",
"    <a class=\"graphic graphic_figure graphicRef85802 \" href=\"mobipreview.htm?2/44/2758\">",
"     figure 3",
"    </a>",
"    ). If PGD is indicated, delaying the transfer until the blastocyst stage allows additional time for the (genetic) analysis of the biopsied blastomere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/86\">",
"     86",
"    </a>",
"    ]. The live birth rate per transfer is generally higher with Day 5 than Day 3 transfer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/87\">",
"     87",
"    </a>",
"    ] (eg, at age 35 to 37 years the live birth rates per transfer were 46.5 and 34 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/5\">",
"     5",
"    </a>",
"    ]). However, the live birth rate per oocyte retrieval may not improve because fewer embryos are available for transfer. Furthermore, embryo culture for five days may not be the best treatment option for all patients because there is a risk that some embryos may not survive to day 5. At this time there is no strong evidence of a major advantage from blastocyst stage transfer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/27/43449?source=see_link&amp;anchor=H10#H10\">",
"     \"Strategies to control the rate of high order multiple gestation\", section on 'Day of transfer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23431?source=see_link\">",
"     \"Preimplantation genetic diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Embryos can be inserted into the uterus using a catheter via the cervix or placed into the fallopian tubes to be carried to the uterus by the peristaltic action of the fallopian tubes as normally occurs after in vivo fertilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/88\">",
"     88",
"    </a>",
"    ]. The transcervical route is the easiest and the least traumatic to the woman. The type of catheter (soft versus hard) and other aspects of the transfer technique, such as use of ultrasound guidance, can affect the success of transfer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/89-92\">",
"     89-92",
"    </a>",
"    ]. However, operator experience remains a major factor in the success of the procedure, and details of the technique must be adapted to each patient on an individual basis.",
"   </p>",
"   <p>",
"    All of the embryos that are to be transferred are loaded into the transfer catheter at one time in a volume of about 20 microliters. Under ultrasound guidance, they are placed 1 to 2 cm from the top of the uterine cavity. Touching the catheter to the top of the cavity or otherwise inducing uterine cramping by a traumatic transfer technique is thought to decrease the success of the procedure.",
"   </p>",
"   <p>",
"    Post-procedure, the catheter is checked to ensure there are no retained embryos. Although there is a possibility of losing embryos out of the cervix or into the fallopian tubes after embryo transfer, a randomized trial found that bedrest post-transfer did not improve the implantation rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/93\">",
"     93",
"    </a>",
"    ]; nevertheless, it is commonly recommended. There is also no evidence that use of a fibrin sealant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/94\">",
"     94",
"    </a>",
"    ] or other types of \"embryo glue\" post-embryo transfer improve clinical pregnancy rates.",
"   </p>",
"   <p>",
"    The usual number of embryos transferred depends on a number of factors, including maternal age, the number of oocytes retrieved and availability of embryos for cryopreservation. Transferring more than one embryo increases the chance for a pregnancy, but also increases the chance of multiple gestation. No more than two embryos should be transferred in young women. Since the rate of implantation is lower among older women (",
"    <a class=\"graphic graphic_table graphicRef59373 \" href=\"mobipreview.htm?26/54/27499\">",
"     table 2",
"    </a>",
"    ), more embryos are often implanted except for those women receiving oocytes from younger donors. The American Society for Reproductive Medicine suggests that no more than three or four embryos be transferred in 38- and 39-year-olds and no more than five embryos be transferred in women 40 years of age or older (",
"    <a class=\"graphic graphic_table graphicRef56555 \" href=\"mobipreview.htm?6/39/6780\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/95\">",
"     95",
"    </a>",
"    ]. However, this is controversial, and some authors suggest transfer of no more than two embryos regardless of maternal age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/96\">",
"     96",
"    </a>",
"    ]. Patient-specific factors are important; cycles that result in a high number of oocytes and yield a large number of embryos for cryopreservation are associated with higher pregnancy rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/97,98\">",
"     97,98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some countries have restricted by law the number of embryos that may be transferred at one time. In the United States, the number of embryos transferred is guided by American Society for Reproductive Medicine publications (",
"    <a class=\"graphic graphic_table graphicRef56555 \" href=\"mobipreview.htm?6/39/6780\">",
"     table 3",
"    </a>",
"    ), but not regulated by law [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/27/43449?source=see_link&amp;anchor=H10#H10\">",
"     \"Strategies to control the rate of high order multiple gestation\", section on 'Day of transfer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of fetal reduction to limit the number of continuing pregnancies has lessened slightly the concern over multiple births. In experienced hands, the risk of losing all the pregnancies from selective fetal reduction is less than 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/99\">",
"     99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39065?source=see_link\">",
"     \"Multifetal pregnancy reduction and selective termination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Luteal phase support",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little doubt that endometrial receptivity plays a major role in the success or failure of embryo implantation after IVF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/100\">",
"     100",
"    </a>",
"    ]. To optimize endometrial receptivity, it is common practice to administer a progesterone supplement during the luteal phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. Progesterone supplementation is generally initiated on the day of oocyte retrieval or at the time of embryo transfer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. The optimum duration of supplementation has not been established; it has been given until a positive or negative pregnancy test was obtained or as long as the end of the first trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/105-109\">",
"     105-109",
"    </a>",
"    ]. Intramuscular progesterone (progesterone in oil) and the various vaginal progesterone preparations (suppositories, tablets, or gel) are equally effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/110-112\">",
"     110-112",
"    </a>",
"    ]; oral progesterone appears to be less effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/113\">",
"     113",
"    </a>",
"    ]. These progesterone preparations and doses are not associated with birth defects or virilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/102\">",
"     102",
"    </a>",
"    ]. Intramuscular progesterone is more painful for the patient, but associated with less luteal phase bleeding than vaginal progesterone, and is commonly used.",
"   </p>",
"   <p>",
"    HCG can be used with progesterone or alone for luteal phase support, but is not more effective than progesterone alone and increases the risk of OHSS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/114\">",
"     114",
"    </a>",
"    ]. Meta-analyses show that estrogen supplementation does not enhance pregnancy rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. However, estradiol is commonly administered along with vaginal progesterone to prevent late luteal vaginal bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cryopreservation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embryos in excess of those that can be safely transferred can be cryopreserved for future use. In fact, cryopreservation of excess embryos is a surrogate marker of embryo quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    About 10 to 20 percent of embryos do not survive the thawing process. This is thought to be due to subtle damage suffered by the embryo during the freezing and thawing process. Despite this risk, systematic reviews of observational studies have found that children born after transfer of frozen-thawed embryos have better perinatal outcomes than those born after transfer of fresh embryos (ie, lower rates of preterm birth, low birthweight, growth restriction, perinatal mortality), and they have comparable malformation rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. Outcome data on growth, childhood morbidity, and mental development were limited, but with few differences between groups. Both slow freezing and vitrification (ultrarapid freezing) were safe and effective methods of cryopreservation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/118,120\">",
"     118,120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reason for some better outcomes of children born after cryopreservation as compared with children born after fresh transfer in most studies is not known, but may be related to differences in endometrial receptivity between women undergoing fresh versus cryopreserved embryo transfer (eg, adverse effects of ovarian stimulation in fresh cycles, asynchrony). The lower serum E2 levels associated with frozen-thawed embryo transfer cycles may result in better placentation. It is also possible that embryos that survive freezing and thawing are of better quality than fresh embryos.",
"   </p>",
"   <p>",
"    A lower incidence of ectopic pregnancy may be another benefit of using cryopreserved embryos. In two retrospective studies, the rate of ectopic pregnancy in cycles using frozen-thawed blastocysts was less than 1 percent versus 1.5 to 1.8 percent in cycles using fresh embryos [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/121,122\">",
"     121,122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no scientific basis for a maximum duration of storage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/123\">",
"     123",
"    </a>",
"    ]. The couple will have to decide whether to transfer these embryos at a later date, donate them to other subfertile couples or research, or dispose of them [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/124,125\">",
"     124,125",
"    </a>",
"    ]. In one US program with 782 cryopreserved embryos, disposition consisted of eventual use by the couple (60 percent), continued storage (23 percent), discard (8 percent), donation to research (5 percent), and anonymous donation to other couples (1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/126\">",
"     126",
"    </a>",
"    ]. By comparison, a series from France reported that there were 17,592 embryos involving 3888 couples in French IVF centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/127\">",
"     127",
"    </a>",
"    ]. A questionnaire to the centers revealed 51 percent of couples with embryos in storage could no longer be found, 24 percent requested a continuance of storage, 12 percent would accept donating their embryos to medical research, 9 percent would wish for other couples to take eventual ownership of the embryo, and in 7 percent of cases the storage center could not provide information concerning the continuing of storage of such embryo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Endometrial preparation for frozen-thawed embryo transfer",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cycles using fresh eggs, the endometrium is primed by endogenously produced hormones. Women undergoing embryo transfer with frozen embryos require priming with exogenous estrogen and progesterone. The regimens used for these cycles are identical to those used during egg donation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24807?source=see_link\">",
"     \"Oocyte donation for assisted reproduction\"",
"    </a>",
"    .) A meta-analysis concluded that no specific protocol for endometrial preparation was superior to any other; all led to similar results in terms of endometrial receptivity and implantation rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/103\">",
"     103",
"    </a>",
"    ]. However, the timing of progesterone administration influenced the outcome: when progesterone was initiated prior to egg retrieval in oocyte donation, the pregnancy rate was lower than when progesterone started on the day of egg retrieval or the day after.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Expected course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-transfer, the patient can resume her regular daily activities. Neither physical activity nor diet has been shown to have an impact upon the success of embryo implantation or conception. However, most programs recommend some form of rest or decreased physical activity after the embryo transfer. Since the cervix is swabbed prior to embryo transfer, some women may pass a small amount of clear or bloody fluid from the vagina shortly after the procedure; this is normal and not a sign that the embryos are being expelled. Breast tenderness and engorgement, bloating, and constipation are not uncommon; they are due to the elevated hormone levels associated with ovarian stimulation, and, to a lesser extent, due to the supplemental hormones used for luteal phase support. Cramping during embryo transfer may be caused by touching the inside of the uterus with the transfer catheter. Cramping after the procedure is likely due to varying degrees of ovarian enlargement and the ovarian hyperstimulation syndrome (OHSS).",
"   </p>",
"   <p>",
"    Mild cramping and bloating are normal; however, patients with moderate or severe pain require evaluation to rule out infection, ovarian torsion, other causes of abdominal pain (such as appendicitis), and more severe forms of OHSS, which is the most common cause of such pain (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Ovarian hyperstimulation syndrome'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Differentiating OHSS from other causes of abdominal pain can be challenging. Diffuse abdominal tenderness and elevations in the white blood cell count are common to several conditions. Doppler ultrasound may help differentiate ovarian enlargement due to OHSS from ovarian torsion. When pregnancy is diagnosed, rising levels of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/60/26564?source=see_link\">",
"     human chorionic gonadotropin",
"    </a>",
"    (hCG) produced by the pregnancy further stimulate the enlarged ovaries, and worsen symptoms of OHSS. It is helpful to remember that pain from ectopic pregnancy is uncommon prior to 5 weeks of gestational age (three weeks after follicle aspiration). In cases of severe pain, laparoscopy may be needed to help determine the exact cause and to rule out ovarian torsion or appendicitis.",
"   </p>",
"   <p>",
"    Pelvic pain occurring weeks after IVF should be evaluated as in any woman with acute pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/44/17095?source=see_link\">",
"     \"Evaluation of acute pelvic pain in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/44/36554?source=see_link\">",
"     \"Approach to abdominal pain and the acute abdomen in pregnant and postpartum women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Monitoring for pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is diagnosed by identification of rising serum hCG levels after transfer. Implantation is thought to occur no earlier than seven days after retrieval; hCG levels may be detected one or two days later. However, late implantations do occur, so the first blood test is usually obtained no earlier than 12 days after egg retrieval, although some programs start testing later. HCG administration prior to oocyte retrieval results in serum hCG levels between 60 and 300",
"    <span class=\"nowrap\">",
"     mIU/mL,",
"    </span>",
"    but this hCG is generally completely cleared by two weeks after administration, which is about 12 days after retrieval, so it should not interfere with pregnancy testing. Serial hCG measurements are performed to monitor whether the rise is normal and consistent with a developing intrauterine pregnancy.",
"   </p>",
"   <p>",
"    If the hCG test is positive, ultrasound evaluation of the pregnancy generally begins at six weeks of gestational age (four weeks after retrieval), which is when the fetal heartbeat may first be detected. The patient is usually referred for obstetrical care at any time after that, but continued contact is worthwhile for the rare case of heterotopic pregnancy that may occur after IVF, and which may not become apparent until later in the first trimester. The major symptom is pelvic pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/4/16457?source=see_link\">",
"     \"Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, a very early positive hCG test becomes negative on follow-up testing and before there is evidence of an intrauterine or extrauterine pregnancy on ultrasound. Menses often occur at the expected time. These very early pregnancy losses are termed &ldquo;chemical pregnancies&rdquo;.",
"   </p>",
"   <p>",
"    Vaginal bleeding after diagnosis of pregnancy is of concern, but is not necessarily a poor prognostic sign. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/6/15465?source=see_link\">",
"     \"Overview of the etiology and evaluation of vaginal bleeding in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A negative hCG level 14 days after egg retrieval is a strong indication of a failed IVF cycle. The patient is instructed to stop luteal phase supplementation, and menstruation commonly occurs after one to three days. Lack of menses or unusual irregular bleeding should be evaluated with hormonal measurements, since ectopic pregnancies may rarely present with very delayed appearance of hCG in the circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Ovarian hyperstimulation syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian hyperstimulation syndrome (OHSS) is a potentially life-threatening complication of ovulation induction that can occur in the setting of ovulation induction with exogenous gonadotropin therapy or IVF. Its most severe manifestations include massive ovarian enlargement and multiple cysts, hemoconcentration, and third-space accumulation of fluid; these changes rarely lead to renal failure, hypovolemic shock, thromboembolic episodes, acute respiratory distress syndrome, and (rarely) death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/128,129\">",
"     128,129",
"    </a>",
"    ]. Mild OHSS occurs in about 25 percent of patients, although some aspects of hyperstimulation are virtually ubiquitous, and a severe form of OHSS is associated with about 0.1 to 0.2 percent of all IVF cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/130\">",
"     130",
"    </a>",
"    ]. The clinical symptoms usually appear 5 to 10 days following the first dose of the ovulatory trigger (hCG, GnRH agonist).",
"   </p>",
"   <p>",
"    Even in the absence of an overt diagnosis of OHSS, patients who conceive after IVF have been observed to have an increased risk of pulmonary and venous thromboembolism during pregnancy, especially during the first trimester. In one study, the risk of pulmonary embolism in the first trimester in women after IVF versus in women with natural pregnancies was",
"    <span class=\"nowrap\">",
"     3/10,000",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     0.4/10,000",
"    </span>",
"    (hazard ratio 6.97, 95% CI 2.21-21.96) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/131\">",
"     131",
"    </a>",
"    ]. This study does not warrant a change in current practice; the results need to be confirmed and the benefits of anticoagulation need to be balanced with the risks in this setting. Although the absolute risk of a serious thromboembolic event in the first trimester is low, it may be prudent to make patients aware of the symptoms of thromboembolism and inform them to call their provider if symptoms develop.",
"   </p>",
"   <p>",
"    Pathogenesis, clinical manifestations, diagnosis, treatment, and prevention of OHSS are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/41/35479?source=see_link\">",
"     \"Classification and treatment of ovarian hyperstimulation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/7/22647?source=see_link\">",
"     \"Prevention of ovarian hyperstimulation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/17/16660?source=see_link\">",
"     \"Pathogenesis of ovarian hyperstimulation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     OTHER TECHNIQUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Natural cycle IVF",
"    </span>",
"    &nbsp;&mdash;&nbsp;From time to time, ART programs reevaluate the feasibility of IVF without the use of exogenous gonadotropins to induce growth of multiple follicles. The spontaneous cycle is commonly augmented with a mid-cycle dose of hCG to stimulate ovulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/132,133\">",
"     132,133",
"    </a>",
"    ]. One series that analyzed implantation rates per embryo implanted and the rate of ongoing pregnancy in spontaneously ovulating women under age 40 years reported a higher implantation rate per embryo transferred for unstimulated as compared with stimulated cycles (13 versus 9 percent), but the pregnancy rate was one-half that achieved in stimulated cycles (14 versus 28 percent) because more embryos were transferred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/134\">",
"     134",
"    </a>",
"    ]. Therefore, the benefit of multiple embryo transfers outweighed the benefit of the more natural uterine environment. Currently, many IVF centers are using single embryo transfer in stimulated cycles for good prognosis patients to reduce the risk of multiple gestation, yet natural cycle IVF is rarely performed. Instead, \"gentle\" stimulation is being used to take advantage of the additional control and margin for error afforded by the use of fertility medications without the risk of ovarian hyperstimulation or the need for the storage of excess embryos. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/27/43449?source=see_link\">",
"     \"Strategies to control the rate of high order multiple gestation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     In vitro maturation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro maturation of immature oocytes from unstimulated cycles is an emerging technology. A major advantage is the avoidance of large doses of gonadotropins and their associated high costs, risk of ovarian hyperstimulation syndrome, and potential adverse effects on hormone-sensitive tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/135\">",
"     135",
"    </a>",
"    ]. Development of the technique and assessment of its role in fertility treatment is ongoing.",
"   </p>",
"   <p>",
"    About 20 percent of oocytes retrieved from stimulated cycles are immature. In vitro maturation of immature oocytes obtained from stimulated cycles has also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/136\">",
"     136",
"    </a>",
"    ]. Fertilization and clinical pregnancy rates may be lower than with oocytes matured in vivo, but data are limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/136-139\">",
"     136-139",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The background conception rate is important when assessing IVF success rates. In one review, the treatment-independent (spontaneous or natural) pregnancy rate over 12 months among subfertile patients in a primary care practice was 27 percent versus 12 percent among patients referred to infertility specialists and 2 to 6 percent in patients referred specifically for IVF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of IVF for treatment of infertility was illustrated in a well-designed trial in which couples planning their first IVF treatment cycle were randomly assigned to receive either IVF within 90 days of randomization or no therapy for 90 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/140\">",
"     140",
"    </a>",
"    ]. The live birth rates were significantly higher in the IVF group: 20 of 68 (29 percent) versus 1 of 71 (1 percent).",
"   </p>",
"   <p>",
"    The cause of infertility affects IVF outcome. Live birth rates are highest in women with ovulatory dysfunction and lowest in those with diminished ovarian reserve (40.4 versus 14.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IVF success rates appear to vary by race and ethnicity: IVF in black, Asian, and Hispanic women in the US is associated with lower live birth rates than in white women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/4,141\">",
"     4,141",
"    </a>",
"    ]. The reasons for these differences are unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Pregnancy rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;On a per-cycle basis, because of the transfer of multiple embryos, the results of IVF treatment now exceed the fecundability of natural conception cycles in the general population (live births per natural cycle 27.7 percent, live births per artificial cycle 30 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/5\">",
"     5",
"    </a>",
"    ]. Life-table analyses from the early phase of IVF showed that the per cycle pregnancy rate stayed relatively constant for at least six cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/142,143\">",
"     142,143",
"    </a>",
"    ], although subsequent data suggested a slight decline in the rate after three to four cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/41\">",
"     41",
"    </a>",
"    ]. Therefore, the cumulative pregnancy rate and live birth rate continue to increase when IVF is attempted on a repetitive basis, but the increase is not linear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medical and gynecologic disorders which may play a role in the probability of pregnancy may also influence subsequent pregnancy outcome. Couples who undergo ART as a treatment for infertility would reasonably be expected to have a higher incidence of these conditions; thus, pregnancy outcome after ART may be influenced by these conditions as well as the procedure itself.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Registry data",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, over 400 fertility clinics provide verified data on the outcomes of all ART cycles started in their clinic. In 2009, the 146,244 ART cycles performed at these clinics resulted in 45,870 live births (deliveries of one or more living infants) and 60,190 infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/5\">",
"     5",
"    </a>",
"    ]. The 2009 annual summary report with detailed descriptions of patient characteristics, procedures, and outcomes is available online [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some highlights from this report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The types of ART cycles were fresh nondonor (70.1 percent), frozen nondonor (17.8 percent), fresh donor (7.5 percent), frozen donor (4.6 percent).",
"     </li>",
"     <li>",
"      IVF was performed with ICSI in 72.9 percent of cases, but male factor infertility was present in only 47 percent of these cases.",
"     </li>",
"     <li>",
"      Of pregnancies resulting from use of fresh nondonor eggs or embryos, 81.5 percent resulted in a live birth, 16.4 percent ended in miscarriage, 0.9 percent ended in induced abortion, and 0.7 percent resulted in stillbirth. In addition, 61.7 percent were singleton, 28.5 percent were twins, 3.1 percent were triplets or more, and no information was available in 6.7 percent.",
"     </li>",
"     <li>",
"      The percentage of ART cycles that resulted in miscarriage was below 13 percent among women younger than 35, but increased to 28 percent at age 40 and almost 59 percent among women older than 44.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The outcome of pregnancies conceived via ART has been generally good. However, there are increased risks of multiple gestation, preterm birth, and low birth weight. Other adverse effects, such as some congenital anomalies and some types of cancer, also may occur more frequently, but data are sparse. Pregnancy outcomes are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/6/2154?source=see_link\">",
"     \"Pregnancy outcome after assisted reproductive technology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Reasons for failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure can occur during any step in the IVF process, and often the reason for failure is not known. Follicles may not develop due to poor ovarian reserve. A mature oocyte may not be retrievable due to technical difficulties. Fertilization failure may be caused by sperm abnormalities or lack of penetration of the zona pellucida, an oocyte activation failure, or a defect in the oocyte.",
"   </p>",
"   <p>",
"    However, in the majority of cases, viable embryos are produced. Therefore, when cycles fail, it is generally due to lack of embryo implantation. It is convenient to classify the many factors involved in embryo implantation into three general categories: embryo quality, endometrial receptivity, and transfer efficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/145\">",
"     145",
"    </a>",
"    ]. Some potential etiologies of failed implantation are listed below, although the impact of some of these conditions is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/145,146\">",
"     145,146",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Poor embryo quality:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diminished ovarian reserve",
"     </li>",
"     <li>",
"      Advanced maternal age",
"     </li>",
"     <li>",
"      Suboptimal ovarian stimulation",
"     </li>",
"     <li>",
"      Suboptimal laboratory culture conditions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Poor endometrial receptivity:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poor endometrial development (thin endometrium, altered expression of adhesive molecules)",
"     </li>",
"     <li>",
"      Uterine abnormalities (submucosal myomas, uterine septum)",
"     </li>",
"     <li>",
"      Hostile environment (hydrosalpinges, infection)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Poor embryo transfer efficiency:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Traumatic embryo transfer (eg, use of rigid transfer catheters)",
"     </li>",
"     <li>",
"      Inaccurate placement of the embryos (eg, lack of ultrasound guidance)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further diagnostic evaluation and treatment of couples with repeated failure of implantation of good quality embryos may be indicated, but is beyond the scope of this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H884328160\">",
"    <span class=\"h2\">",
"     Maternal outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morbidity and mortality rates directly related to IVF are low. Complications are predominantly due to hormonal stimulation and egg retrieval, and include ovarian hyperstimulation syndrome (OHSS), thromboembolism, infection, abdominal bleeding, adnexal torsion, allergic reaction, and anesthetic complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/129,147\">",
"     129,147",
"    </a>",
"    ]. If IVF is successful, the woman is at risk of usual pregnancy-related morbidity and mortality (eg,",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia,",
"    </span>",
"    hemorrhage, thromboembolism, sepsis, amniotic fluid embolism). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/6/2154?source=see_link\">",
"     \"Pregnancy outcome after assisted reproductive technology\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    A 2013 meta-analysis including eight cohort studies (n = 746,455 participants) observed no significant associations between IVF treatment and all cancer risk (RR 0.99, 95% CI 0.74&ndash;1.32), breast cancer risk (RR 0.89, 95% CI 0.79&ndash;1.01), or cervical cancer risk (RR 1.07, 95% CI 0.45&ndash;2.55) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/148\">",
"     148",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20062509\">",
"    <span class=\"h3\">",
"     Ovarian cancer risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of fertility drugs has been associated with ovarian neoplasia, but experts have generally concluded that infertility, by reducing the number of successful pregnancies, is an important risk factor for ovarian cancer and that infertility treatment does not independently increase the risk. A 2010 review of studies on this issue concluded that the existing literature on ovarian cancer risk associated with fertility drug treatment is &ldquo;reassuring but not definitive&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/149\">",
"     149",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/10/13482?source=see_link&amp;anchor=H25#H25\">",
"     \"Overview of ovulation induction\", section on 'Ovarian cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether IVF increases the risk of ovarian malignancy as a result of induction of ovulation or repeated ovarian punctures for egg retrieval remains controversial, but data are generally reassuring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/148,150\">",
"     148,150",
"    </a>",
"    ]. The 2013 meta-analysis cited above reported a positive association between IVF and risk of ovarian cancer (RR 1.59, 95% CI 1.24&ndash;2.03) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/148\">",
"     148",
"    </a>",
"    ]. However, the increased risk estimate was not statistically significant in some subgroup analyses (eg, women followed for more than eight years; after exclusion of women diagnosed within one year of the IVF treatment; when subfertile women who did not undergo IVF were used as the control group). More large cohort studies are needed to determine the influence of confounding factors, including detection bias, since women undergoing IVF undergo frequent ultrasound examinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32944653\">",
"    <span class=\"h3\">",
"     Breast cancer risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no clear evidence that IVF increases a woman&rsquo;s risk of developing breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/148,151-158\">",
"     148,151-158",
"    </a>",
"    ]. Reproductive hormones appear to have a relationship with breast cancer risk; however, this relationship is complicated because of multiple confounders. The potential effects of endogenous and exogenous reproductive hormones, pregnancy and breastfeeding, and infertility and infertility therapy on breast cancer risk are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/10/13482?source=see_link&amp;anchor=H26#H26\">",
"     \"Overview of ovulation induction\", section on 'Breast cancer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18754188\">",
"    <span class=\"h2\">",
"     Spontaneous pregnancy after IVF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous pregnancy after successful or unsuccessful IVF is not a rare occurrence, especially among women with good prognostic factors (young, short duration infertility, unexplained infertility) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/159\">",
"     159",
"    </a>",
"    ]. About one-fifth of couples who become pregnant using IVF subsequently have a naturally conceived pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/160-163\">",
"     160-163",
"    </a>",
"    ]. In one study conducted via a survey by mail, about one in four couples without a livebirth after IVF eventually had a naturally conceived pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/56/37770/abstract/160\">",
"     160",
"    </a>",
"    ]. Among the 37 couples with &lt;5 years of infertility, a diagnosis of unexplained infertility, and a female partner &lt;35 years of age, 57 percent became pregnant (95% CI 39-73) over a median follow-up of seven years after their last IVF attempt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/62/40932?source=see_link\">",
"       \"Patient information: In vitro fertilization (IVF) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For in vitro fertilization (IVF) procedures, the ovaries are stimulated by a combination of fertility medications and then one or more oocyte(s) are aspirated from the ovarian follicles. The oocytes are fertilized in the laboratory, after which, one or more embryo(s) are transferred into the uterine cavity. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Controlled ovarian hyperstimulation'",
"      </a>",
"      above.) and (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Follicle aspiration and fertilization'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Embryo management'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The proportion of IVF procedures by infertility diagnosis are shown in the figure (",
"      <a class=\"graphic graphic_figure graphicRef65638 \" href=\"mobipreview.htm?27/36/28224\">",
"       figure 4",
"      </a>",
"      ). The most important procedure-related factors affecting success are the number of oocytes retrieved and the number of high quality embryos derived from them in the laboratory. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fertilized embryos in excess of those that can be safely transferred can be cryopreserved indefinitely for future use. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Cryopreservation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      On a per-cycle basis, because of the transfer of multiple embryos, the results of IVF treatment now slightly exceed the fecundability of natural conception cycles in the general population. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major reason for failure to achieve pregnancy with IVF is lack of implantation due to poor embryo quality, poor endometrial receptivity, or poor embryo transfer efficiency. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Reasons for failure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/1\">",
"      Steptoe PC, Edwards RG. Reimplantation of a human embryo with subsequent tubal pregnancy. Lancet 1976; 1:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/2\">",
"      Steptoe PC, Edwards RG. Birth after the reimplantation of a human embryo. Lancet 1978; 2:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/3\">",
"      Ledger WL, Anumba D, Marlow N, et al. The costs to the NHS of multiple births after IVF treatment in the UK. BJOG 2006; 113:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/4\">",
"      Baker VL, Luke B, Brown MB, et al. Multivariate analysis of factors affecting probability of pregnancy and live birth with in vitro fertilization: an analysis of the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System. Fertil Steril 2010; 94:1410.",
"     </a>",
"    </li>",
"    <li>",
"     2009 SART file://www.cdc.gov/ART/ART2009 (Accessed on February 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/6\">",
"      Malizia BA, Hacker MR, Penzias AS. Cumulative live-birth rates after in vitro fertilization. N Engl J Med 2009; 360:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/7\">",
"      Hull MG. Effectiveness of infertility treatments: choice and comparative analysis. Int J Gynaecol Obstet 1994; 47:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/8\">",
"      Sauer MV, Paulson RJ, Lobo RA. Reversing the natural decline in human fertility. An extended clinical trial of oocyte donation to women of advanced reproductive age. JAMA 1992; 268:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/9\">",
"      van Rooij IA, Bancsi LF, Broekmans FJ, et al. Women older than 40 years of age and those with elevated follicle-stimulating hormone levels differ in poor response rate and embryo quality in in vitro fertilization. Fertil Steril 2003; 79:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/10\">",
"      Klipstein S, Regan M, Ryley DA, et al. One last chance for pregnancy: a review of 2,705 in vitro fertilization cycles initiated in women age 40 years and above. Fertil Steril 2005; 84:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/11\">",
"      Spandorfer SD, Bendikson K, Dragisic K, et al. Outcome of in vitro fertilization in women 45 years and older who use autologous oocytes. Fertil Steril 2007; 87:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/12\">",
"      Toner JP, Philput CB, Jones GS, Muasher SJ. Basal follicle-stimulating hormone level is a better predictor of in vitro fertilization performance than age. Fertil Steril 1991; 55:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/13\">",
"      Martin JS, Nisker JA, Tummon IS, et al. Future in vitro fertilization pregnancy potential of women with variably elevated day 3 follicle-stimulating hormone levels. Fertil Steril 1996; 65:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/14\">",
"      Roberts JE, Spandorfer S, Fasouliotis SJ, et al. Taking a basal follicle-stimulating hormone history is essential before initiating in vitro fertilization. Fertil Steril 2005; 83:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/15\">",
"      Bancsi LF, Broekmans FJ, Mol BW, et al. Performance of basal follicle-stimulating hormone in the prediction of poor ovarian response and failure to become pregnant after in vitro fertilization: a meta-analysis. Fertil Steril 2003; 79:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/16\">",
"      Taylor AE, Khoury RH, Crowley WF Jr. A comparison of 13 different immunometric assay kits for gonadotropins: implications for clinical investigation. J Clin Endocrinol Metab 1994; 79:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/17\">",
"      Licciardi FL, Liu HC, Rosenwaks Z. Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization. Fertil Steril 1995; 64:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/18\">",
"      Maheshwari A, Fowler P, Bhattacharya S. Assessment of ovarian reserve--should we perform tests of ovarian reserve routinely? Hum Reprod 2006; 21:2729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/19\">",
"      Hendriks DJ, Broekmans FJ, Bancsi LF, et al. Repeated clomiphene citrate challenge testing in the prediction of outcome in IVF: a comparison with basal markers for ovarian reserve. Hum Reprod 2005; 20:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/20\">",
"      Jain T, Soules MR, Collins JA. Comparison of basal follicle-stimulating hormone versus the clomiphene citrate challenge test for ovarian reserve screening. Fertil Steril 2004; 82:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/21\">",
"      Hazout A, Bouchard P, Seifer DB, et al. Serum antim&uuml;llerian hormone/m&uuml;llerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril 2004; 82:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/22\">",
"      Muttukrishna S, Suharjono H, McGarrigle H, Sathanandan M. Inhibin B and anti-Mullerian hormone: markers of ovarian response in IVF/ICSI patients? BJOG 2004; 111:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/23\">",
"      Hendriks DJ, Mol BW, Bancsi LF, et al. Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level. Fertil Steril 2005; 83:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/24\">",
"      Kwee J, Schats R, McDonnell J, et al. The clomiphene citrate challenge test versus the exogenous follicle-stimulating hormone ovarian reserve test as a single test for identification of low responders and hyperresponders to in vitro fertilization. Fertil Steril 2006; 85:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/25\">",
"      Hendriks DJ, Kwee J, Mol BW, et al. Ultrasonography as a tool for the prediction of outcome in IVF patients: a comparative meta-analysis of ovarian volume and antral follicle count. Fertil Steril 2007; 87:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/26\">",
"      La Marca A, Giulini S, Tirelli A, et al. Anti-M&uuml;llerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 2007; 22:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/27\">",
"      Gnoth C, Schuring AN, Friol K, et al. Relevance of anti-Mullerian hormone measurement in a routine IVF program. Hum Reprod 2008; 23:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/28\">",
"      Broer SL, Mol BW, Hendriks D, Broekmans FJ. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril 2009; 91:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/29\">",
"      Mol BW, Verhagen TE, Hendriks DJ, et al. Value of ovarian reserve testing before IVF: a clinical decision analysis. Hum Reprod 2006; 21:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/30\">",
"      Practice Committee of American Society for Reproductive Medicine in collaboration with Society of Reproductive Surgeons. Salpingectomy for hydrosalpinx prior to in vitro fertilization. Fertil Steril 2008; 90:S66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/31\">",
"      Johnson NP, Mak W, Sowter MC. Surgical treatment for tubal disease in women due to undergo in vitro fertilisation. Cochrane Database Syst Rev 2004; :CD002125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/32\">",
"      Strandell A, Lindhard A. Why does hydrosalpinx reduce fertility? The importance of hydrosalpinx fluid. Hum Reprod 2002; 17:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/33\">",
"      Strandell A, Lindhard A, Eckerlund I. Cost--effectiveness analysis of salpingectomy prior to IVF, based on a randomized controlled trial. Hum Reprod 2005; 20:3284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/34\">",
"      Sunkara SK, Khairy M, El-Toukhy T, et al. The effect of intramural fibroids without uterine cavity involvement on the outcome of IVF treatment: a systematic review and meta-analysis. Hum Reprod 2010; 25:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/35\">",
"      Van Voorhis BJ. Outcomes from assisted reproductive technology. Obstet Gynecol 2006; 107:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/36\">",
"      Raffi F, Shaw RW, Amer SA. National survey of the current management of endometriomas in women undergoing assisted reproductive treatment. Hum Reprod 2012; 27:2712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/37\">",
"      Tsoumpou I, Kyrgiou M, Gelbaya TA, Nardo LG. The effect of surgical treatment for endometrioma on in vitro fertilization outcomes: a systematic review and meta-analysis. Fertil Steril 2009; 92:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/38\">",
"      Benschop L, Farquhar C, van der Poel N, Heineman MJ. Interventions for women with endometrioma prior to assisted reproductive technology. Cochrane Database Syst Rev 2010; :CD008571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/39\">",
"      Younglai EV, Holloway AC, Foster WG. Environmental and occupational factors affecting fertility and IVF success. Hum Reprod Update 2005; 11:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/40\">",
"      Fuentes A, Mu&ntilde;oz A, Barnhart K, et al. Recent cigarette smoking and assisted reproductive technologies outcome. Fertil Steril 2010; 93:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/41\">",
"      Meldrum DR, Silverberg KM, Bustillo M, Stokes L. Success rate with repeated cycles of in vitro fertilization-embryo transfer. Fertil Steril 1998; 69:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/42\">",
"      Groeneveld E, Broeze KA, Lambers MJ, et al. Is aspirin effective in women undergoing in vitro fertilization (IVF)? Results from an individual patient data meta-analysis (IPD MA). Hum Reprod Update 2011; 17:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/43\">",
"      Siristatidis CS, Dodd SR, Drakeley AJ. Aspirin for in vitro fertilisation. Cochrane Database Syst Rev 2011; :CD004832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/44\">",
"      Dentali F, Ageno W, Rezoagli E, et al. Low-dose aspirin for in vitro fertilization or intracytoplasmic sperm injection: a systematic review and a meta-analysis of the literature. J Thromb Haemost 2012; 10:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/45\">",
"      Zheng CH, Huang GY, Zhang MM, Wang W. Effects of acupuncture on pregnancy rates in women undergoing in vitro fertilization: a systematic review and meta-analysis. Fertil Steril 2012; 97:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/46\">",
"      Ingerslev HJ, H&oslash;jgaard A, Hindkjaer J, Kesmodel U. A randomized study comparing IVF in the unstimulated cycle with IVF following clomiphene citrate. Hum Reprod 2001; 16:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/47\">",
"      Paulson, RJ, Marrs, RP. Ovulation stimulation and monitoring for in vitro fertilization. Curr Probl Obstet Gynecol Infert 1986; 10:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/48\">",
"      Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e691S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/49\">",
"      Maheshwari A, Gibreel A, Siristatidis CS, Bhattacharya S. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database Syst Rev 2011; :CD006919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/50\">",
"      Albuquerque LE, Tso LO, Saconato H, et al. Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database Syst Rev 2013; 1:CD002808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/51\">",
"      van Wely M, Westergaard LG, Bossuyt PM, van der Veen F. Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis. Fertil Steril 2003; 80:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/52\">",
"      Coomarasamy A, Afnan M, Cheema D, et al. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod 2008; 23:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/53\">",
"      Chung K, Fogle R, Bendikson K, et al. Microdose gonadotropin-releasing hormone agonist in the absence of exogenous gonadotropins is not sufficient to induce multiple follicle development. Fertil Steril 2011; 95:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/54\">",
"      Hill MJ, Levens ED, Levy G, et al. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertil Steril 2012; 97:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/55\">",
"      Griesinger G, Venetis CA, Marx T, et al. Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis. Fertil Steril 2008; 90:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/56\">",
"      Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2011; :CD001750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/57\">",
"      Al-Inany HG, Aboulghar M, Mansour R, Proctor M. Recombinant versus urinary human chorionic gonadotrophin for ovulation induction in assisted conception. Cochrane Database Syst Rev 2005; :CD003719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/58\">",
"      Ludwig M, Doody KJ, Doody KM. Use of recombinant human chorionic gonadotropin in ovulation induction. Fertil Steril 2003; 79:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/59\">",
"      European Recombinant LH Study Group. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab 2001; 86:2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/60\">",
"      Youssef MA, Van der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev 2010; :CD008046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/61\">",
"      Gibreel A, Maheshwari A, Bhattacharya S. Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database Syst Rev 2012; 11:CD008528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/62\">",
"      Saadat P, Slater CC, Jain JK, et al. Treatment-associated serum FSH levels in very poor responders to ovarian stimulation. J Assist Reprod Genet 2003; 20:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/63\">",
"      Ferraretti AP, La Marca A, Fauser BC, et al. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011; 26:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/64\">",
"      Polyzos NP, Devroey P. A systematic review of randomized trials for&nbsp;the&nbsp;treatment of poor ovarian responders: is&nbsp;there&nbsp;any light at the end of the tunnel? Fertil Steril 2011; 96:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/65\">",
"      Shanbhag S, Aucott L, Bhattacharya S, et al. Interventions for 'poor responders' to controlled ovarian hyperstimulation (COH) in in-vitro fertilisation (IVF). Cochrane Database Syst Rev 2007; :CD004379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/66\">",
"      Kyrou D, Kolibianakis EM, Venetis CA, et al. How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Fertil Steril 2009; 91:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/67\">",
"      Arslan M, Bocca S, Mirkin S, et al. Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr. Fertil Steril 2005; 84:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/68\">",
"      Kwan I, Bhattacharya S, Knox F, McNeil A. Pain relief for women undergoing oocyte retrieval for assisted reproduction. Cochrane Database Syst Rev 2013; 1:CD004829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/69\">",
"      Evers JL, Larsen JF, Gnany GG, Sieck UV. Complications and problems in transvaginal sector scan-guided follicle aspiration. Fertil Steril 1988; 49:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/70\">",
"      Howe RS, Wheeler C, Mastroianni L Jr, et al. Pelvic infection after transvaginal ultrasound-guided ovum retrieval. Fertil Steril 1988; 49:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/71\">",
"      Kroon B, Hart RJ, Wong BM, et al. Antibiotics prior to embryo transfer in ART. Cochrane Database Syst Rev 2012; 3:CD008995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/72\">",
"      Sauer MV, Paulson RJ. Pelvic abscess complicating transcervical embryo transfer. Am J Obstet Gynecol 1992; 166:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/73\">",
"      Sunkara SK, Rittenberg V, Raine-Fenning N, et al. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod 2011; 26:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/74\">",
"      Paulson RJ, Sauer MV, Francis MM, et al. A prospective controlled evaluation of TEST-yolk buffer in the preparation of sperm for human in vitro fertilization in suspected cases of male infertility. Fertil Steril 1992; 58:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/75\">",
"      Palermo G, Joris H, Devroey P, Van Steirteghem AC. Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet 1992; 340:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/76\">",
"      Society for Assisted Reproductive Technology, American Society for Reproductive Medicine. Assisted reproductive technology in the United States: 2001 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology registry. Fertil Steril 2007; 87:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/77\">",
"      Nagy Z, Liu J, Cecile J, et al. Using ejaculated, fresh, and frozen-thawed epididymal and testicular spermatozoa gives rise to comparable results after intracytoplasmic sperm injection. Fertil Steril 1995; 63:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/78\">",
"      Silber SJ, Van Steirteghem AC, Liu J, et al. High fertilization and pregnancy rate after intracytoplasmic sperm injection with spermatozoa obtained from testicle biopsy. Hum Reprod 1995; 10:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/79\">",
"      Bhattacharya S, Hamilton MP, Shaaban M, et al. Conventional in-vitro fertilisation versus intracytoplasmic sperm injection for the treatment of non-male-factor infertility: a randomised controlled trial. Lancet 2001; 357:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/80\">",
"      van Rumste MM, Evers JL, Farquhar CM. Intra-cytoplasmic sperm injection versus conventional techniques for oocyte insemination during in vitro fertilisation in patients with non-male subfertility. Cochrane Database Syst Rev 2003; :CD001301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/81\">",
"      Mahadevan MM. Optimization of culture conditions for human in vitro fertilization and embryo transfer. Semin Reprod Endocrinol 1998; 16:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/82\">",
"      Boiso I, Veiga A, Edwards RG. Fundamentals of human embryonic growth in vitro and the selection of high-quality embryos for transfer. Reprod Biomed Online 2002; 5:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/83\">",
"      Practice Committee of Society for Assisted Reproductive Technology, Practice Committee of American Society for Reproductive Medicine. The role of assisted hatching in in vitro fertilization: a review of the literature. A Committee opinion. Fertil Steril 2008; 90:S196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/84\">",
"      Mansour RT, Rhodes CA, Aboulghar MA, et al. Transfer of zona-free embryos improves outcome in poor prognosis patients: a prospective randomized controlled study. Hum Reprod 2000; 15:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/85\">",
"      Edi-Osagie E, Hooper L, Seif MW. The impact of assisted hatching on live birth rates and outcomes of assisted conception: a systematic review. Hum Reprod 2003; 18:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/86\">",
"      Practice Committee of the American Society for Reproductive Medicine. Blastocyst production and transfer in clinical assisted reproduction. Fertil Steril 2004; 82 Suppl 1:S149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/87\">",
"      Glujovsky D, Blake D, Farquhar C, Bardach A. Cleavage stage versus blastocyst stage embryo transfer in assisted reproductive technology. Cochrane Database Syst Rev 2012; :CD002118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/88\">",
"      Abou-Setta AM, Al-Inany HG, Mansour RT, et al. Soft versus firm embryo transfer catheters for assisted reproduction: a systematic review and meta-analysis. Hum Reprod 2005; 20:3114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/89\">",
"      Buckett WM. A review and meta-analysis of prospective trials comparing different catheters used for embryo transfer. Fertil Steril 2006; 85:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/90\">",
"      Derks RS, Farquhar C, Mol BW, et al. Techniques for preparation prior to embryo transfer. Cochrane Database Syst Rev 2009; :CD007682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/91\">",
"      Mains L, Van Voorhis BJ. Optimizing the technique of embryo transfer. Fertil Steril 2010; 94:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/92\">",
"      Brown J, Buckingham K, Abou-Setta AM, Buckett W. Ultrasound versus 'clinical touch' for catheter guidance during embryo transfer in women. Cochrane Database Syst Rev 2010; :CD006107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/93\">",
"      Purcell KJ, Schembri M, Telles TL, et al. Bed rest after embryo transfer: a randomized controlled trial. Fertil Steril 2007; 87:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/94\">",
"      Abou-Setta AM, D'Angelo A, Sallam HN, et al. Post-embryo transfer interventions for in vitro fertilization and intracytoplasmic sperm injection patients. Cochrane Database Syst Rev 2009; :CD006567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/95\">",
"      Practice Committee of Society for Assisted Reproductive Technology, Practice Committee of American Society for Reproductive Medicine. Guidelines on number of embryos transferred. Fertil Steril 2008; 90:S163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/96\">",
"      Lawlor DA, Nelson SM. Effect of age on decisions about the numbers of embryos to transfer in assisted conception: a prospective study. Lancet 2012; 379:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/97\">",
"      Combelles CM, Orasanu B, Ginsburg ES, Racowsky C. Optimum number of embryos to transfer in women more than 40 years of age undergoing treatment with assisted reproductive technologies. Fertil Steril 2005; 84:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/98\">",
"      Stern JE, Goldman MB, Hatasaka H, et al. Optimizing the number of cleavage stage embryos to transfer on day 3 in women 38 years of age and older: a Society for Assisted Reproductive Technology database study. Fertil Steril 2009; 91:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/99\">",
"      Macones GA, Schemmer G, Pritts E, et al. Multifetal reduction of triplets to twins improves perinatal outcome. Am J Obstet Gynecol 1993; 169:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/100\">",
"      Paulson RJ, Sauer MV, Lobo RA. Embryo implantation after human in vitro fertilization: importance of endometrial receptivity. Fertil Steril 1990; 53:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/101\">",
"      Pados, G, Devroey, P. Luteal phase support. Assist Reprod Rev 1992; 2:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/102\">",
"      Practice Committee of the American Society for Reproductive Medicine. Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. Fertil Steril 2008; 89:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/103\">",
"      Glujovsky D, Pesce R, Fiszbajn G, et al. Endometrial preparation for women undergoing embryo transfer with frozen embryos or embryos derived from donor oocytes. Cochrane Database Syst Rev 2010; :CD006359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/104\">",
"      Hubayter ZR, Muasher SJ. Luteal supplementation in in vitro fertilization: more questions than answers. Fertil Steril 2008; 89:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/105\">",
"      Aboulghar MA, Amin YM, Al-Inany HG, et al. Prospective randomized study comparing luteal phase support for ICSI patients up to the first ultrasound compared with an additional three weeks. Hum Reprod 2008; 23:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/106\">",
"      Nyboe Andersen A, Popovic-Todorovic B, Schmidt KT, et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Hum Reprod 2002; 17:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/107\">",
"      Kyrou D, Fatemi HM, Zepiridis L, et al. Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Hum Reprod 2011; 26:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/108\">",
"      Prietl G, Diedrich K, van der Ven HH, et al. The effect of 17 alpha-hydroxyprogesterone caproate/oestradiol valerate on the development and outcome of early pregnancies following in vitro fertilization and embryo transfer: a prospective and randomized controlled trial. Hum Reprod 1992; 7 Suppl 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/109\">",
"      Kohls G, Ruiz F, Mart&iacute;nez M, et al. Early progesterone cessation after in vitro fertilization/intracytoplasmic sperm injection: a randomized, controlled trial. Fertil Steril 2012; 98:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/110\">",
"      Zarutskie PW, Phillips JA. A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone. Fertil Steril 2009; 92:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/111\">",
"      Polyzos NP, Messini CI, Papanikolaou EG, et al. Vaginal progesterone gel for luteal phase support in IVF/ICSI cycles: a meta-analysis. Fertil Steril 2010; 94:2083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/112\">",
"      Bergh C, Lindenberg S, Nordic Crinone Study Group. A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection. Hum Reprod 2012; 27:3467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/113\">",
"      Daya S, Gunby J. Luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev 2004; :CD004830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/114\">",
"      van der Linden M, Buckingham K, Farquhar C, et al. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2011; :CD009154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/115\">",
"      Gelbaya TA, Kyrgiou M, Tsoumpou I, Nardo LG. The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis. Fertil Steril 2008; 90:2116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/116\">",
"      Jee BC, Suh CS, Kim SH, et al. Effects of estradiol supplementation during the luteal phase of in vitro fertilization cycles: a meta-analysis. Fertil Steril 2010; 93:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/117\">",
"      Stern JE, Lieberman ES, Macaluso M, Racowsky C. Is cryopreservation of embryos a legitimate surrogate marker of embryo quality in studies of assisted reproductive technology conducted using national databases? Fertil Steril 2012; 97:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/118\">",
"      Wennerholm UB, S&ouml;derstr&ouml;m-Anttila V, Bergh C, et al. Children born after cryopreservation of embryos or oocytes: a systematic review of outcome data. Hum Reprod 2009; 24:2158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/119\">",
"      Maheshwari A, Pandey S, Shetty A, et al. Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of frozen thawed versus fresh embryos generated through in vitro fertilization treatment: a systematic review and meta-analysis. Fertil Steril 2012; 98:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/120\">",
"      Shi W, Xue X, Zhang S, et al. Perinatal and neonatal outcomes of 494 babies delivered from 972 vitrified embryo transfers. Fertil Steril 2012; 97:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/121\">",
"      Ishihara O, Kuwahara A, Saitoh H. Frozen-thawed blastocyst transfer reduces ectopic pregnancy risk: an analysis of single embryo transfer cycles in Japan. Fertil Steril 2011; 95:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/122\">",
"      Shapiro BS, Daneshmand ST, De Leon L, et al. Frozen-thawed embryo transfer is&nbsp;associated with a significantly reduced incidence of ectopic pregnancy. Fertil Steril 2012; 98:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/123\">",
"      Riggs R, Mayer J, Dowling-Lacey D, et al. Does storage time influence postthaw survival and pregnancy outcome? An analysis of 11,768 cryopreserved human embryos. Fertil Steril 2010; 93:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/124\">",
"      American Society for Reproductive Medicine. Guidelines for cryopreserved embryo donation. Fertil Steril 2004; 82 Suppl 1:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/125\">",
"      Bankowski BJ, Lyerly AD, Faden RR, Wallach EE. The social implications of embryo cryopreservation. Fertil Steril 2005; 84:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/126\">",
"      Elford K, Lawrence C, Leader A. Research implications of embryo cryopreservation choices made by patients undergoing in vitro fertilization. Fertil Steril 2004; 81:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/127\">",
"      Moutel G, Gregg E, Meningaud JP, Herv&eacute; C. Developments in the storage of embryos in France and the limitations of the laws of bioethics. Analysis of procedures in 17 storage centres and the destiny of stored embryos. Med Law 2002; 21:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/128\">",
"      Elchalal U, Schenker JG. The pathophysiology of ovarian hyperstimulation syndrome--views and ideas. Hum Reprod 1997; 12:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/129\">",
"      Braat DD, Schutte JM, Bernardus RE, et al. Maternal death related to IVF in the Netherlands 1984-2008. Hum Reprod 2010; 25:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/130\">",
"      Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002; 8:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/131\">",
"      Henriksson P, Westerlund E, Wall&eacute;n H, et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ 2013; 346:e8632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/132\">",
"      Ranoux C, Foulot H, Dubuisson JB, et al. Returning to spontaneous cycles in in vitro fertilization. J In Vitro Fert Embryo Transf 1988; 5:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/133\">",
"      Paulson RJ, Sauer MV, Francis MM, et al. In vitro fertilization in unstimulated cycles: a clinical trial using hCG for timing of follicle aspiration. Obstet Gynecol 1990; 76:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/134\">",
"      Paulson RJ, Sauer MV, Francis MM, et al. In vitro fertilization in unstimulated cycles: the University of Southern California experience. Fertil Steril 1992; 57:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/135\">",
"      Jurema MW, Nogueira D. In vitro maturation of human oocytes for assisted reproduction. Fertil Steril 2006; 86:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/136\">",
"      Balakier H, Sojecki A, Motamedi G, Librach C. Time-dependent capability of human oocytes for activation and pronuclear formation during metaphase II arrest. Hum Reprod 2004; 19:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/137\">",
"      De Vos A, Van de Velde H, Joris H, Van Steirteghem A. In-vitro matured metaphase-I oocytes have a lower fertilization rate but similar embryo quality as mature metaphase-II oocytes after intracytoplasmic sperm injection. Hum Reprod 1999; 14:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/138\">",
"      Strassburger D, Friedler S, Raziel A, et al. The outcome of ICSI of immature MI oocytes and rescued in vitro matured MII oocytes. Hum Reprod 2004; 19:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/139\">",
"      Shu Y, Gebhardt J, Watt J, et al. Fertilization, embryo development, and clinical outcome of immature oocytes from stimulated intracytoplasmic sperm injection cycles. Fertil Steril 2007; 87:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/140\">",
"      Hughes EG, Beecroft ML, Wilkie V, et al. A multicentre randomized controlled trial of expectant management versus IVF in women with Fallopian tube patency. Hum Reprod 2004; 19:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/141\">",
"      Huddleston HG, Cedars MI, Sohn SH, et al. Racial and ethnic disparities in reproductive endocrinology and infertility. Am J Obstet Gynecol 2010; 202:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/142\">",
"      Guzick DS, Wilkes C, Jones HW Jr. Cumulative pregnancy rates for in vitro fertilization. Fertil Steril 1986; 46:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/143\">",
"      Kovacs GT, Rogers P, Leeton JF, et al. In-vitro fertilization and embryo transfer. Prospects of pregnancy by life-table analysis. Med J Aust 1986; 144:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/144\">",
"      Luke B, Brown MB, Wantman E, et al. Cumulative birth rates with linked assisted reproductive technology cycles. N Engl J Med 2012; 366:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/145\">",
"      Paulson RJ, Sauer MV, Lobo RA. Factors affecting embryo implantation after human in vitro fertilization: a hypothesis. Am J Obstet Gynecol 1990; 163:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/146\">",
"      Margalioth EJ, Ben-Chetrit A, Gal M, Eldar-Geva T. Investigation and treatment of repeated implantation failure following IVF-ET. Hum Reprod 2006; 21:3036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/147\">",
"      Serour GI, Aboulghar M, Mansour R, et al. Complications of medically assisted conception in 3,500 cycles. Fertil Steril 1998; 70:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/148\">",
"      Li LL, Zhou J, Qian XJ, Chen YD. Meta-analysis on the possible association between in vitro fertilization and cancer risk. Int J Gynecol Cancer 2013; 23:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/149\">",
"      Vlahos NF, Economopoulos KP, Creatsas G. Fertility drugs and ovarian cancer risk: a critical review of the literature. Ann N Y Acad Sci 2010; 1205:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/150\">",
"      Brinton LA, Trabert B, Shalev V, et al. In&nbsp;vitro fertilization and risk of breast&nbsp;and gynecologic cancers: a retrospective cohort study within&nbsp;the Israeli Maccabi Healthcare Services. Fertil Steril 2013; 99:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/151\">",
"      Stewart LM, Holman CD, Hart R, et al. In&nbsp;vitro fertilization and breast cancer: is there cause for concern? Fertil Steril 2012; 98:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/152\">",
"      Dor J, Lerner-Geva L, Rabinovici J, et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril 2002; 77:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/153\">",
"      Lerner-Geva L, Geva E, Lessing JB, et al. The possible association between in vitro fertilization treatments and cancer development. Int J Gynecol Cancer 2003; 13:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/154\">",
"      Pappo I, Lerner-Geva L, Halevy A, et al. The possible association between IVF and breast cancer incidence. Ann Surg Oncol 2008; 15:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/155\">",
"      Katz D, Paltiel O, Peretz T, et al. Beginning IVF treatments after age 30 increases the risk of breast cancer: results of a case-control study. Breast J 2008; 14:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/156\">",
"      K&auml;ll&eacute;n B, Finnstr&ouml;m O, Nygren KG, et al. In vitro fertilisation in Sweden: obstetric characteristics, maternal morbidity and mortality. BJOG 2005; 112:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/157\">",
"      Kristiansson P, Bj&ouml;r O, Wramsby H. Tumour incidence in Swedish women who gave birth following IVF treatment. Hum Reprod 2007; 22:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/158\">",
"      K&auml;ll&eacute;n B, Finnstr&ouml;m O, Lindam A, et al. Malignancies among women who gave birth after in vitro fertilization. Hum Reprod 2011; 26:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/159\">",
"      Hunault CC, Habbema JD, Eijkemans MJ, et al. Two new prediction rules for spontaneous pregnancy leading to live birth among subfertile couples, based on the synthesis of three previous models. Hum Reprod 2004; 19:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/160\">",
"      Troude P, Bailly E, Guibert J, et al. Spontaneous pregnancies among couples previously treated by in vitro fertilization. Fertil Steril 2012; 98:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/161\">",
"      Ludwig AK, Katalinic A, Jendrysik J, et al. Spontaneous pregnancy after successful ICSI treatment: evaluation of risk factors in 899 families in Germany. Reprod Biomed Online 2008; 17:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/162\">",
"      Shimizu Y, Kodama H, Fukuda J, et al. Spontaneous conception after the birth of infants conceived through in vitro fertilization treatment. Fertil Steril 1999; 71:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/56/37770/abstract/163\">",
"      Pinborg A, Hougaard CO, Nyboe Andersen A, et al. Prospective longitudinal cohort study on cumulative 5-year delivery and adoption rates among 1338 couples initiating infertility treatment. Hum Reprod 2009; 24:991.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7404 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-118.97.94.19-7F317C0ADA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_56_37770=[""].join("\n");
var outline_f36_56_37770=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pre-cycle factors associated with success",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Younger maternal age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Adequate ovarian reserve",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Absence of hydrosalpinges",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Factors with no or a negative effect on success",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CONTROLLED OVARIAN HYPERSTIMULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2702884\">",
"      Long and short protocols",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2356164\">",
"      - GnRH agonist (long) protocol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3357294\">",
"      - GnRH agonist flare protocol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2356171\">",
"      - GnRH antagonist (short) protocol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2356269\">",
"      - Triggers for ovulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2356276\">",
"      Other options",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Poor responders and high responders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FOLLICLE ASPIRATION AND FERTILIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Oocyte retrieval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Fertilization in vitro",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EMBRYO MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Embryo transfer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Luteal phase support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cryopreservation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Endometrial preparation for frozen-thawed embryo transfer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Expected course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Monitoring for pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Ovarian hyperstimulation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      OTHER TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Natural cycle IVF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      In vitro maturation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Pregnancy rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Registry data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Reasons for failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H884328160\">",
"      Maternal outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20062509\">",
"      - Ovarian cancer risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32944653\">",
"      - Breast cancer risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18754188\">",
"      Spontaneous pregnancy after IVF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/7404\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7404|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/12/33998\" title=\"figure 1\">",
"      Long and short stimulat cycles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/44/2758\" title=\"figure 3\">",
"      Oocyte fertilization and zygote migration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/36/28224\" title=\"figure 4\">",
"      Reasons for ART",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7404|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/23/11647\" title=\"figure 2\">",
"      Technique for oocyte recovery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7404|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/63/43003\" title=\"table 1\">",
"      IVF GIFT ZIFT TET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/54/27499\" title=\"table 2\">",
"      Effect of maternal age and embryos transferred on outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/39/6780\" title=\"table 3\">",
"      ASRM revised guidelines for embryo transfer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/4/16457?source=related_link\">",
"      Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/44/36554?source=related_link\">",
"      Approach to abdominal pain and the acute abdomen in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18968?source=related_link\">",
"      Benefits and risks of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3367?source=related_link\">",
"      Causes of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/41/35479?source=related_link\">",
"      Classification and treatment of ovarian hyperstimulation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5863?source=related_link\">",
"      Diagnosis and management of ovarian endometriomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31865?source=related_link\">",
"      Effect of advanced age on fertility and pregnancy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/44/17095?source=related_link\">",
"      Evaluation of acute pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40921?source=related_link\">",
"      Evaluation of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33481?source=related_link\">",
"      Evaluation of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15546?source=related_link\">",
"      Intracytoplasmic sperm injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/0/44041?source=related_link\">",
"      Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39065?source=related_link\">",
"      Multifetal pregnancy reduction and selective termination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24807?source=related_link\">",
"      Oocyte donation for assisted reproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/10/13482?source=related_link\">",
"      Overview of ovulation induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/6/15465?source=related_link\">",
"      Overview of the etiology and evaluation of vaginal bleeding in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/5/14425?source=related_link\">",
"      Overview of treatment of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9626?source=related_link\">",
"      Ovulation induction with clomiphene citrate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38136?source=related_link\">",
"      Pathogenesis and treatment of infertility in women with endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/17/16660?source=related_link\">",
"      Pathogenesis of ovarian hyperstimulation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/62/40932?source=related_link\">",
"      Patient information: In vitro fertilization (IVF) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/6/2154?source=related_link\">",
"      Pregnancy outcome after assisted reproductive technology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23431?source=related_link\">",
"      Preimplantation genetic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/7/22647?source=related_link\">",
"      Prevention of ovarian hyperstimulation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30662?source=related_link\">",
"      Reproductive issues in women with uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/18/9513?source=related_link\">",
"      Reproductive surgery for female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/27/43449?source=related_link\">",
"      Strategies to control the rate of high order multiple gestation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15015?source=related_link\">",
"      Surrogate pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_56_37771="Parkinson vs essential tremor";
var content_f36_56_37771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F60694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F60694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differentiating Parkinson disease and essential tremor",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Clinical features",
"      </td>",
"      <td class=\"subtitle1\">",
"       Parkinson disease tremor",
"      </td>",
"      <td class=\"subtitle1\">",
"       Essential tremor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Age at onset",
"      </td>",
"      <td>",
"       &gt;50",
"      </td>",
"      <td>",
"       Bimodal 2nd and 6th decade",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gender",
"      </td>",
"      <td>",
"       M&ge;W",
"      </td>",
"      <td>",
"       M=W",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Family history",
"      </td>",
"      <td>",
"       &gt;25 percent",
"      </td>",
"      <td>",
"       &gt;50 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Asymmetry",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Frequency",
"      </td>",
"      <td>",
"       4 to 6 Hz",
"      </td>",
"      <td>",
"       4 to 10 Hz",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Character",
"      </td>",
"      <td>",
"       At rest",
"      </td>",
"      <td>",
"       Postural, kinetic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Supination-pronation",
"      </td>",
"      <td>",
"       Flexion-extension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Distribution",
"      </td>",
"      <td>",
"       Hands, legs, chin, tongue",
"      </td>",
"      <td>",
"       Hands, head, voice",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Associated features",
"      </td>",
"      <td>",
"       Bradykinesia, rigidity, gait difficulty, postural instability, micrographia",
"      </td>",
"      <td>",
"       Deafness, dystonia, parkinsonism",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jankovic J. Essential tremor: clinical characteristics. Neurology 2000; 54(suppl 4):s21. Copyright &copy; 2000 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_56_37771=[""].join("\n");
var outline_f36_56_37771=null;
var title_f36_56_37772="Expressions of MEN1";
var content_f36_56_37772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F74208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F74208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Expressions of MEN1 with estimated penetrance (in parentheses) at age 40 years",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Endocrine features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nonendocrine features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Parathyroid adenoma (90 percent)",
"       </td>",
"       <td>",
"        Lipomas (30 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Entero-pancreatic tumor",
"       </td>",
"       <td>",
"        Facial angiofibromas (85 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gastrinoma (30 to 40 percent)",
"       </td>",
"       <td>",
"        Collagenomas (70 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Insulinoma (10 percent)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        NF* including pancreatic polypeptide (30 to 40 percent",
"        <sup>",
"         &bull;",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        Rare, maybe innate, endocrine or nonendocrine features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other: glucagonoma, VIPoma, somatostatinoma, etc. (2 percent)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Foregut carcinoid",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thymic carcinoid NF (2 percent)",
"       </td>",
"       <td>",
"        Pheochromocytoma (&lt;1 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bronchial carcinoid NF (2 percent)",
"       </td>",
"       <td>",
"        Ependymoma (1 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gastric enterochromaffin-like tumor NF (10 percent)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Anterior pituitary tumor",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prolactinoma (20 percent)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other: GH + PRL, GH, NF (each 5 percent)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ACTH (2 percent), TSH (rare)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Adrenal cortex NF (25 percent)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NF: nonfunctioning.",
"     <br>",
"      * May synthesize a peptide hormone or other factors (such as small amine), but does not usually oversecrete enough to produce a hormonal expression.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Omits nearly 100 percent prevalence of NF and clinically silent tumors, some of which are detected incidental to pancreatico-duodenal surgery in MEN1.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86:5658. Copyright &copy; 2001 The Endocrine Society. Updated according to Triponez F, Dosseh D, Goudet P, et al. Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg 2006; 243:265 and Kouvaraki MA, Shapiro SE, Cote GJ, et al. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg 2006; 30:643.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_56_37772=[""].join("\n");
var outline_f36_56_37772=null;
var title_f36_56_37773="Measurement of cell pH";
var content_f36_56_37773=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extracellular and intracellular pH",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 268px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relationship between skeletal muscle cell pH and the extracellular pH in metabolic acidosis and alkalosis, in which the extracellular pH is changed by alterations in the plasma HCO3- concentration. A similar relationship is present in respiratory acidosis and alkalosis. The cell pH can be seen to be heterogeneous as evidenced by the difference between measuring the pH with a weak acid (DMO; 5,5-dimethyl-2,4- oxazolidinedione) (solid line) or a weak base (nicotine) (dashed line).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Adler, S, J Clin Invest 1972; 51:256, by copyright permission of the American Society for Clinical Investigation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_56_37773=[""].join("\n");
var outline_f36_56_37773=null;
var title_f36_56_37774="Energy spent with activity";
var content_f36_56_37774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Leisure activity energy expenditure in metabolic equivalents (METs)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Activity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mean",
"       </td>",
"       <td class=\"subtitle1\">",
"        Range",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Archery",
"       </td>",
"       <td>",
"        3.9",
"       </td>",
"       <td>",
"        3-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Backpacking",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        5-11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Badminton",
"       </td>",
"       <td>",
"        5.8",
"       </td>",
"       <td>",
"        4-9+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Basketball",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gameplay",
"       </td>",
"       <td class=\"sublist_other\">",
"        8.3",
"       </td>",
"       <td class=\"sublist_other\">",
"        7-12+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Non-game",
"       </td>",
"       <td class=\"sublist_other\">",
"        --",
"       </td>",
"       <td class=\"sublist_other\">",
"        3-9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Billiards",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bowling",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        2-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Boxing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        In-ring",
"       </td>",
"       <td class=\"sublist_other\">",
"        13.3",
"       </td>",
"       <td class=\"sublist_other\">",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sparring",
"       </td>",
"       <td class=\"sublist_other\">",
"        8.3",
"       </td>",
"       <td class=\"sublist_other\">",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Canoeing, rowing, kayaking",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        3-8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Conditioning exercise",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        3-8+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Climbing hills",
"       </td>",
"       <td>",
"        7.2",
"       </td>",
"       <td>",
"        5-10+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cricket",
"       </td>",
"       <td>",
"        5.2",
"       </td>",
"       <td>",
"        4.6-7.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Croquet",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Cycling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pleasure or to work",
"       </td>",
"       <td class=\"sublist_other\">",
"        --",
"       </td>",
"       <td class=\"sublist_other\">",
"        3-8+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        10 mph",
"       </td>",
"       <td class=\"sublist_other\">",
"        7.0",
"       </td>",
"       <td class=\"sublist_other\">",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dancing (social, square, tap)",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        3.7-7.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dancing (aerobic)",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        6-9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fencing",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        6-10+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Field hockey",
"       </td>",
"       <td>",
"        8.0",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Fishing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        From bank",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.7",
"       </td>",
"       <td class=\"sublist_other\">",
"        2-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Wading in stream",
"       </td>",
"       <td class=\"sublist_other\">",
"        --",
"       </td>",
"       <td class=\"sublist_other\">",
"        5-6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Football (touch)",
"       </td>",
"       <td>",
"        7.9",
"       </td>",
"       <td>",
"        6-10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Golf",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Power cart",
"       </td>",
"       <td class=\"sublist_other\">",
"        --",
"       </td>",
"       <td class=\"sublist_other\">",
"        2-3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Walking (carrying bag or pulling cart)",
"       </td>",
"       <td class=\"sublist_other\">",
"        5.1",
"       </td>",
"       <td class=\"sublist_other\">",
"        4-7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Handball",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        8-12+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hiking (cross country)",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        3-7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Horseback riding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Galloping",
"       </td>",
"       <td class=\"sublist1\">",
"        8.2",
"       </td>",
"       <td class=\"sublist1\">",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Trotting",
"       </td>",
"       <td class=\"sublist1\">",
"        6.6",
"       </td>",
"       <td class=\"sublist1\">",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Walking",
"       </td>",
"       <td class=\"sublist1\">",
"        2.4",
"       </td>",
"       <td class=\"sublist1\">",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Horseshoe pitching",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Hunting (bow or gun)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Small game (walking, carrying light load)",
"       </td>",
"       <td class=\"sublist_other\">",
"        --",
"       </td>",
"       <td class=\"sublist_other\">",
"        3-7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Big game (dragging carcass, walking)",
"       </td>",
"       <td class=\"sublist_other\">",
"        --",
"       </td>",
"       <td class=\"sublist_other\">",
"        3-14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Judo",
"       </td>",
"       <td>",
"        13.5",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mountain climbing",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        5-10+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Music playing",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paddleball, raquetball",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        8-12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Rope jumping",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        11",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        60-80 skips/min",
"       </td>",
"       <td class=\"sublist_other\">",
"        9",
"       </td>",
"       <td class=\"sublist_other\">",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        120-140 skips/min",
"       </td>",
"       <td class=\"sublist_other\">",
"        --",
"       </td>",
"       <td class=\"sublist_other\">",
"        11-12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Running",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        12 min/mile",
"       </td>",
"       <td class=\"sublist_other\">",
"        8.7",
"       </td>",
"       <td class=\"sublist_other\">",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        11 min/mile",
"       </td>",
"       <td class=\"sublist_other\">",
"        9.4",
"       </td>",
"       <td class=\"sublist_other\">",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        10 min/mile",
"       </td>",
"       <td class=\"sublist_other\">",
"        10.2",
"       </td>",
"       <td class=\"sublist_other\">",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        9 min/mile",
"       </td>",
"       <td class=\"sublist_other\">",
"        11.2",
"       </td>",
"       <td class=\"sublist_other\">",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        8 min/mile",
"       </td>",
"       <td class=\"sublist_other\">",
"        12.5",
"       </td>",
"       <td class=\"sublist_other\">",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        7 min/mile",
"       </td>",
"       <td class=\"sublist_other\">",
"        14.1",
"       </td>",
"       <td class=\"sublist_other\">",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        6 min/mile",
"       </td>",
"       <td class=\"sublist_other\">",
"        16.3",
"       </td>",
"       <td class=\"sublist_other\">",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sailing",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        2-5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scuba diving",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        5-10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shuffleboard",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skating, ice and roller",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        5-8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Skiing, snow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Downhill",
"       </td>",
"       <td class=\"sublist_other\">",
"        --",
"       </td>",
"       <td class=\"sublist_other\">",
"        5-8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cross country",
"       </td>",
"       <td class=\"sublist_other\">",
"        --",
"       </td>",
"       <td class=\"sublist_other\">",
"        6-12+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skiing, water",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        5-7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sledding, tobogganing",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        4-8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Snowshoeing",
"       </td>",
"       <td>",
"        9.9",
"       </td>",
"       <td>",
"        7-14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Squash",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        8-12+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soccer",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        5-12+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stairclimbing",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        4-8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Swimming",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        4-8+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Table tennis",
"       </td>",
"       <td>",
"        4.1",
"       </td>",
"       <td>",
"        3-5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tennis",
"       </td>",
"       <td>",
"        6.5",
"       </td>",
"       <td>",
"        4-9+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Volleyball",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        3-6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: American College of Sports Medicine, Guidelines for Exercise Testing and Prescription, 3rd Ed, Lea and Febiger, Philadelphia 1986, p.20.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_56_37774=[""].join("\n");
var outline_f36_56_37774=null;
var title_f36_56_37775="Tophus of the knee";
var content_f36_56_37775=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F81692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F81692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tophus of the knee",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large tophus and multiple superficial tophi of the knee in patient with chronic uncontrolled gout.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter H Schur, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_56_37775=[""].join("\n");
var outline_f36_56_37775=null;
